etidronate has been researched along with risedronic acid in 977 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 66 (6.76) | 18.2507 |
| 2000's | 612 (62.64) | 29.6817 |
| 2010's | 290 (29.68) | 24.3611 |
| 2020's | 9 (0.92) | 2.80 |
| Authors | Studies |
|---|---|
| Martin, MB; Oldfield, E; Szabo, CM | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Almeida Paz, FA; Barbosa, JS; Braga, SS | 1 |
| Jee, WS; Ke, HZ; Kimmel, DB; Tang, LY | 1 |
| Bauss, F; Bosies, E; Fleisch, H; Janner, M; Mühlbauer, RC; Schenk, R; Strein, K | 1 |
| Horiuchi, H; Shinoda, H; Shoji, K | 1 |
| Jee, WS; Ke, HZ; Lin, BY; Ma, YF | 1 |
| Boyce, BF; Boyce, R; Chapman, M; Mundy, GR; Sasaki, A; Story, B; Wright, KR; Yoneda, T | 1 |
| Li, M; Mosekilde, L; Søgaard, CH; Thomsen, JS; Wronski, TJ | 1 |
| Boyce, RW; Eriksen, EF; Gleason, JR; Paddock, CL; Sletsema, WK | 1 |
| Boyce, RW; Ebert, DC; Gundersen, HJ; Paddock, CL; Stevens, ML; Wronski, TJ; Youngs, TA | 1 |
| Danielsen, CC; McOsker, JE; Mosekilde, L; Søgaard, CH; Wronski, TJ | 1 |
| Baumann, BD; Wronski, TJ | 1 |
| Altman, RD; Axelrod, DW; Bekker, PJ; Brown, JP; Kylstra, JW; Singer, FR; Siris, ES | 1 |
| Adachi, H; Igarashi, K; Mitani, H; Shinoda, H | 2 |
| Hall, DG; Stoica, G | 1 |
| Chole, RA; Richardson, AC; Tinling, SP | 1 |
| Dann, LM; Qi, H; Wronski, TJ; Yen, CF | 1 |
| McOsker, JE; Mosekilde, L; Søgaard, CH; Wronski, TJ | 1 |
| Ballah, A; Hosking, DJ; Mundy, GR; Reasner, CA; Stone, MD | 1 |
| Huang, LF; Jee, WS; Ke, HZ; Li, QN; Liang, NC; Ma, YF; Xie, H | 1 |
| Chen, YY; Ijiri, K; Jee, WS; Ke, HZ; Ma, Y | 1 |
| Chen, HK; Jee, WS; Li, XJ; Ma, YF; McOsker, JE; Pan, Z | 1 |
| Jee, WS; Li, XJ; Ma, YF; McOsker, JE; Pan, Z | 1 |
| Jee, WS; Li, XJ; Liang, HH; Ma, YF; McOsker, JE; Pan, Z; Setterberg, RB | 1 |
| Chen, Y; Gasser, J; Jee, WS; Ke, HZ; Kimmel, DB; Li, XJ; Ma, Y | 1 |
| Boyce, BF; Hughes, DE; Mundy, GR; Roodman, GD; Sasaki, A; Uy, HL; Wright, KR; Yoneda, T | 1 |
| Licata, AA | 1 |
| Chen, YY; Jee, WS; Ke, HZ; Li, XJ; Lin, BY; Lin, CH; Ma, YF | 1 |
| Berman, SK; Blank, MA; Ems, BL; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN | 1 |
| Balena, R; Bremond, A; Confravreux, E; Delmas, PD; Hardouin, C; Hardy, P | 1 |
| McOsker, JE; Mosekilde, L; Thomsen, JS | 1 |
| Boyce, RW; Eriksen, EF; Franks, AF; Jankowsky, ML; Paddock, CL | 1 |
| Chen, H; Jee, WS; Li, XJ; Liang, HH; Lin, CH; Ma, YF; Pan, Z; Pun, S | 1 |
| Christiansen, C; Clemmesen, B; Ravn, P; Reginster, JY; Taquet, AN; Zegels, B | 1 |
| Chines, AA; Eusebio, RA; Hosking, DJ | 1 |
| Bekker, PJ; Charles, P; Digennaro, J; Johnston, CC; Mortensen, L | 1 |
| Bhallah, A; Hosking, DJ; Maslanka, W; Patel, S; Pearson, D; White, DA | 1 |
| Bekker, PJ; Clay, ME; Dunlap, LE; Eusebio, RA; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA | 1 |
| Funaba, Y; Kawabe, N; Nakadate-Matsushita, T; Tanahashi, M; Tateishi, A | 1 |
| Coxon, FP; Graham, R; Hughes, DE; Luckman, SP; Rogers, MJ; Russell, G | 1 |
| Kindt, MV; Majka, JA; Peter, CP | 1 |
| Bekker, PJ; Clemens, TL; Eusebio, RA; Singer, FR | 1 |
| Altman, RD; Bekker, PJ; Brown, JP; Chines, AA; Eusebio, RA; Johnston, CC; Lang, R; Mallette, LE; McClung, MR; Miller, PD; Ryan, WG; Singer, FR; Siris, ES; Tucci, JR | 1 |
| Andreassen, TT; Ejersted, C; Eriksen, EF; Oxlund, H | 1 |
| Balfour, JA; Goa, KL | 1 |
| Hu, JK; Schwecke, WP; Smith, BJ | 1 |
| Handt, LK; Peter, CP; Smith, SM | 1 |
| Ebetino, FH; Löwik, CW; Papapoulos, SE; van Beek, ER | 1 |
| Bekker, PJ; Brown, JP; Hosking, DJ; Johnson, TD; Johnston, CC; Reginster, J; Ryan, WG; Ste-Marie, L | 1 |
| Hu, B; Huang, LF; Li, QN; Liang, NC; Mo, LE; Wu, T | 2 |
| Hosking, DJ | 1 |
| Miller, PD | 2 |
| Axelrod, DW; Bekker, PJ; Brown, JP; Hoseyni, MS; Miller, PD; Siris, ES | 1 |
| Mundy, GR | 1 |
| Hussar, DA | 1 |
| Bekker, PJ; Blackshaw, PE; Dansereau, RJ; Frier, M; Juhlin, KD; Perkins, AC; Spiller, RC; Vincent, RM; Wilson, CG | 1 |
| Axelrod, DW; Brown, J; Chesnut, CH; Eriksen, EF; Genant, HK; Hangartner, T; Harris, ST; Hoseyni, MS; Keller, M; McKeever, CD; Miller, PD; Watts, NB | 1 |
| Dunlop, MB; Lane, NE | 1 |
| Axelrod, DW; Boling, E; Chines, AA; Cohen, S; Emkey, RD; Greenwald, M; Keller, M; Levy, RM; Lukert, BP; Sewell, KL; Wallach, S; Zizic, TM | 1 |
| Halasy-Nagy, JM; Masarachia, PJ; Reszka, AA; Rodan, GA | 1 |
| Clay, ME; Heise, MA; Melson, CW; Mitchell, DY; Nesbitt, JD; Pallone, KA; Russell, DA | 1 |
| Hamdy, RC | 1 |
| Berenson, J; Hortobagyi, G; Lipton, A; Major, PP | 1 |
| Lindsay, R | 1 |
| Brandi, ML; Eastell, R; Ethgen, D; Hooper, M; Lund, B; Minne, HW; Pack, S; Reginster, J; Roumagnac, I; Roux, C; Sorensen, OH | 1 |
| Brezovic, CP; Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Sacco-Gibson, NA; Thompson, GA | 1 |
| Brown, JP; Chines, AA; Eusebio, RA; Hayes, CW; Myers, WR; Ritter-Hrncirik, C | 1 |
| Eusebio, RA; Kelly, SC; Mitchell, DY; Nesbitt, JD; Pallone, KA; Powell, JH; Russell, DA; St Peter, JV; Thompson, GA | 1 |
| Goldstein, MR | 1 |
| Kessenich, CR | 1 |
| Burr, DB; Forwood, MR; Hirano, T; Johnston, CC; Mashiba, T; Turner, CH | 1 |
| Brown, RJ; Grove, JE; Watts, DJ | 1 |
| Adami, S; Devogelaer, JP; Eusebio, RA; Hughes, RA; Laan, RF; Reid, DM; Sacco-Gibson, NA; Wenderoth, DH | 1 |
| Ethgen, D; Fogelman, I; Reginster, JY; Ribot, C; Smith, R; Sod, E | 1 |
| Hunziker, J; Miller, SC; Wronski, TJ | 1 |
| Bax, DE; Chines, AA; Devogelaer, JP; Eastell, R; Nagant de Deuxchaisnes, C; Peel, NF; Russell, RG; Sacco-Gibson, N | 1 |
| Prestwood, KM; Raisz, LG | 2 |
| Blank, MA; Dierckman, TA; Gibson, GW; Myers, WR; Phipps, RJ; Smith, PN | 1 |
| Blank, MA; Hunt, RH; Lanza, FL; Provenza, JM; Thomson, AB | 1 |
| Kronenberg, HM; Leder, BZ | 1 |
| Barton, I; Brown, J; Chines, AA; Cohen, S; Doherty, SM; Hosking, DJ; Hughes, RA; Laan, RF; Maricic, M; Reid, DM; Rosen, C; Wallach, S | 1 |
| Dijkmans, BA; Lems, WF | 1 |
| Blank, MA; Gibson, GW; Lichtenberger, LM; Romero, JJ | 1 |
| Baran, DT | 1 |
| Mackey, MS; Mosekilde, L; Phipps, RJ; Thomsen, JS | 1 |
| Digennaro, J; Fall, P; Raisz, L; Sacco-Gibson, N; Shoukri, K; Smith, JA; Trahiotis, M | 1 |
| Graham, DY; Lanza, F; Malaty, HM; Musliner, T; Quan, H; Reyes, R; Sahba, B; Schwartz, H | 1 |
| Papapoulos, SE | 1 |
| Fisher, JE; Reszka, AA; Rodan, GA | 1 |
| Compston, JE | 1 |
| Blank, MA; Krajewski, SA; Lanza, FL; Li, Z; Rack, MF | 1 |
| Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Juan, D; Li, Z; Long, P; Perkins, AC; Spiller, RC; Wilson, CG | 1 |
| Collette, J; Eastell, R; Ethgen, D; Reginster, JY; Roumagnac, I; Russell, RG; Zegels, B | 1 |
| Adami, S; Bensen, WG; Diamond, T; Eastell, R; Fogelman, I; Geusens, P; McClung, MR; Meunier, PJ; Miller, PD; Reginster, JY; Roux, C; Zippel, H | 1 |
| Crandall, C | 1 |
| Cullen, DM; Iwaniec, UT; Kimmel, DB; Recker, RR; Samnegård, E | 1 |
| Watts, NB | 3 |
| Irani, M | 1 |
| Heaney, RP; Recker, RR | 1 |
| Baylink, DJ; Chines, AA; Crusan, CE; Davidson, M; Eriksen, EF; Ettinger, MP; Harris, ST; Moffett, AH | 1 |
| Brown, JP; Drake, WM; Kendler, DL | 1 |
| Dunn, CJ; Goa, KL | 1 |
| Goodman, RL | 1 |
| Royce, PC | 1 |
| Dargent-Molina, P; Meunier, PJ; Schott, AM | 1 |
| McCormack, J | 1 |
| Bailey, BN; Docampo, R; Kuhlenschmidt, M; Luo, S; Martin, MB; Moreno, B; Moreno, SN; Oldfield, E | 1 |
| Barr, WH; Duke, FP; Eusebio, RA; Mitchell, DY; Nesbitt, JD; Powell, JH; Russell, DA; Stevens, KA; Thompson, GA | 1 |
| Chapurlat, RD; Delmas, PD | 2 |
| Blank, MA; Thomson, AB | 1 |
| Crail, D; Dansereau, R; Lane, M; McCargar, L; Myers, W | 1 |
| Blackshaw, PE; Dansereau, RJ; Frier, M; Hathaway, S; Li, Z; Perkins, AC; Spiller, RC; Vincent, RM; Wenderoth, D; Wilson, CG | 1 |
| Cefalu, CA | 1 |
| Bailey, BN; Docampo, R; Martin, MB; Montalvetti, A; Oldfield, E; Severin, GW | 1 |
| Netelenbos, JC | 1 |
| Jennings, JC; Kauffman, RP; Overton, TH; Shiflett, M | 1 |
| Ringe, JD | 3 |
| Bukowski, JF; Das, H; Kamath, A; Wang, L | 1 |
| McClung, B; McClung, M | 1 |
| Boyce, EG; Umland, EM | 1 |
| Cullen, DM; Iwaniec, UT; Kimmel, DB; Samnegård, E | 1 |
| Leonard, M; Licata, AA; Peters, ML | 1 |
| Halasy-Nagy, JM; Reszka, AA; Rodan, GA | 1 |
| Adami, S; Chines, AA; Devogelaer, JP; Reid, DM | 1 |
| Hoseyni, MS; Li, Z; Meredith, MP | 1 |
| Burr, DB; Li, J; Mashiba, T | 1 |
| Trémollières, F | 1 |
| Kruse, HP | 1 |
| Adachi, JD; Adami, S; Gomez-Panzani, E; Kendler, DL; Li, Z; Licata, AA; Miller, PD; Olszynski, WP; Silverman, SL | 1 |
| Geusens, P; McClung, M | 1 |
| Adami, S; Bolognese, MA; Ernst, TF; Ettinger, MP; Josse, RG; Lindsay, R; Mulder, H; Roberts, A; Stevens, KP; Taggart, H; Zippel, H | 1 |
| Dougherty, JA | 1 |
| Bannwarth, B | 1 |
| Nip, CS; Sickels, JM | 1 |
| Duthie, EH; Kamel, HK | 1 |
| Bearne, A; Bose, U; Iglesias, CP; Torgerson, DJ | 1 |
| Shiraki, M | 1 |
| Costa, J; Holgado, S; Olivé, A; Viñas, G | 1 |
| Audran, M; Baslé, MF; Chappard, D; Legrand, E; Libouban, H; Moreau, MF | 1 |
| Hanley, DA; Hodsman, AB; Josse, R | 1 |
| Iwaniec, UT; Mitova-Caneva, NG; Mosekilde, L; Thomsen, JS; Wronski, TJ | 1 |
| Roll, KT | 1 |
| Adachi, JD; Balske, A; Bolognese, MA; Brown, JP; Emkey, RD; Kendler, DL; Li, Z; Lindsay, R; McClung, MR | 1 |
| Borah, B; Chmielewski, PA; Dufresne, TE; Gross, GJ; Phipps, RJ; Prenger, MC | 1 |
| Alsayed, N; Chesnut, CH; Davie, MW; Fogelman, I; Geusens, P; Heaney, RP; Isaia, G; Kasibhatla, C; Olszynski, WP; Zizic, TM | 1 |
| Baker, DE | 1 |
| Erben, RG; Leyshon, A; Mosekilde, L; Phipps, R; Smith, SY; Stahr, K; Thomsen, JS; Weber, K | 1 |
| Välimäki, MJ | 1 |
| Graham, DY | 1 |
| D'Agostino, RB; Gabrielson, E; Hofman, A; Mandel, JS; McClung, MR; Steinbuch, M; Stemhagen, A | 1 |
| Adachi, J; Cranney, A; Guyatt, G; Papaioannou, A; Robinson, V; Shea, B; Tugwell, P; Weaver, B; Wells, G; Zytaruk, N | 1 |
| Adachi, JD; Kherani, RB; Papaioannou, A | 1 |
| Blank, MA; Hunt, RH; Lanza, FL; Li, Z; Marshall, JK; Provenza, JM; Royer, MG; Thomson, AB | 1 |
| Collier, J | 1 |
| Diez-Perez, A | 1 |
| Khosla, S; Tremaine, WJ | 1 |
| Deal, C; Srivastava, M | 1 |
| Boissier, S; Cabon, F; Clézardin, P; Colombel, M; Filleur, S; Fournier, P; Guglielmi, J | 1 |
| Phipps, RJ; Scutt, A; Still, K | 1 |
| Fukunaga, M; Inoue, T; Kishimoto, H; Kushida, K; Minaguchi, H; Morii, H; Morita, R; Ohashi, Y; Orimo, H; Shiraki, M; Taketani, Y; Yamamoto, K | 2 |
| Baranauskaite, A; Savickiene, A | 1 |
| Baranauskaite, A | 1 |
| Barton, I; Chines, A; Eriksen, EF; Melsen, F; Sod, E | 1 |
| Begerow, B; Hinz, C; Minne, HW; Pfeifer, M; Pollähne, W | 1 |
| Deal, CL | 1 |
| Borgström, F; Zethraeus, N | 1 |
| Barton, I; Calligeros, D; Felsenberg, D; Hamdy, RC; Hughes, RA; Josse, RG; Manhart, MD; Watts, NB | 1 |
| Gossman, WL; Oldfield, E; Wilson, SR | 1 |
| Bartl, R | 2 |
| Ito, M | 1 |
| Fukunaga, M | 2 |
| Sohen, S | 1 |
| Appleman, S; Keelan, M; Thomson, AB; Wallace, JL | 1 |
| Delaney, MF; Hurwitz, S; LeBoff, MS; Shaw, J | 1 |
| Itoh, K; Nagai, K; Sahara, T; Sasaki, T; Suda, K; Takahashi, N; Takami, M; Udagawa, N | 1 |
| Hamilton, B; McCoy, K; Taggart, H | 1 |
| Brown, J; Kasibhatla, C; Li, Z; Lindsay, R; Watts, NB | 1 |
| Derman, R | 1 |
| Barton, I; Chines, A; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA | 1 |
| Reid, IR | 2 |
| Traut, V | 1 |
| Kline, WF; Matuszewski, BK; Shugarts, SB; Vallano, PT; Woolf, EJ | 1 |
| Larocque, D | 1 |
| Borah, B; Chmielewski, PA; Dufresne, TE; Johnson, TD; Manhart, MD | 1 |
| Adami, S; Andia, JC; Benhamou, L; Felsenberg, D; Hosking, D; Petruschke, RA; Reginster, JY; Rybak-Feglin, A; Santora, AC; Välimäki, M; Yacik, C; Zaru, L | 1 |
| Hiraoka, BY; Horiuchi, H; Kobayashi, Y; Matsuura, S; Miyazawa, H; Mogi, M; Nakamura, H; Nakamura, M; Ozawa, H; Saito, N; Takahashi, N; Takaoka, K; Udagawa, N | 1 |
| Bifulco, G; Colao, A; Di Somma, C; Esposito, M; Lombardi, G; Orio, F; Palomba, S; Rotoli, B; Selleri, C; Tauchmanovà, L | 1 |
| Ettinger, MP | 1 |
| Burr, DB; Day, JS; Ding, M; Hirano, T; Hvid, I; Mashiba, T; Sumner, DR; Weinans, H | 1 |
| Adachi, JD; Cranney, A; Guyatt, G; Papaioannou, A; Robinson, V; Shea, B; Tugwell, P; Waldegger, L; Weaver, B; Wells, G; Zytaruk, N | 1 |
| Taha, EA; Youssef, NF | 1 |
| Barton, I; Boonen, S; Brandi, ML; Civitelli, R; Fardellone, P; Grauer, A; Harrington, JT; Ste-Marie, LG | 1 |
| Benatar, NA; Blake, GM; Cook, GJ; Fogelman, I; Frost, ML; Marsden, PK | 1 |
| Boyde, A; Burr, DB; Grynpas, M; Hirano, T; Johnston, CC; Li, J; Mashiba, T; Miller, L | 1 |
| Sparrowhawk, M; Steele, P | 1 |
| Cohen, SB | 1 |
| Callaci, JJ; Frost, N; Juknelis, D; Patwardhan, A; Sartori, M; Wezeman, FH | 1 |
| Barton, I; Grauer, A; Naganathan, V; Seibel, MJ | 1 |
| Kessenich, C | 1 |
| Cyong, JC; Gonsho, A; Ogura, Y; Orimo, H | 2 |
| Hatzigeorgiou, C; Jackson, JL; Tofferi, JK; Wei, GS | 1 |
| Matsumoto, T | 2 |
| Kishimoto, H | 3 |
| Ohta, H | 1 |
| Im, GI; Kenney, J; Qureshi, SA; Rubash, HE; Shanbhag, AS | 1 |
| Borah, B; Chines, A; Chmielewski, PA; Dufresne, TE; Johnson, TD; Manhart, MD | 1 |
| Aihara, E; Kanatsu, K; Kato, S; Okayama, M; Takeuchi, K | 1 |
| Curković, B | 1 |
| Bednarz, P; Burr, DB; Day, JS; Ding, M; Hirano, T; Hvid, I; Johnston, CC; Mashiba, T; Sumner, DR; van der Linden, JC; Weinans, H | 1 |
| Adachi, J; Di Munno, O; Eastell, R; Felsenberg, D; Horlait, S; Jackson, RD; Rizzoli, R; Roux, C; Seeman, E; Songcharoen, S; Valent, D; Watts, NB | 1 |
| Brown, JP; Chines, AA; Hanley, DA; Harris, ST; Li, Z; Watts, NB | 1 |
| Mossetti, G; Nunziata, V; Rendina, D; Sorrentino, M; Viceconti, R | 1 |
| Hershman, D; Narayanan, R | 1 |
| Caldera, A; de Castro, SL; Docampo, R; Garzoni, LR; Meints, GA; Meirelles, Mde N; Oldfield, E; Urbina, JA | 1 |
| Baptista, MM; Britto, CC; de Castro, SL; Docampo, R; Garzoni, LR; Meirelles, Mde N; Oldfield, E; Urbina, JA; Waghabi, MC | 1 |
| Borgstrom, F; Johnell, O; Jonsson, B; Kanis, JA | 1 |
| Fujishima, M; Fujishima, N; Hirokawa, M; Miura, I; Nishimura, H; Sawada, K | 1 |
| Brecht, JG; Felsenberg, D; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A | 1 |
| Saag, KG | 1 |
| Burr, D; Finestone, A; Goldich, Y; Kaufman, S; Kreiss, Y; Liebergall, M; Milgrom, C; Novack, V; Pereg, D; Zimlichman, E | 1 |
| Grieco, KA; Grinspoon, S; Herzog, DB; Klibanski, A; Mickley, D; Miller, KK; Mulder, J; Yehezkel, R | 1 |
| Bray, RC; Doschak, MR; Hanley, DA; Wohl, GR; Zernicke, RF | 1 |
| Ikeda, S; Ito, M; Nakamura, T; Otomo, H; Phipps, RJ; Sakai, A; Tanaka, S | 1 |
| Fukunaga, M; Inoue, T; Itabashi, A; Kaneda, K; Kishimoto, H; Kushida, K; Morii, H; Nawata, H; Ohashi, Y; Orimo, H; Shiraki, M; Yamamoto, K | 1 |
| Adachi, JD; Barton, IP; Cooper, C; Eastell, R; Lindsay, R; Manhart, MD; van Staa, TP; Watts, NB | 1 |
| Ott, S | 1 |
| Marx, J | 1 |
| Boonen, S; Vanderschueren, D | 1 |
| Chines, AA; Goemaere, S; Johnson, TD; Mellström, DD; Roux, C; Sörensen, OH | 1 |
| Chines, A; Johnson, T; Sod, E; Ste-Marie, LG | 1 |
| Barton, IP; Boonen, S; Delmas, P; Eastell, R; El-Hajj Fuleihan, G; McClung, MR | 1 |
| Zizic, TM | 1 |
| Emkey, R | 1 |
| Keller, MI | 1 |
| Adachi, JD | 1 |
| Brecht, JG; Huppertz, E; Kruse, HP; Möhrke, W; Oestreich, A | 1 |
| Nakamura, T | 1 |
| Sarioglu, M; Taneli, F; Tikiz, C; Tuzun, C; Unlu, Z; Uyanik, BS | 1 |
| Kendler, DL; Li, WW | 1 |
| Crail, DJ; Dansereau, RJ | 2 |
| Chauhan, B; Mahadik, K; Paradkar, A; Shimpi, S | 1 |
| Ando, K; Higashi, M; Ichinose, H; Kanaji, A; Nakagawa, M; Namisato, M; Sakamaki, T; Yamada, H; Yato, Y | 1 |
| Clement, M; Delisser, K; Jepsen, KJ; Laudier, D; Li, CY; Nasser, P; Price, C; Schaffler, MB | 1 |
| Bonnick, SL; Broy, S; Chen, E; de Papp, AE; Hochberg, MC; Kagan, R; McClung, M; Miller, P; Petruschke, RA; Rosen, CJ; Thompson, DE | 1 |
| Illgner, U; Lange, U; Schleenbecker, H; Teichmann, J | 1 |
| Abe, E; Fallon, JT; Fisher, EA; Shimshi, M; Zaidi, M | 1 |
| Bonnick, SL; Chen, E; de Papp, AE; Kagan, R; Sebba, AI; Skalky, CS; Thompson, DE | 1 |
| Chang, JT; Wysowski, DK | 1 |
| Aoyagi, K; Hayashi, K; Ito, M; Kawase, M; Nishida, A; Uetani, M | 1 |
| Bigalow-Kern, A; Cambron, RT; Dicks, M; Lester, C; Lubey, G; Redman-Furey, N; Vaughn, D | 1 |
| Iwamoto, J; Kanoko, T; Sato, Y; Satoh, K | 1 |
| Hosking, DJ; Pande, I | 2 |
| Cioffi, M; De Filippo, G; Di Domenico, G; Mossetti, G; Nunziata, V; Postiglione, L; Rendina, D; Viceconti, R | 1 |
| Ho, AY; Ip, TP; Kung, AW; Lee, G; Leung, JY | 1 |
| Chapurlat, RD | 2 |
| Awayda, MS; Orlando, RC; Shao, W | 1 |
| Barger-Lux, J; Recker, RR | 1 |
| Abrahamsen, B; Brixen, KT; Kassem, MS; Mosekilde, L | 1 |
| Christensen, PM; Sørensen, HA; Vestergaard, P | 1 |
| Bouzahzah, B; Jelicks, LA; Morris, SA; Tanowitz, HB; Weiss, LM | 1 |
| Chapurlat, R | 1 |
| Barut, A; Sarikaya, S; Tanriverdi, HA | 1 |
| Akiyama, J; Fujita, H; Muranaka, S; Ogino, T; Utsumi, K; Utsumi, T; Yano, H; Yasuda, T | 1 |
| Barton, IP; Johnell, O; Kanis, JA | 1 |
| Borah, B; Dufresne, TE; Jorgensen, SM; Liu, S; Phipps, RJ; Ritman, EL; Sacha, J; Turner, RT | 1 |
| Beary, JF; Buckland-Wright, JC; Cline, GA; Conaghan, PG; Garnero, P; Meyer, JM; Spector, TD; Valent, DJ | 1 |
| Güliter, S; Keleş, H; Keleş, I; Ozkurt, ZN | 1 |
| Høiseth, A | 1 |
| Colao, A; Doldo, P; Falbo, A; Manguso, F; Mastrantonio, P; Orio, F; Palomba, S; Russo, T; Tauchmanovà, L; Tolino, A; Zullo, F | 1 |
| Brewer, N; Davis, S; De Nigris, E; Jones, ML; Oakley, J; Stevenson, M | 1 |
| Delmas, PD | 1 |
| Orcel, P; Rousière, M | 1 |
| Adachi, JD; Boonen, S; Chesnut, CH; Li, Z; Meredith, MP; Rizzoli, R | 1 |
| Cambron, RT; Hausman, DS; Sakr, A | 1 |
| Perry, CM; White, NJ | 1 |
| Barton, IP; Boonen, S; Laan, RF; Watts, NB | 1 |
| Arai, T; Hayashi, S; Inoue, Y; Sakatani, M; Yamamoto, S | 1 |
| Coward, SM; Finch, MB; Millar, AM; Wright, SA | 1 |
| Dorst, A; Faber, H; Farahmand, P; Ringe, JD | 2 |
| Laudier, DM; Majeska, RJ; Mann, R; Schaffler, MB; Yang Li, C | 1 |
| Armitage, GC; Hsieh, S; Jeffcoat, M; Lane, N; Loomer, P; Majumdar, S; Munoz, T; Wang, HY | 1 |
| McClung, M | 1 |
| Maricic, M | 2 |
| Brennan, O; Kennedy, OD; Lee, TC; O'Brien, FJ | 1 |
| Rackoff, PJ; Sebba, A | 1 |
| Kikuchi, T; Shinoda, H; Sodek, J; Suzuki, K; Takeyama, S; Yamada, S | 1 |
| Barrera, BA; Harris, S; Shakir, SA; Wilton, L | 1 |
| Barton, IP; Heaney, RP; Valent, DJ | 1 |
| Brown, JP; Fraser, W; Hosking, D; Luchi, M; Lyles, K; Mesenbrink, P; Miller, P; Pak, J; Reid, IR; Richardson, P; Saidi, Y; Su, G; Zelenakas, K | 1 |
| Brunner, S; Finsterer, J | 1 |
| Jack, D | 1 |
| Altman, R; Amonkar, MM; Cramer, JA; Hebborn, A | 1 |
| Adami, S; Barton, IP; Bensen, WG; Cline, GA; Cohen, SB; Hosterman, MA; Pavelka, K | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Takeda, T; Yamada, H | 1 |
| Burr, DB; Hui, S; Johnston, CC; Mashiba, T; Mori, S; Turner, CH | 1 |
| Fujii, N; Hamano, T; Imai, E; Isaka, Y; Ito, T | 1 |
| Poole, KE; Reeve, J; Warburton, EA | 1 |
| Ijiri, S | 2 |
| García, LL; Muñoz, VL; Roger, DR; Valle, MB | 1 |
| Amzel, LM; Docampo, R; Gabelli, SB; McLellan, JS; Montalvetti, A; Oldfield, E | 1 |
| Barton, IP; Felsenberg, D; Geusens, P; Watts, NB | 1 |
| Barton, IP; Boonen, S; Burgio, DE; Dunlap, LE; Miller, PD; Roux, C | 1 |
| Chesnut, CH; Gass, ML; Hamdy, RC; Holick, MF; Leib, ES; Lewiecki, ME; Maricic, M; Watts, NB | 1 |
| Christoffersen, H; Holmegaard, SN | 1 |
| Chauhan, B; Mahadik, KR; Paradkar, A; Shimpi, S | 1 |
| Orcel, P | 1 |
| Liel, Y | 2 |
| De Filippo, G; Mossetti, G; Rendina, D | 1 |
| Dogru, T; Genc, H; Sonmez, A; Tasci, I | 1 |
| D'Emden, M; Ebeling, PR; Ernst, TF; Graham, JJ; Hooper, MJ; Nicholson, GC; Roberts, AP; Wenderoth, D | 1 |
| Füessl, HS | 1 |
| Henderson, S; Hoffman, N; Prince, R | 1 |
| Hosking, D | 1 |
| Siris, ES | 1 |
| Blackshaw, PE; Dansereau, RJ; Fairbairn, KJ; Frier, M; Hosking, D; Kinghorn, T; Perkins, AC; San, P; Spiller, RC | 1 |
| Dobnig, H; Fahrleitner-Pammer, A; Hofbauer, LC; Obermayer-Pietsch, B; Viereck, V | 1 |
| Delaney, MF | 1 |
| Takada, J | 1 |
| Aurich-Barrera, B; Harris, S; Shakir, SA; Wilton, L | 1 |
| Chen, L; Deng, X; Li, Y; Zhang, Z | 1 |
| Richmond, BK | 1 |
| Scully, C | 1 |
| Allison, J; Curtis, JR; Freeman, A; Kovac, SH; Saag, KG; Westfall, AO | 1 |
| Corners, J; Doi, K; Fukao, A; Komatsu, Y; Majima, T; Morimoto, T; Nakao, K; Shigemoto, M; Takagi, C | 1 |
| Lespessailles, E; Reach, G; Thomas, T | 1 |
| Delmas, PD; Emkey, R; Epstein, S; Hiltbrunner, V; Schimmer, RC; Wilson, KM | 1 |
| Cao, R; Goddard, A; Oldfield, E; Yin, F; Zhang, Y | 1 |
| Hillman, JJ; Lee, E; Wutoh, AK; Xue, Z; Zuckerman, IH | 1 |
| Khapra, AP; Rose, S | 1 |
| Dawson-Hughes, B; Gass, M | 1 |
| Boonen, S; Borgström, F; Burge, R; Carlsson, A; Haentjens, P; Johnell, O; Jönsson, B; Kanis, JA; Sintonen, H | 1 |
| Doukova, P; Kinov, P; Leithner, A; Tivchev, P | 1 |
| Borah, B; Chmielewski, PA; Dufresne, TE; Jorgensen, SM; Liu, S; Phipps, RJ; Ritman, EL; Sibonga, JD; Turner, RT; Zhou, X | 1 |
| Ikeda, K; Ito, M; Konaka, A; Maruyama, T; Nakayama, K; Sakata, K | 1 |
| Burr, DB; Miller, LM; Ruppel, ME | 1 |
| Ebetino, FH; Hulley, PA; Meijer, A; Roelofs, AJ; Russell, RG; Shipman, CM | 1 |
| Naunton, M | 1 |
| Franke, HR; Verdijk, R; Vermes, I; Wolbers, F | 1 |
| Bonnick, S; Burnett, SM; Chen, E; de Papp, AE; Hochberg, M; Kagan, R; Kiel, DP; McClung, M; Saag, KG; Sebba, A; Thompson, DE | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Shen, CL; Takeda, T; Yamada, H; Yeh, JK | 2 |
| Aldrich, W; Harris, KW; Merrell, MA; Millender-Swain, T; Selander, KS; Triozzi, P; Wakchoure, S | 1 |
| Erkens, JA; Goettsch, WG; Herings, RM; Penning-van Beest, FJ | 1 |
| Dunford, JE; Ebetino, FH; Guo, K; Kavanagh, KL; Knapp, S; Oppermann, U; Rogers, MJ; Russell, RG; Wu, X | 1 |
| Agrawal, S; Binkley, NC; Drinka, PJ; Engelke, JA; Krause, PF; Krueger, DC; Nest, LJ | 1 |
| Troen, BR | 1 |
| Bivi, N; Deganuto, M; Moro, L; Pines, A; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Batur, O; Ilter, E; Karalok, H; Tufekci, EC | 1 |
| Iwamoto, J; Sato, Y; Takeda, T | 2 |
| Balooch, G; Balooch, M; Jiang, Y; Kinney, J; Lane, NE; Nalla, RK; Wronski, TJ; Yao, W | 1 |
| Allison, JJ; Curtis, JR; Freeman, A; Saag, KG; Westfall, AO | 1 |
| Hochberg, MC; Rizzoli, R | 1 |
| Neumaier, J | 1 |
| Allen, MR; Burr, DB; Iwata, K; Phipps, R | 1 |
| Lobaugh, B; Lyles, KW; Whitson, HE | 1 |
| Fujii, N; Hamano, T; Horio, M; Imai, E; Isaka, Y; Ito, T; Moriyama, T; Nagasawa, Y; Okada, N | 1 |
| Bezerra, MM; Carvalho, AP; Cunha, FQ; Girão, VC; Rocha, FA | 1 |
| Boccuzzi, SJ; Downey, TW; Foltz, SH; Kahler, KH; Omar, MA | 1 |
| Burr, DB; Follet, H; Iwata, K; Li, J; Phipps, RJ | 1 |
| Durchschlag, E; Fratzl, P; Hofstaetter, JG; Klaushofer, K; Paschalis, EP; Phipps, R; Roschger, P; Zoehrer, R | 1 |
| Adachi, J; Blackhouse, G; Goeree, R | 1 |
| Carrero-Lérida, J; Estévez, AM; González-Pacanowska, D; Jiménez, C; Ortiz-Gómez, A; Ruiz-Pérez, LM | 1 |
| Bingham, CO; Buckland-Wright, JC; Messent, EA; Tonkin, C; Ward, RJ | 1 |
| Khong, JJ | 1 |
| Iwamoto, J; Sato, Y; Seki, A; Takeda, T; Yamada, H; Yeh, JK | 3 |
| Aerts, K; Bridts, CH; Cos, P; De Clerck, LS; De Tollenaere, CB; Dombrecht, EJ; Ebo, DG; Schuerwegh, AJ; Stevens, WJ; Van Offel, JF | 1 |
| Ando, K; Higashi, M; Kanaji, A; Namisato, M; Nishio, M; Yamada, H | 1 |
| Andol, G; Cambron, RT; Dicks, M; Lester, C; Lubey, G; Poiesz, K; Redman-Furey, N; Vaughn, D | 1 |
| Möller, G; Ringe, JD; van der Geest, SA | 1 |
| Krane, SM | 1 |
| Fukunaga, M; Itabashi, A; Kishimoto, H; Kushida, K; Nakamura, T; Nawata, H; Ohashi, Y; Ohta, H; Shiraki, M; Takaoka, K | 1 |
| Takata, S | 1 |
| Langdahl, B; Mosekilde, L; Vestergaard, P | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Iori, N; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Sinigaglia, L | 1 |
| Durchschlag, E; Fratzl, P; Klaushofer, K; Paschalis, EP; Phipps, R; Recker, R; Roschger, P; Zoehrer, R | 1 |
| Carter, JD; Cruse, LM; Valeriano, J; Vasey, FB | 1 |
| Brown, JP; Curiel, MD; Devogelaer, JP; Eriksen, EF; Fashola, T; Fraser, WD; Hooper, M; Hosking, D; Lyles, K; Miller, P; Pak, J; Reid, IR; Saidi, Y; Su, G; Zelenakas, K | 1 |
| Allen, MR; Burr, DB; Follet, H; Khurana, M; Sato, M | 1 |
| Higashi, K; Hyodo, N; Hyodo, T; Imakiire, T; Kikuchi, Y; Kushiyama, T; Miura, S; Saigusa, T; Suzuki, S; Yamada, M; Yamamoto, K | 1 |
| Bhattacharya, RK; Brufsky, A; Greenspan, SL; Sereika, SM; Vogel, VG | 1 |
| Basir, YJ; Briscoe, C; Kafonek, C; Lapko, VN; Lee, JW; Olsen, R; Zhu, LS | 1 |
| Ginai, AZ; Pols, HA; Zillikens, MC | 1 |
| Saha, PK; Takahashi, M; Wehrli, FW | 1 |
| Adami, S; Beary, JF; Bingham, CO; Buckland-Wright, JC; Clauw, DJ; Cline, GA; Cohen, SB; Dougados, M; Garnero, P; Meyer, JM; Pelletier, JP; Raynauld, JP; Simon, LS; Spector, TD; Strand, V | 1 |
| Bornstein, MM; Buser, D; Oberli, K; Stauffer, E | 1 |
| Suzuki, Y | 1 |
| Iwamoto, J; Sato, Y; Shen, CL; Takeda, T; Yeh, JK | 2 |
| Delmas, PD; Lange, JL; Lindsay, R; Silverman, SL; Watts, NB | 2 |
| Fujii, N; Hamano, T; Hori, M; Horio, M; Imai, E; Isaka, Y; Ito, T; Mikami, S; Moriyama, T; Nagasawa, Y | 1 |
| Adachi, JD; Beattie, K; Bobba, RS; Kumbhare, D; Parkinson, B | 1 |
| Brandi, ML; Gaines, KA; Hosking, D; Kendler, D; Marques-Neto, JF; Melton, ME; Reid, DM; Verbruggen, N; Wark, JD; Weryha, G | 1 |
| Briot, K; Roux, C; Thomas, T; Trémollières, F | 1 |
| Ashman, SG; Brooks, JK; Gilson, AJ; Nikitakis, NG; Schwartz, KG; Sindler, AJ | 1 |
| Fadillioglu, E; Kaya, H; Ozgocmen, S; Yilmaz, Z | 1 |
| Burr, DB; Condon, K; Follet, H; Hui, S; Li, J; Phipps, RJ | 1 |
| Cahall, D; Delmas, PD; Eastell, R; Grauer, A; Pols, HA; Ringe, JD; Roux, C; Vrijens, B; Watts, NB | 1 |
| Kamaguchi, R; Kataoka, M; Kokubo, H; Kozaki, T; Masaoka, Y; Sakuma, S; Tanno, FK; Yamashita, S | 1 |
| Gold, DT; Iolascon, G; Jodar, E; Keen, R; Kruse, HP; Mann, B; Varbanov, A | 1 |
| Gold, DT; Safi, W; Trinh, H | 2 |
| Botsis, D; Christodoulakos, G; Lambrinoudaki, I | 1 |
| Chen, SH; Chen, YJ; Hall, BJ; Khan, MA; Kung, AW; Mirasol, R; Pasion, EG; Shah, GA; Sivananthan, SK; Tam, F; Tay, BK; Thiebaud, D | 1 |
| Iba, K; Imoto, K; Takada, J; Yamashita, T | 1 |
| Phillips, MB | 1 |
| Arnold, M; Avorn, J; Brookhart, MA; Finkelstein, JS; Katz, JN; Mogun, H; Patrick, AR; Polinski, JM; Solmon, DH | 1 |
| Halbekath, JM; Meyer, G; Mühlhauser, I; Schenk, S; von Maxen, A | 1 |
| Honda, Y; Iwamoto, J; Sato, Y | 2 |
| Kyriakides, D; Panderi, I | 1 |
| Sato, S | 1 |
| Iwamoto, J; Sato, Y; Takeda, T; Yeh, JK | 1 |
| Epstein, S | 1 |
| Felson, DT; Kim, YJ | 1 |
| Altintaş, F; Beyzadeoğlu, T; Eren, A; Güven, M; Ozkut, AT | 1 |
| Beirne, JC; Khosa, AD; Nayyar, MS | 1 |
| Akçay, A; Bavbek, N; Inegöl, I; Kanbay, M; Turgut, FH; Uz, E; Yanik, B; Yanik, T | 1 |
| Bunyaratavej, N | 1 |
| Fuji, T; Masuhara, K; Nakai, T; Seino, Y; Yamaguchi, K; Yamasaki, S | 1 |
| Campistol, JM; Diekmann, F; Fuster, D; Oppenheimer, F; Pedroso, S; Rubí, S; Torregrosa, JV | 1 |
| Denk, E; Fattinger, K; Häuselmann, HJ; Hillegonds, D; Hurrell, RF; Kraenzlin, M; Vogel, J; Walczyk, T | 1 |
| Giljević, Z; Vlak, T | 1 |
| Díaz-Curiel, M; Moro Alvarez, MJ | 1 |
| Fratzl, P; Fratzl-Zelman, N; Klaushofer, K; Paschalis, EP; Phipps, R; Roschger, P | 1 |
| Malden, NJ; Pai, AY | 1 |
| Jojima, H; Kinoshita, K; Naito, M | 1 |
| Camm, J; Karam, R; McClung, M | 1 |
| Akasaka, E; Kamatari, M; Koto, S; Ozawa, N; Sakota, K; Suzuki, Y; Urao, C; Yanagimoto, K | 1 |
| Broulík, P; Necas, E; Pelichovská, T; Sefc, L | 1 |
| Allen, MR; Burr, DB | 1 |
| Blanton, C; Jee, WS; Lundy, MW; Phipps, R; Setterberg, RB; Su, M; Tian, X; Yao, W; Zhang, Q | 1 |
| Civitelli, R; Emkey, R; Strampel, W | 1 |
| Abram, F; Beary, JF; Berthiaume, MJ; Choquette, D; Cline, GA; Haraoui, B; Martel-Pelletier, J; Meyer, JM; Pelletier, JP; Raynauld, JP | 1 |
| Fugazzotto, PA; Jaffin, R; Kumar, A; Lightfoot, WS | 1 |
| Hawker, G; Kopp, A; Mamdani, M | 1 |
| Ichimura, A; Iwata, H; Nakajima, T; Ochiai, H; Takagi, H; Toriyama, T; Tsuchiya, H; Yamada, S | 1 |
| Douchi, T; Iwamoto, I; Kosha, S; Rai, Y; Sagara, Y; Yonehara, Y | 1 |
| Rizzoli, R | 1 |
| Christodoulakos, GE; Marín, F; Mellström, D; Nickelsen, T; Pavo, I; Petto, H; Ringe, JD | 1 |
| Nakayama, H | 1 |
| Noguchi, Y; Saito, Y; Shibata, T; Suyama, K; Tanaka, T; Tatsuno, I; Yoshida, T | 1 |
| Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, PD; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR | 1 |
| Klaushofer, K; Koller, B; Muschitz, C; Patsch, J; Pollhammer, I; Resch, H; Roschger, P | 1 |
| Campbell, MJ; Delmas, PD; Eastell, R; Garnero, P; Hannon, RA | 1 |
| Chines, A; Grauer, A; McClung, MR; McKeever, CD; Olszynski, WP; Watts, NB; Zhou, X | 1 |
| Reginster, JY | 1 |
| Bernabei, P; Brianza, SZ; Cristofaro, MA; D'Amelio, P; Di Bella, S; Grimaldi, A; Isaia, G; Pescarmona, GP; Ravazzoli, MG; Tamone, C | 1 |
| Barton, IP; Grauer, A; McClung, MR; Simon, JA; Siris, ES | 1 |
| Ager, JW; Balooch, G; Balooch, M; Lane, NE; Nalla, RK; Porter, AE; Ritchie, RO; Yao, W | 1 |
| Burgio, DE; Cahall, DL; Cline, GA; Racewicz, AJ; Schofield, PJ | 1 |
| Baron, R; Coxon, F; Dunford, JE; Ebetino, FH; Kashemirov, BA; Marma, MS; McKenna, CE; Russell, RG; Stewart, C; Triffitt, JT; Xia, Z | 1 |
| Aronstein, WS; Beary, JF; Bingham, CO; Christiansen, C; Cline, GA; Cohen, SB; Conaghan, PG; Garnero, P; Meyer, JM | 1 |
| Bertoldo, F; Dalle Carbonare, L; Fassina, A; Giannini, S; Lo Cascio, V; Realdi, G; Sella, S; Turco, G; Valenti, MT; Zordan, S | 1 |
| Adachi, JD; Grima, DT; Papaioannou, A; Pasquale, MK; Thompson, MF | 1 |
| Cillo, JE; Marx, RE; Ulloa, JJ | 1 |
| Audran, M; Baslé, MF; Blouin, S; Chappard, D; Libouban, H; Moreau, MF | 1 |
| Farrerons-Minguella, J; Halse, J; Kröger, H; Maroni, M; Mulder, H; Muñoz-Torres, M; Sääf, M; Snorre Øfjord, E; Välimäki, MJ | 1 |
| Ishizaka, K; Kanbe, N; Kitahara, S; Kobayashi, S; Machida, T; Yoshida, K | 1 |
| Ma, KM; Mok, CC; Siu, YP; To, CH; Tong, KH | 1 |
| Adachi, JD; Bobba, R | 1 |
| Boyd, SK; Doschak, MR; MacNeil, JA; Zernicke, RF | 1 |
| Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, RR; Tlustochowicz, W; Zanchetta, J | 1 |
| Alva, D; Cesareo, R; Contini, S; De Rosa, B; Iozzino, M; Lauria, A; Mallardo, L; Napolitano, C; Orsini, A; Reda, G | 1 |
| Allen, MR; Burr, DB; Delmas, PD; Gineyts, E; Leeming, DJ | 1 |
| Ding, H; Ito, M; Koinuma, N; Monma, Y; Stevenson, M | 1 |
| Itabashi, A | 1 |
| Oshima, H; Tanaka, I | 1 |
| Nakamura, T; Narusawa, K | 1 |
| Soen, S | 2 |
| Mukherjee, S; Oldfield, E; Song, Y | 1 |
| Abe, Y; Fukao, A; Ishikawa, H | 1 |
| Díaz Curiel, M; Díez Pérez, A; Farrerons Minguella, J; Filgueira Rubio, J; Gómez Alonso, C; González Macías, J; Hernández Hernández, D; Mellibovsky Saidler, L; Nogués Solán, X; Sosa Henríquez, M | 1 |
| Abelson, A | 1 |
| Boucher, M; Coyle, D; Cranney, A; Peterson, J; Robinson, V; Shea, B; Tugwell, P; Wells, G | 1 |
| Morishita, M; Nagashima, M; Takahashi, H; Takenouchi, K; Wauke, K | 1 |
| Bab, S; Hayakawa, K; Hyodo, T; Iwamura, M; Kimura, M; Matsumoto, K; Okazaki, M; Satoh, T; Soh, S; Tabata, K; Tsuboi, T; Yokoyama, E | 1 |
| González Macías, J; Hernández Hernández, JL; Martínez García, J; Olmos Martínez, JM | 1 |
| Katayama, K; Matsuno, T | 1 |
| Anastasilakis, AD; Avramidis, A; Gerou, S; Goulis, DG; Kita, M; Koukoulis, G; Polyzos, SA | 1 |
| Adami, S; Agnusdei, D; Gentilella, R; Isaia, G; Luisetto, G; Minisola, S; Nuti, R; Silvestri, S; Sinigaglia, L | 1 |
| Nagae, Y; Saitoh, E; Seyama, Y; Wachi, H | 1 |
| Brandi, ML; Hosking, D; Hustad, CM; Kendler, D; Mahlis, EM; Marques-Neto, JF; Melton, ME; Reid, DM; Verbruggen, N; Wark, JD; Weryha, G | 1 |
| Coxon, FP; Ebetino, FH; Roelofs, AJ; Rogers, MJ; Thompson, K | 1 |
| Crail, DJ; Dansereau, RJ; Perkins, AC | 1 |
| Anić, B | 1 |
| Erkens, JA; Herings, RM; Olson, M; Penning-van Beest, FJ | 1 |
| Cetin, A; Dane, B; Dane, C; Erginbas, M | 1 |
| Iwamoto, J; Matsumoto, H; Takeda, T | 1 |
| Khan, A | 1 |
| Fukao, A; Komatsu, Y; Majima, T; Matsumura, T; Nakao, K; Ninomiya, K; Satoh, N; Shimatsu, A | 2 |
| Anastasilakis, AD; Avramidis, A; Efstathiadou, Z; Gerou, S; Goulis, DG; Kita, M; Koukoulis, GN; Polyzos, SA | 1 |
| Bhattacharya, R; Brufsky, A; Greenspan, SL; Lembersky, BC; Perera, S; Sereika, SM; Vogel, VG; Vujevich, KT | 1 |
| Barnett, BL; Deprèle, S; Ebetino, FH; Evdokimov, A; Hogan, JM; Kashemirov, BA; McKenna, CE | 1 |
| Gärtner, R | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Blouin, J; Dragomir, A; Fernandes, JC; Moride, Y; Perreault, S; Ste-Marie, LG | 1 |
| Adams, JS; Geller, JL; Hu, B; Mirocha, J; Reed, S | 1 |
| Burr, DB; Fuchs, RK; Phipps, RJ | 1 |
| Ikeda, H; Ishijima, M; Kawasaki, T; Kim, SG; Kubota, M; Kurosawa, H; Osawa, A; Takazawa, Y | 1 |
| Boaz, M; Cernes, R; Fux, A; Gavish, D; Luckish, A; Matas, Z; Shargorodsky, M | 1 |
| Bhattacharya, R; Greenspan, SL; Perera, S; Sereika, SM; van Londen, GJ; Vujevich, KT | 2 |
| Hosoda, N; Ishii, M; Iwasaki, T; Nakamura, S; Takei, K; Yokota, Y | 1 |
| Iwamoto, J; Liu, X; Matsumoto, H; Sato, Y; Takeda, T; Yeh, JK | 1 |
| Carrascal, MT; de la Piedra, C; Díaz-Curiel, M; Gómez, S; Lefort, M; Montero, M; Phipps, RJ; Romero, FI | 1 |
| Adami, S; Bianchi, G; Di Munno, O; Fiore, CE; Giannini, S; Minisola, S; Rossini, M; Sinigaglia, L | 1 |
| Atherton, CT; Blackshaw, PE; Dansereau, RJ; Hay, PD; Lawes, SC; Perkins, AC; Schnell, DJ; Spiller, RC; Wagner, LK | 1 |
| Brookler, KH | 2 |
| Kim, KJ; Nguyen, TN | 1 |
| Blackburn, GM; Brown, RJ; Carran, J; Hounslow, AM; Rejman, D; Watts, DJ | 1 |
| Allen, MR; Burr, DB; Fyhrie, DP; Jeremić, B; Lavernia, EJ; Wang, X | 1 |
| Ivaska, KK; Kumm, J; Rohtla, K; Tamm, A; Vaananen, K | 1 |
| Martens, MG; Shaw, H | 1 |
| Iizuka, T; Matsukawa, M | 1 |
| Fratzl, P; Klaushofer, K; Phipps, R; Roschger, P; Ruffoni, D; Weinkamer, R | 1 |
| Adachi, J; Bilezikian, JP; Boonen, S; Delmas, PD; Greenspan, SL; Lang, TF; Lindsay, R; Luckey, M; Meeves, S; Miller, PD; Saag, K; Seeman, E; Watts, NB | 1 |
| Díaz-Curiel, M; Moro-Alvarez, MJ | 1 |
| Kanzaki, S; Matsuo, K; Ogawa, K; Takada, Y | 1 |
| Geusens, PP; Lems, WF | 1 |
| Hochberg, MC | 1 |
| Cuzick, J | 1 |
| Capitelli, F; Margiotta, N; Natile, G; Ostuni, R | 1 |
| Burge, RT; Lindsay, R; Marshall, DA; Tosteson, AN | 1 |
| Aouam, K; Belhadjali, H; Slim, R; Youssef, M; Zili, J | 1 |
| Beck, TJ; Bonnick, SL; Cosman, F; de Papp, AE; Hochberg, MC; Wang, H | 1 |
| Ayas, B; Cetinkaya, BO; Gurgor, P; Keles, GC | 1 |
| Silverman, SL | 1 |
| Lakhotia, SM | 1 |
| Olson, M; Rietbrock, S; van Staa, TP | 1 |
| Hatakeyama, N; Iba, K; Ozasa, Y; Takada, J; Wada, T; Yamashita, T | 1 |
| Allen, MR; Burr, DB; Phipps, R; Tang, SY; Vashishth, D | 1 |
| Bijlsma, A; Blokzijl, H; Vecht, J | 1 |
| Abe, Y; Li, J; Masuda, K; Muehleman, C; Pfister, B; Phipps, R; Sah, RL | 1 |
| Coulton, L; Croucher, PI; Ebetino, FH; Lawson, MA; Vanderkerken, K | 1 |
| Cheng, H; Curtis, JR; Delzell, E; Saag, KG; Westfall, AO | 1 |
| Clézardin, P; Daubiné, F; Ebetino, FH; Fournier, PG; Lundy, MW; Rogers, MJ | 1 |
| Busse, C; Cheng, Z; Lane, NE; Pham, A; Ritchie, RO; Yao, W; Zimmermann, EA | 1 |
| Verhaar, HJ | 1 |
| Bennani, A; El Wady, W; Rerhrhaye, W; Soualhi, H | 1 |
| Barbeau, M; Kindundu, CM; LeLorier, J; Sheehy, O | 1 |
| Giljević, Z | 1 |
| Bala, JL; Chen, X; Coxon, FP; Ebetino, FH; Kashemirov, BA; McKenna, CE; Roelofs, AJ; Rogers, MJ; Russell, RG; Xia, Z | 1 |
| Fontanella, V; Mahl, CR | 1 |
| Boonen, S; Delmas, PD; Eusebio, R; Orwoll, ES; Stoner, KJ; Wenderoth, D | 1 |
| Atherton, PJ; Carlson, MD; Chottiner, E; Hines, SL; Loprinzi, CL; Mincey, BA; Perez, EA; Salim, M; Sloan, JA; Thomas, SP | 1 |
| Bruyère, O; Burlet, N; Cooper, C; Delmas, PD; Reginster, JY; Rizzoli, R | 1 |
| Blouin, J; Dragomir, A; Fernandes, JC; Fredette, M; Perreault, S; Ste-Marie, LG | 1 |
| Okazaki, R | 1 |
| Foo, AC; Glendenning, P; Inderjeeth, CA; Lai, MM | 1 |
| Albagha, OM; Kruk, M; Ralston, SH | 1 |
| Stepan, JJ; Zikan, V | 1 |
| Ohbayashi, H | 1 |
| Bilezikian, JP | 1 |
| Brookler, K | 1 |
| Fujii, Y; Fujita, T; Miyauchi, A; Ohue, M; Takagi, Y | 1 |
| Garcia, I; Hernández, G; Herrero, A; Rivera, B; Sobrino, JA; Tamimi, F; Torres, J | 1 |
| Bereszczak, JZ; Bivi, N; Brancia, FL; Delneri, D; Moro, L; Quadrifoglio, F; Romanello, M; Tell, G; Zeef, LA | 1 |
| Geusens, P | 1 |
| Cheung, M; Glorieux, FH; Land, C; Munns, CF; Rauch, F | 1 |
| Douglas, I; Grosso, A; Hingorani, A; MacAllister, R; Smeeth, L | 1 |
| Brookhart, MA; Cadarette, SM; Katz, JN; Levin, R; Solomon, DH; Stedman, MR; Stürmer, T | 1 |
| Adachi, JD; Ioannidis, G; Kennedy, CC; Leslie, WD; Papaioannou, A; Walker, V | 1 |
| Kashima, I; Kawamata, R; Kozai, Y; Matsumoto, Y; Mikuni-Takagaki, Y; Miyagawa, K; Naruse, K; Sakurai, T; Wakao, H | 1 |
| Allen, MR; Burr, DB; Erickson, AM; Hazelwood, SJ; Martin, RB; Wang, X | 2 |
| Delmas, PD; Kendler, DL; Ringe, JD; Ste-Marie, LG; Taylor, EB; Vrijens, B | 1 |
| Cakir, T; Ciftci, IH; Dundar, U; Evcik, D; Kavuncu, V; Solak, O | 1 |
| Levy, S; Odvina, CV; Rao, DS; Rao, S; Zerwekh, JE | 1 |
| Beary, JF; Brown, JP; Burgio, DE; Darbie, LM; Matzkin, E; Racewicz, AJ; Ste-Marie, LG | 1 |
| Blumentals, WA; Cole, RE; Harris, ST; Huang, L; Silverman, SL | 1 |
| Argyropoulou, MI; Botzoris, VG; Drosos, AA; Voulgari, PV; Zikou, AK | 1 |
| Ayogu, N; Bouxsein, ML; Chacko, AT; Rozental, TD; Vazquez, MA | 1 |
| Amling, M; Fardellone, P; Kruse, HP; Möller, G; Ringe, JD; van der Geest, SA | 1 |
| Bilezikian, JP; Gennari, L | 1 |
| Devogelaer, JP; Fashola, T; Ferreira, A; Hartl, F; Lau, CS; Mesenbrink, P; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN | 1 |
| Chen, JT; Zhong, ZM | 1 |
| Izumi, K; Kadono, Y; Koh, E; Maeda, Y; Miwa, S; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K; Takashima, M | 1 |
| Bachmann, GA; Binkley, N; Derman, RJ; Greenwald, M; Kohles, JD; Martens, MG; Silverman, SL | 1 |
| Baytur, Y; Demir, BC; Gumuser, G; Inceboz, U; Ozbilgin, K; Uyar, Y | 1 |
| Harada, A; Sumi, Y; Takagi, Y | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Tadeda, T; Yeh, JK | 1 |
| Möller, G; Ringe, JD | 1 |
| Hagino, H | 1 |
| Croucher, PI; Ding, M; Ebetino, FH; Gallagher, O; Hald, A; Hansen, RR; Heegaard, AM; Kassem, M; Thomsen, MW | 1 |
| Goss, A; Hughes, T; Kunchur, R; Need, A | 1 |
| Greiner, RA; Krieg, MA; Lamy, O; Wasserfallen, JB | 1 |
| Hu, SJ; Ye, Y | 1 |
| Atherton, PJ; Dakhil, SR; Dentchev, T; Dueck, AC; Flynn, PJ; Fuloria, J; Kearns, AE; Loprinzi, CL; Northfelt, DW; Rowland, KM | 1 |
| Frampton, JE | 1 |
| Bell, A; Brooklyn, TN; Creed, TJ; Fraser, WD; Kriel, MH; Linehan, J; Lockett, M; Probert, CS; Przemioslo, R; Smithson, JE; Tobias, JH | 1 |
| Rackoff, P | 1 |
| Akiyoshi, T; Anami, S; Matsuyama, K; Matzno, S; Nakabayashi, T; Nishiguchi, T | 1 |
| Ito, M; Mihara, M; Miyabe, S; Nakano, T; Shiraishi, A; Umakoshi, Y | 1 |
| Borgström, F; Coelho, J; Johansson, H; Kanis, JA; McCloskey, EV; Oden, A; Ström, O | 1 |
| Bae, JM; Cho, HJ; Choi, MK; Chun, CH; Han, JK; Hong, GY; Juhng, SK; Kim, HS; Kim, JJ; Kim, JW; Kim, JY; Kim, KJ; Kim, KM; Kwak, HB; Lee, MS; Oh, J; Park, BH; Shin, YI; Yoon, KH | 1 |
| Ahmed, F; Bishop, N; Campbell, M; Chapman, S; Eastell, R; Hall, C; Harrison, R; Hill, C; Knowles, E; Rigby, A; Shaw, N; Sprigg, A | 1 |
| Borah, B; Bouxsein, M; Chmielewski, P; Dufresne, T; Lundy, M; Nurre, J; Phipps, R; Seeman, E; Wagner, L; Zebaze, R | 1 |
| Barnes, S; Boris, ME; Jackson, GS; Martin, BR; McCabe, GP; McCabe, LD; Nolan, JR; Peacock, M; Reinwald, S; Weaver, CM | 1 |
| Göke, B; Ihrler, S; Kolligs, FT; Winkler-Budenhofer, UC | 1 |
| Jung, ST; Kim, YK; Xin, ZF | 1 |
| Keel, C; Kraenzlin, CA; Kraenzlin, ME; Meier, C; Müller, B | 1 |
| Asano, S; Itoh, M; Suzuki, A | 1 |
| Atmani, H; Benkirane-Jessel, N; Clézardin, P; Cortial, D; Daubiné, F; Haïkel, Y; Ladam, G; Voegel, JC | 1 |
| Bruyère, O; Hiligsmann, M; Reginster, JY | 1 |
| Abelson, A; Gold, DT; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Bivi, N; Bonetti, A; Clarke, I; Delneri, D; Harrison, R; Hoyle, DC; Moro, L; Ortolani, F; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Bateman, TA; Bourland, JD; Livingston, EW; Robbins, ME; Smith-Sielicki, H; Tirado-Lee, L; Willey, JS | 1 |
| Chandra, M; Go, AS; Gordon, NP; Hui, RL; Hutchinson, M; Lathon, PV; Lo, JC; Martin, D; McCloskey, CA; O'Ryan, FS; Sanchez, G; Selby, JV; Silver, P; Staffa, JA; Willy, M; Yang, J | 1 |
| Borah, B; Chevalier, Y; Gross, G; Lang, T; Quek, E; Stewart, J; Zysset, P | 1 |
| Berg, K; Gross, GJ; Kupzyk, K; Lindsey, AM; Moore, TE; Ott, CD; Twiss, JJ; Waltman, NL | 1 |
| Byun, DW; Choi, WH; Chung, DJ; Chung, HY; Chung, YS; Kang, MI; Kim, GS; Kim, YK; Kwon, NH; Lee, IK; Lee, YS; Lim, SK; Min, YK; Park, IH; Park, JH; Shin, CS; Shong, MH; Yoon, HK | 1 |
| Epstein, S; Jeglitsch, M; McCloskey, E | 1 |
| Glickman, G; He, J; Hsiao, A | 1 |
| Allen, MR; Burr, DB; Feher, A; Fuchs, RK; Koivunemi, A; Koivunemi, M; Phipps, RJ; Reinwald, S | 1 |
| Barnett, BL; Dunford, JE; Ebetino, FH; Lawson, MA; Locklin, RM; Phipps, RJ; Russell, RG; Triffitt, JT; Xia, Z | 1 |
| Allen, MR; Boskey, AL; Burr, DB; Gourion-Arsiquaud, S; Tang, SY; Vashishth, D | 1 |
| Kim, DY; Kwon, YD; Ohe, JY; Walter, C; Yoo, JY | 1 |
| Abdelmoula, J; Bahlous, A; Bouzid, K; Sahli, H; Sallami, S | 2 |
| Geusens, P; Masud, T; McClung, M | 1 |
| Hino, S; Imaizumi, K; Murakami, T; Ochiai, K; Saito, A; Sekiya, H; Tsumagari, K | 1 |
| Akazawa, T; Aoki, Y; Eguchi, Y; Inoue, G; Kinoshita, T; Kishida, S; Murata, Y; Nakagawa, K; Nakamura, J; Ochiai, N; Ohtori, S; Orita, S; Suzuki, M; Takahashi, K; Takaso, M; Yamashita, M; Yamauchi, K | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Oizumi, T; Sugawara, S; Yamaguchi, K | 1 |
| Apffelstaedt, JP; Barlow, D; Campone, M; Clack, G; Eastell, R; Hannon, RA; Mackey, JR; Makris, A; Van Poznak, C | 1 |
| Bolland, MJ; Gamble, GD; Grey, AB; Reid, IR | 1 |
| Dobbins, EK; Duvall, CA; Gates, BJ; Sonnett, TE | 1 |
| Barbier, S; Beard, MK; Chen, E; de Papp, AE; Rosenberg, E; Stovall, DW | 1 |
| Berto, P; Lopatriello, S; Maggi, S; Noale, M | 1 |
| Endo, Y; Funayama, H; Kawamura, H; Kumamoto, H; Kuroishi, T; Oizumi, T; Sasaki, K; Sugawara, S; Takahashi, H; Yamaguchi, K; Yamamoto, M; Yokoyama, M | 1 |
| Hashimoto, J; Takata, S; Yoh, K; Yoshimura, N | 1 |
| Hayashi, T; Hisahara, S; Hozuki, T; Imai, T; Matsumura, A; Shimohama, S; Suzuki, S; Toyoshima, T; Tsuda, E; Yamamoto, D; Yamauchi, R | 1 |
| Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T | 1 |
| Henry, C; Jahnke, W | 1 |
| Zhang, L | 1 |
| Hosoi, T; Okano, T; Shiraki, M; Shiraki, Y; Tsugawa, N; Yamazaki, Y | 1 |
| Boonen, S; Klemes, AB; Lindsay, R; Zhou, X | 1 |
| Bravo, J; Burgos, D; Fuster, D; García, S; Gentil, MA; Guirado, L; Marcen, R; Monegal, A; Muxí, A; Torregrosa, JV; Zarraga, S | 1 |
| Bala, JL; Baron, RA; Błazewska, KM; Coxon, FP; Dunford, JE; Ebetino, FH; Kashemirov, BA; Kirsten, ML; Lundy, MW; Mallard-Favier, I; Marma, MS; McKenna, CE; Rogers, MJ; Rojas, J; Seabra, MC; Stewart, CA | 1 |
| Antonopoulou, Z; Dafni, U; Gogas, H; Kalogerakos, K; Koukouras, D; Lazarou, S; Markopoulos, C; Misitzis, J; Papadiamantis, J; Polychronis, A; Sarantopoulou, A; Siasos, N; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Hayashi, K; Kanazawa, I; Shimizu, T; Sugimoto, T; Takase, H; Yamaguchi, T | 1 |
| Karatas, M; Yalbuzdag, SA; Yemisci, OU | 1 |
| Bala, JL; Blazewska, KM; Coxon, FP; Ebetino, FH; Henneman, ZJ; Kashemirov, BA; Khalid, AB; Lundy, MW; McKenna, CE; Nancollas, GH; Roelofs, AJ; Rogers, MJ; Sun, S | 1 |
| Mattos, K; Migliorati, CA; Palazzolo, MJ | 1 |
| Albertsen, P; Dowsett, R; Fall, P; Klepinger, A; Richter, L; Taxel, P | 1 |
| Girgis, CM; Seibel, MJ; Sher, D | 1 |
| Aspenberg, P; Fahlgren, A; Schilcher, J | 1 |
| Itabashi, K; Iwamoto, J; Konishi, M; Takakuwa, M; Zhou, Q | 1 |
| Doschak, MR; Jones, MD; Li, G; Maksymowych, WP; Tran, CW; Zernicke, RF | 1 |
| Baldoni, M; Lauritano, D; Leonida, A; Rossi, G; Vescovi, P | 1 |
| Charle-Crespo, MÁ; Gomes-Carvalho, CS; Guerra-García, MM; Prejigueiro-Santás, A; Puga-Sarmiento, E; Rodríguez-Fernández, JB | 1 |
| Glendenning, P; Inderjeeth, CA; Lee, S | 1 |
| Beggiato, S; Bignozzi, CA; Bozzi, P; Dalpiaz, A; Dissette, V; Ferraro, L; Leo, E; Pasti, L; Vighi, E | 1 |
| Allen, MR; Burr, DB; Phipps, RJ; Turek, JJ | 1 |
| Clézardin, P; Ebetino, FH; Fournier, PG; Stresing, V | 1 |
| Aapro, MS | 1 |
| Adams, M; Duque, G; Li, W; Phipps, R; Xu, S | 1 |
| Blouin, S; Fratzl-Zelman, N; Klaushofer, K; Misof, BM; Paschalis, EP; Roschger, P | 1 |
| Bertoldo, F; Dalle Carbonare, L; Donatelli, L; Giannini, S; Lo Cascio, V; Ossi, E; Realdi, G; Sella, S; Valenti, MT; Vilei, MT; Zanatta, M | 1 |
| Al Shamy, A; Awad, GA; Mansour, S; Mortada, ND; Nasr, M | 1 |
| De Schutter, JW; Pause, A; Tsantrizos, YS; Welbourn, S; Zaretsky, S | 1 |
| Kou, TD; Masud, T; Ralston, SH; Steinbuch, M; Wick-Urban, B | 1 |
| Abbaspour, A; Amanpour, S; Amiri, HR; Baghdadi, T; Espandar, R; Farzan, M; Heidari, P; Mohagheghi, MA; Rasouli, MR; Yasui, N | 1 |
| Sato, Y | 1 |
| Ebetino, FH; Palnitkar, S; Phipps, RJ; Qiu, S; Sudhaker Rao, D | 1 |
| Barrier, A; Descroix, V; Goudot, P; Lescaille, G; Rigolet, A; Ruhin, B | 1 |
| Benítez, D; Caruso, F; Castiglioni, J; Cerecetto, H; Demoro, B; Docampo, R; Galizzi, M; Gambino, D; Gonzalez, M; Otero, L; Parajón-Costa, B; Rossi, M | 1 |
| Bellahcène, A; Benzaïd, I; Castronovo, V; Clézardin, P; Colombel, M; Ebetino, FH; Fournier, PG; Mönkkönen, H; Stresing, V | 1 |
| Amemiya, N; Itabashi, M; Karasawa, K; Kawanishi, K; Kojima, C; Moriyama, T; Nitta, K; Ogawa, T; Shimizu, A; Shiohira, S; Sugiura, H; Takei, T; Tsuchiya, K; Tsukada, M; Uchida, K | 1 |
| Eisman, JA; Jönsson, B; Kanis, JA; Papaioannou, A; Siris, ES; Ström, O; Tosteson, A | 1 |
| Ban, A; Furumitsu, Y; Imanishi, Y; Inaba, M; Mori, N; Nishizawa, Y; Okamoto, K; Yukioka, K | 1 |
| Aoki, Y; Arai, G; Eguchi, Y; Inoue, G; Ishikawa, T; Kamoda, H; Kishida, S; Koshi, T; Miyagi, M; Ochiai, N; Ohtori, S; Orita, S; Suzuki, M; Takahashi, K; Takaso, M; Toyone, T; Yamashita, M; Yamauchi, K | 1 |
| Alig, E; Bolte, M; Brüning, J; Dressman, JB; Petereit, AC; Schmidt, MU | 1 |
| Brufsky, A; Greenspan, SL; Lembersky, B; Perera, S; Rastogi, P; van Londen, GJ; Vogel, V; Vujevich, K | 1 |
| Bachmeyer, C; Gauthier, M | 1 |
| Iba, K; Katahira, G; Takada, J; Yamashita, T; Yoshizaki, T | 1 |
| Alvarez, A; Benedetti, A; Haziza, M; Kremer, R; Trojan, DA; Weiss, DR | 1 |
| Abrams, J; Bhargaval, A; Graff, JJ; Nahleh, Z; Nirmal, K | 1 |
| Pazianas, M | 1 |
| Choi, SJ; Ji, JD; Kim, S; Lee, YH; Song, GG; Woo, JH | 1 |
| Jones, G; Winzenberg, T | 1 |
| Dincel, AS; Karatas, GK; Kosova, F; Sepici, V; Zinnuroglu, M | 1 |
| Ferrari, S; Fujiwara, S; Hagino, H; Lange, JL; Nakamura, T; Watts, NB | 1 |
| Eriguchi, M; Fujitake, J; Hataya, Y; Hayashi, M; Komatsu, Y; Mizuta, H; Nishikawa, A | 1 |
| Bliuc, D; Center, JR; Eisman, JA; Nguyen, ND; Nguyen, TV | 1 |
| Stern, PH; Wang, J | 1 |
| Anastasilakis, AD; Bratengeier, C; Papatheodorou, A; Polyzos, SA; Terpos, E; Woloszczuk, W | 1 |
| Cahall, DL; Eastell, R; Garnero, P; Ringe, JD; Vrijens, B; Watts, NB | 1 |
| Fujita, H; Kobayashi, N; Kurokawa, K; Nakanishi, T; Ogawa, T; Ogino, T; Oka, T; Ono, M; Sasaki, J; Suzaki, E; Tanaka, N; Utsumi, K; Yamamoto, M | 1 |
| Smith, EM | 1 |
| de Jesus Peres, V; Jordão, FM; Katzin, AM; Kimura, EA; Miguel, DC; Saito, AY | 1 |
| Goldstein, JL; Klemes, A; Lindsay, R; Roux, C; Zhou, X | 1 |
| Kľoc, J; Kľoc, P; Tomčovčík, L | 1 |
| Fujita, Y; Maki, K; Uchikanbori, S; Watanabe, K | 1 |
| Aoyagi, K; Chiba, K; Doiguchi, Y; Furuichi, I; Hashikawa, T; Motokawa, S; Norimatsu, T; Osaki, M; Shindo, H; Tatsuki, K | 1 |
| El Rachkidi, R; Sari-Leret, ML; Wolff, S | 1 |
| Izumi, K; Kitagawa, Y; Koh, E; Mizokami, A; Namiki, M; Narimoto, K; Sugimoto, K | 1 |
| Fujii, Y; Fujita, T; Miyauchi, A; Nakajima, M; Ohue, M; Takagi, Y | 1 |
| Blouin, S; Chappard, D; Cros, M; de Vernejoul, MC; Geoffroy, V; Libouban, H; Ostertag, A; Paschalis, EP; Phipps, R | 1 |
| Cobaleda, B; Gómez-Juaristi, M; González, EM; Guadalix, S; Hawkins, F; Lora, D; Martínez-Díaz-Guerra, G; Vargas, C | 1 |
| Ebetino, FH; Galea, GL; Jackson, BF; Lanyon, LE; Meakin, LB; Price, JS; Russell, RG; Sugiyama, T | 1 |
| Chandran, M; Cheen, MH; Kong, MC; Tee, FM; Zhang, RF | 1 |
| Bivi, N; Moro, L; Müller, LN; Picotti, P; Quadrifoglio, F; Romanello, M; Tell, G | 1 |
| Chin, SO; Chung, HY; Chung, YS; Kang, MI; Koh, JM; Moon, SH; Park, HM; Yoon, BK; Yoon, HK | 1 |
| Gleysteen, S; Herzog, D; Klibanski, A; Lawson, EA; Meenaghan, E; Miller, KK; Misra, M; Schoenfeld, D | 1 |
| Dammer, O; Dohnal, J; Harokova, P; Havlicek, J; Hruskova, J; Jampílek, J; Kos, J; Kral, V; Krejcik, L; Mandelova, Z; Oktabec, Z; Pekarek, T; Pentakova, M; Tkadlecova, M; Vinsova, J | 1 |
| Lee, JH; Lee, SH | 1 |
| Cowling, NR; Forwood, MR; Kelly, WL; Kidd, LJ; Wu, AC | 1 |
| Akyuz, G; Ay, P; Bizargity, P; Karadag-Saygi, E | 1 |
| Gulseren, A; Peyman, B; Pinar, A | 1 |
| Landfeldt, E; Lang, A; Robbins, S; Ström, O | 1 |
| Bhattacharyya, I; Bowers, LM; Cohen, DM; Fitzpatrick, SG; Green, JG; Hinkson, DW; Neuman, AN; Stavropoulos, MF | 1 |
| Barlow, S; Bradbury, LA; Brown, MA; Duncan, EL; Geoghegan, F; Hannon, RA; Russell, RG; Stuckey, SL; Wass, JA | 1 |
| Guañabens, N; Martínez-Ferrer, A; Monegal, A; Olivares, V; Peris, P; Reyes, R; Torra, M | 1 |
| Hayashida, N; Honda, Y; Iwamoto, J; Matsumoto, H; Sato, Y; Takeda, T; Umeno, K | 1 |
| Madanat, R; Mäkinen, TJ; Ovaska, MT | 1 |
| Adachi, JD; Walker, AD | 1 |
| An, S; Jeong, Y; Jin, GW; Nam, H; Nam, SH; Park, JS; Xu, YJ | 1 |
| Al Shamy, A; Awad, GA; Mansour, S; Mortada, ND; Nasr, M; Taha, I | 1 |
| Barker, HC; Bearcroft, PW; Compston, JE; Conway, SP; Elborn, JS; Elkin, SL; Elliott, J; Etherington, C; Haworth, CS; Hlaing, T; Hodson, ME; Hughes, V; Kadri, E; Rendall, J; Sharples, L; Wheaton, E | 1 |
| Eastell, R; Hannon, RA; Rodriguez-Moreno, J; Sawicki, A; Wenderoth, D | 1 |
| Ott, SM | 1 |
| Kapil, N; Patel, DS; Roth, M | 1 |
| Buchinger, B; Gamsjaeger, S; Klaushofer, K; Paschalis, EP; Phipps, R; Zoehrer, R | 1 |
| Iwasawa, M; Kadono, Y; Masuda, H; Matsumoto, T; Nagase, Y; Nakamura, K; Tanaka, S; Yasui, T | 1 |
| Bartlett, SJ; Bingham, CO; Ling, SM; Mayo, NE; Scott, SC | 1 |
| Chan, SP; Chew, YY; Chua, SS; Lai, PS | 1 |
| Abarca, J; Campbell, HE; Martin, KE; White, TJ; Yu, J | 1 |
| Balske, A; Benhamou, CL; Bolognese, MA; Brown, JP; Burgio, DE; McClung, MR; McCullough, LK; Miller, PD; Recker, RR; Sarley, J; Zanchetta, J | 1 |
| Baskol, M; Bayram, F; Gursoy, S; Kalkan, AO; Karaman, A; Kula, M; Ozbakir, O; Torun, E; Yucesoy, M; Yurci, A | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Papanastasiou, P; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| Blake, GM; Eastell, R; Fogelman, I; Frost, ML; Marsden, PK; Moore, AE; Schleyer, PJ; Siddique, M | 1 |
| Adolphson, PY; Ahl, TE; Bodén, HS; Salemyr, MO; Sköldenberg, OG | 1 |
| Che, X; Choi, JY; Jeong, JH; Lim, KE; Nam, H; Nam, SH; Park, JS | 1 |
| Bucci-Rechtweg, C; Devogelaer, JP; Lau, CS; Reginster, JY; Reid, DM; Roux, C; Saag, K; Sambrook, PN; Su, G | 1 |
| Landfeldt, E; Ström, O | 1 |
| Ishii, M; Iwasaki, T; Nonoda, Y | 1 |
| Alam, J; Burge, RT; Hadji, P; Krege, JH; Lakshmanan, MC; Masica, DN; McKiernan, FE; Mitlak, BH; Recknor, CP; Russo, L; Saag, KG; Silverman, SL; Stock, JL; Zanchetta, JR | 1 |
| Basso, U; Berton, L; Brunello, A; Coin, A; Falci, C; Manzato, E; Monfardini, S; Perissinotto, E; Pintore, G; Sergi, G; Veronese, N | 1 |
| Itabashi, K; Iwamoto, J; Takakuwa, M | 1 |
| Dejager, AD; Ghassabian, S; Smith, MT; Wright, LA | 1 |
| Amagase, K; Inaba, A; Ishikawa, Y; Murakami, T; Nukui, K; Senta, T; Takeuchi, K | 1 |
| Ebetino, FH; Gamsjaeger, S; Hofstetter, B; Klaushofer, K; Paschalis, EP; Phipps, RJ; Recker, RR | 1 |
| Cooper, C; Cortet, B; Diaz-Curiel, M; Kanis, JA; Lorenc, RS; Reginster, JY; Rizzoli, R | 1 |
| Chan, SP; Chua, SS; Lai, PS | 1 |
| de Macedo Dossin, F; Feng, X; Freitas-Junior, LH; Hui, R; Lee, E; Liu, YL; No, JH; Oldfield, E; Wang, K; Yoo, JA; Zhang, Y; Zhu, W | 1 |
| Britton, C; Walsh, J | 1 |
| Fedorak, RN; McQueen, B; Siffledeen, J; Siminoski, K; Soo, I | 1 |
| Abrahamsen, B; Pazianas, M; Russell, RG; Wang, Y | 1 |
| Auleley, GR; Boutron, I; Konrat, C; Ravaud, P; Ricordeau, P; Trinquart, L | 1 |
| Namazi, H | 1 |
| Bai, XC; Chen, JT; Huang, MJ; Jin, DD; Jin, J; Lai, PL; Wang, L; Wang, XK; Zhong, ZM | 1 |
| Gogas, H; Koukouras, D; Markopoulos, C; Misitzis, J; Tzoracoleftherakis, E; Venizelos, B; Xepapadakis, G; Zobolas, V | 1 |
| Davey, DA | 1 |
| Arias, M; Barros, X; Blasco, M; Campistol, JM; Cases, A; Durán, CE; Torregrosa, JV | 1 |
| Kharazmi, M; Persson, U; Warfvinge, G | 1 |
| Bae, SJ; Kim, BJ; Kim, GS; Kim, HK; Koh, JM; Lee, SH; Lim, KH | 1 |
| Angthong, C; Angthong, W | 1 |
| Coenen, JL; Creemers, GJ; Dalesio, O; de Jong, PC; de Wit, R; Fosså, SD; Gerritsen, W; Loosveld, OJ; Meulenbeld, HJ; Polee, M; Ten Tije, AJ; van Werkhoven, ED | 1 |
| Ha, YC; Kang, BJ; Kim, TY; Koo, KH; Lee, YK | 1 |
| Abelson, A; Atlan, P; Gold, DT; Horlait, S; Lange, JL; Ringe, JD; Thomas, T | 1 |
| Hirata, S; Inokuchi, N; Mori, H; Okada, Y; Saito, K; Tanaka, Y; Yamamoto, S | 1 |
| Boonen, S; Eusebio, R; Lorenc, RS; Orwoll, ES; Stoner, KJ; Wenderoth, D | 1 |
| Beary, JF; Benhamou, CL; Boonen, S; Burgio, DE; Delmas, P; Eusebio, RA; Man, Z; Matzkin, E; McClung, MR; Racewicz, A; Roux, C; Zanchetta, JR | 1 |
| El-Abd, EE; El-Ashmawy, NE; El-Bahrawy, HA; Haggag, AA; Khedr, NF | 1 |
| Barlow, DH; Clack, G; Eastell, R; Makris, A; Van Poznak, C | 1 |
| Iwamoto, J; Takakuwa, M | 1 |
| Coco, M; Cohen, HW; Glicklich, D; Greenstein, S; Lee, S; Pullman, J; Shapiro, C; Solorzano, C | 1 |
| Chen, M; Chen, Y; Chen, Z; Liu, Y; Zhu, Y | 1 |
| Hemmati, I; Kelsall, J; Wade, J | 1 |
| Hayakawa, Y; Iinuma, N; Itoh, M; Iwayama, S; Kamisaki, T; Nakamura, T; Nishikawa, M; Osawa, M; Suzuki, H; Yamaguchi, H | 1 |
| Aoki, Y; Eguchi, Y; Inage, K; Inoue, G; Ishikawa, T; Kamoda, H; Kishida, S; Kubota, G; Kuniyoshi, K; Miyagi, M; Nakamura, J; Ochiai, N; Ohtori, S; Oikawa, Y; Orita, S; Ozawa, T; Sainoh, T; Sakuma, Y; Suzuki, M; Takahashi, K; Takaso, M; Toyone, T; Yamauchi, K | 1 |
| Halpin, C; McKenna, MJ; Merchant, SN; Quesnel, AM; Seton, M | 1 |
| Benzaïd, I; Bonnelye, E; Clézardin, P; Mönkkönen, H; Mönkkönen, J | 1 |
| Adachi, JD; Becker, DL; Chau, D; Coombes, ME; Goeree, R; Ioannidis, G | 1 |
| Benoliel, R; Lehman, H; Neuman, T; Zadik, Y | 1 |
| Balske, A; Burgio, DE; McClung, MR; Recker, RR; Wenderoth, D | 1 |
| Bilezikian, JP; Cusano, NE; McMahon, DJ; Romano, M; Sliney, J; Walker, MD; Zhang, C | 1 |
| Yates, J | 1 |
| Arranz Caso, JA; Dominguez-Mompello, JL; Flores Ballester, E; López Pizarro, V; Ngo Pombe, S; Restoy Lozano, A | 1 |
| Itoh, S; Sekino, Y; Shinomiya, K; Takeda, S | 1 |
| Ishiguro, N; Nishida, Y; Sugiura, H; Tsukushi, S; Urakawa, H; Yamada, Y | 1 |
| Faillace, ME; Miller, LM; Phipps, RJ | 1 |
| Garcia-Munozguren, S; Salmeron, MP; Sanchez-Ayaso, PA | 1 |
| Balske, AM; Benhamou, CL; Delmas, PD; Eusebio, R; Man, Z; Matzkin, E; McClung, MR; Olszynski, WP; Recker, R; Tlustochowicz, W; Zanchetta, JR | 1 |
| Lei, C; Li, M; Liu, F; Liu, M; Mao, Y; Tang, T; Wang, G; Yu, Z; Zhao, X; Zhu, Z | 1 |
| Jönsson, B; Kanis, JA; Ström, O | 1 |
| Atkinson, EJ; Gössl, M; Kane, TL; Khosla, S; Lerman, A; McCready, LK; McGregor, UI; Peris, P | 1 |
| Airia, P; Borisova, N; Ferko, NC; Grima, DT; Thompson, MF | 1 |
| Briones-Urbina, R; Cheung, P; Choo, R; Corbett, T; Danjoux, C; Ehrlich, L; Kiss, A; Lukka, H; Vieth, R | 1 |
| Aboge, G; Aboulaila, M; Cao, S; Igarashi, I; Nishikawa, Y; Terkawi, MA; Ueno, A; Xuan, X; Yokoyama, M; Yokoyama, N | 1 |
| Crowder, MW; Feng, L; Liu, CC; Xiao, JM; Yang, KW; Zhang, YL; Zhou, LS | 1 |
| Farahmand, P; Glüer, CC; Graeff, C; Guañabens, N; Hawkins, F; Kapetanos, G; Marin, F; Martín-Mola, E; Martínez, G; Minisola, S; Möricke, R; Niedhart, C; Nolla, JM; Nuti, R; Papaioannu, N; Peña, J; Petto, H; Reisinger, A; Ringe, JD; Sanz, B; Thomasius, F; Zysset, PK | 1 |
| Asahina, I; Hasegawa, T; Ikeda, H; Kobayashi, M; Komatsubara, H; Komori, T; Ri, S; Shibuya, Y; Shigeta, T; Umeda, M; Yoshitomi, I | 1 |
| Aoki, Y; Eguchi, Y; Inage, K; Inoue, G; Ishikawa, T; Kamoda, H; Kishida, S; Kubota, G; Kuniyoshi, K; Miyagi, M; Nakamura, J; Ochiai, N; Ohtori, S; Oikawa, Y; Orita, S; Sainoh, T; Sakuma, Y; Suzuki, M; Takahashi, K; Takaso, M; Toyone, T; Yamauchi, K | 1 |
| Bucci-Rechtweg, C; Collette, J; Devogelaer, JP; Goemaere, S; Ish-Shalom, S; Papanastasiou, P; Reginster, JY; Reid, DM; Sambrook, P; Su, G | 1 |
| Cho, DH; Choi, YH; Chung, DJ; Chung, JO; Chung, MY; Civitelli, R; Jeong, HM; Jin, YH; Lee, KY | 1 |
| Barker-Griffith, A; Eagle, RC; Geneva, II; Stefanyszyn, M; Weisenthal, R | 1 |
| Dambacher, MA; Dukas, L; Ringe, JD; Von Schacht, E | 1 |
| Cruz, L; Ferreira, LM; Mattiazzi, J; Pohlmann, L; Rolim, CM; Silva, CB; Velasquez, AA | 1 |
| Brüel, A; Danielsen, CC; Oxlund, H; Straarup, TS; Thomsen, JS | 1 |
| de Boer, PT; Postma, MJ; van Boven, JF; Vegter, S | 1 |
| Cosman, F | 1 |
| Bhat, MR; Khajuria, DK; Mahapatra, DR; Mariappan, L; Rao, RR; Razdan, R; Sahana, H; Suresh, S | 1 |
| Hagino, H; Hashimoto, J; Ito, M; Mizunuma, H; Nakamura, T; Nakano, T; Tobinai, M | 1 |
| Antoniou, J; Dontas, I; Fakidari, E; Galanos, A; Katsalira, K; Liakou, C; Lyritis, GP; Makris, K; Marketou, H; Papaioannou, N; Tournis, S; Trovas, G | 1 |
| Farahmand, P; Gentzel, A; Glüer, CC; Graeff, C; Guañabens, N; Hawkins, F; Kapetanos, G; Marin, F; Martín-Mola, E; Martínez, G; Minisola, S; Möricke, R; Niedhart, C; Nolla, JM; Nuti, R; Papaioannou, N; Peña, J; Petto, H; Reisinger, A; Ringe, JD; Thomasius, F; Zysset, PK | 1 |
| Chang, JS; Chung, HY; Chung, YS; Kang, MI; Koo, J; Kwon, SK; Moon, SH; Park, HM; Park, JY; Shin, CS; Yoon, BK; Yoon, HK | 1 |
| Bean, J; Cassedy, A; Cohran, V; Hawkins, A; Heubi, J | 1 |
| Anitha, D; Kim, KJ; Lee, T; Lim, SK | 1 |
| Fukunaga, M; Hagino, H; Hosoi, T; Itoi, E; Kuroda, T; Miyakawa, N; Miyazaki, T; Mori, S; Nakamura, T; Ohashi, Y; Ohta, H; Orimo, H; Shiraki, M; Sugimoto, T; Tanaka, S; Uemura, Y | 1 |
| Aizawa, T; Chida, S; Ebina, T; Hongo, M; Ishikawa, Y; Kasukawa, Y; Miyakoshi, N; Nozaka, K; Saito, H; Shimada, Y | 1 |
| Blaisse, RJ; de Wit, R; Erjavec, Z; Gerritse, FL; Los, M; Meulenbeld, HJ; Roodhart, JM; Smilde, TJ; van der Velden, AM | 1 |
| Chung, YH; Jeong, JH; Lim, CH; Seo, YH | 1 |
| Alsarraj, A; El-Serag, HB; Graham, DY; Kramer, JR; Lin, D; Parente, P; Ramsey, D; Rugge, M; Verstovsek, G | 1 |
| Diz, P; Feijoo, JF; García, A; Limeres, J; López-Cedrún, JL; Peñarrocha, M; Sanromán, JF | 1 |
| Casado-Díaz, A; Dorado, G; Quesada-Gómez, JM; Santiago-Mora, R | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Haga, T; Hashimoto, A; Kambayashi, Y | 1 |
| Huang, J; Kruse, M; Parthan, A; Taylor, D; Viswanathan, HN; Yurgin, N | 1 |
| Fujimoto, Y; Muramatsu, K; Murayama, M; Nakata, E; Nomura, T; Ogane, S; Sekine, R; Shibahara, T; Shibui, T; Uchiyama, T; Watanabe, A; Yakushiji, T; Yamamoto, N | 1 |
| Rauch, F; Ward, LM | 1 |
| Adami, S; Ahmed, SF; Antón, J; Arundel, P; Bishop, N; Burren, CP; Devogelaer, JP; Hangartner, T; Hosszú, E; Lane, JM; Lorenc, R; Mäkitie, O; Munns, CF; Paredes, A; Pavlov, H; Plotkin, H; Raggio, CL; Reyes, ML; Schoenau, E; Semler, O; Sillence, DO; Steiner, RD | 1 |
| Damm, DD; Jones, DM | 1 |
| Gong, T; Häfeli, UO; Sun, C; Troczynski, T; Wang, Z; Yang, Q; Zhang, Y | 1 |
| Ehlert, KM; Hernandez, CJ; Lin, I; Matheny, JB; Slyfield, CR; Tkachenko, EV; Tomlinson, RE; Wilson, DL | 1 |
| Amano, N; Honda, Y; Iwamoto, J; Sato, Y | 1 |
| Ben-Aharon, I; Rizel, S; Shpilberg, O; Stemmer, SM; Sulkes, A; Vidal, L; Yerushalmi, R | 1 |
| Handayani, LR; Rosa, TA; Setiawati, A; Setiawati, E; Sholeh, AB; Simanjuntak, R; Utami, BS; Yunaidi, DA | 1 |
| Capaldo, A; Di Somma, C; Gimigliano, F; Iolascon, G; Menditto, E; Orlando, V | 1 |
| Hathout, RM; Nasr, M; Taha, I | 1 |
| Gandhi, S; Modi, A; Sen, S; Siris, ES; Tang, J | 1 |
| Bala, Y; Bock, O; Chapurlat, R; Cheung, AM; Djoumessi, RM; Felsenberg, D; Ghasem-Zadeh, A; LaRoche, M; Morris, E; Reeve, J; Rizzoli, R; Seeman, E; Thomas, T; Zanchetta, J | 1 |
| Antoniali, G; Brancia, FL; Cesaratto, L; Delneri, D; Iozzo, RV; Piatkowska, E; Romanello, M; Vascotto, C | 1 |
| Brown, JP; Fahrleitner-Pammer, A; Ferreira, I; Hawkins, F; Ho, PR; Hofbauer, LC; Micaelo, M; Minisola, S; Papaioannou, N; Roux, C; Siddhanti, S; Stone, M; Wagman, RB; Wark, JD; Zillikens, MC | 1 |
| Bravenboer, N; Dijkstra, G; Dik, VK; Hommes, DW; Lips, P; Netelenbos, JC; Oldenburg, B; Oostlander, AE; Pierik, M; Roos, JC; Russel, MG; Stokkers, PC; van Bodegraven, AA; van de Langerijt, L; van der Woude, CJ; van Hogezand, RA; Witte, BI | 1 |
| Ishii, M; Kikuta, J | 1 |
| Hagino, H; Horii, S; Kishimoto, H; Nakamura, T; Ohishi, H | 1 |
| Bernstein, CN; Leslie, WD; Targownik, LE | 1 |
| Byun, Y; Park, JW | 1 |
| Elahian, F; Lage, H; Mansouri, M; Mirzaei, SA; Mousavi, SS | 1 |
| Inoue, D; Konda, T; Shiozaki, M; Yamada, M; Yano, T | 1 |
| Aiba, S; Fujimura, T; Furudate, S; Kakizaki, A; Kambayashi, Y | 1 |
| Chikazu, D; Hamada, H; Koizumi, T; Matsuo, A; Satomi, T | 1 |
| Beck-Peccoz, P; Cairoli, E; Chiodini, I; Eller-Vainicher, C; Morelli, V; Palmieri, S; Ulivieri, FM; Zhukouskaya, VV | 1 |
| Gopal, GK; Krishnan, SP; Maddern, IL; Tam, KL | 1 |
| Barroug, A; Errassifi, F; Legrouri, A; Rey, C; Sarda, S; Sfihi, H | 1 |
| Abbagoni, S; Banji, D; Banji, OJ; Chiluka, VL | 1 |
| Hviid, A; Pasternak, B; Svanström, H | 1 |
| Cruz, L; da Silva, Cde B; de Arce Velasquez, A; Ferreira, LM; Rolim, CM; Stangarlin, MF | 1 |
| Bolognese, MA; Bone, HG; Bonnick, S; Brown, JP; Dakin, P; Ferreira, I; Hall, J; Ho, PR; Recknor, C; Roux, C; van den Bergh, JP; Wagman, RB | 1 |
| Ervolino, E; Falcai, MJ; Issa, JP; Macedo, AP; Shimano, AC; Shimano, RC | 1 |
| Mizuguchi, M; Niimura, N; Ostermann, A; Schrader, TE; Tanaka, I; Yokoyama, T | 1 |
| Bentinger, M; Brismar, K; Chojnacki, T; Dallner, G; Danikiewicz, W; Kaczorowska, E; Kania, M; Swiezewska, E; Tekle, M; Wojcik, J | 1 |
| Caeiro, JR; González-Cantalapiedra, A; Guede, D; López-Peña, M; Muñoz, F; Permuy, M | 1 |
| Barroug, A; Brouillet, F; Errassifi, F; Legrouri, A; Pascaud, P; Rey, C; Sarda, S | 1 |
| Han, HK; Jung, IW | 1 |
| Jang, SW; Kang, MJ; Lee, JW; Ryu, DS; Son, M | 1 |
| Fadda, V; Maratea, D; Marinai, C; Messori, A; Trippoli, S | 1 |
| Berg, L; Bindslev, N; Johansson, B; Laurent, AJ | 1 |
| Cheung, P; Harrison, SD; McMurry, AS; Meshaw, KR; Rainbolt, EA; Roix, JJ; Saha, S | 1 |
| Biamonte, F; Biondi, P; Cipriani, C; Del Fiacco, R; Diacinti, D; Falciano, M; Iaiani, G; Isidori, AM; Lenzi, A; Minisola, S; Pepe, J; Piemonte, S; Raimo, O; Salotti, A; Sbardella, E | 1 |
| Andreatta, P; Bertolini, T; Boschetti, S; Gatti, R; Vicentini, L | 1 |
| Cai, HF; Li, YT; Zhang, ZL | 1 |
| Garellick, G; Landfeldt, E; Ström, O | 1 |
| Chavassieux, P; Lundy, MW; McClung, MR; Recker, RR; Ste-Marie, LG | 1 |
| Benlidayi, IC; Kozanoglu, E; Ortac, EA | 1 |
| Dedkova, K; Devinsky, F; Jampilek, J; Peikertova, P; Pisarcik, M; Placha, D; Vaculikova, E | 1 |
| Hagino, H; Hashimoto, J; Matsunaga, M; Nakamura, T; Tobinai, M; Yoshida, S | 1 |
| Casado-Díaz, A; Dorado, G; Navarro-Valverde, C; Quesada-Gómez, JM; Santiago-Mora, R | 1 |
| Blake, GM; Coleman, R; Cuzick, J; Dowsett, M; Eastell, R; Forbes, JF; Gossiel, F; Howell, A; Patel, R; Sestak, I; Singh, S | 1 |
| Akashi, M; Hasegawa, T; Imai, Y; Komori, T; Takeda, D | 1 |
| Auriola, S; Coimbra de Sousa, S; Ebert, R; Graser, S; Hofbauer, LC; Jakob, F; Määttä, J; Meissner-Weigl, J; Mentrup, B; Rachner, TD; Zeck, S | 1 |
| Agodoa, I; Bonnick, S; Brown, JP; Ferreira, I; Ho, PR; Palacios, S; Van den Bergh, JP | 1 |
| Babinets', LS; Borovyk, IO; Semenova, IV | 2 |
| Arponen, H; Haukka, J; Mäkitie, O; Valta, H; Vuorimies, I; Waltimo-Sirén, J | 1 |
| Aspenberg, P; Koeppen, V; Michaëlsson, K; Schilcher, J | 1 |
| Baker, S; Jeremiah, C; Johnson, D; Shah, S | 1 |
| Lorenc, R; Oral, A | 1 |
| Intorcia, M; Karlsson, L; Mesterton, J; Overbeek, J; Ström, O; Tepie, MF | 1 |
| Geusens, P; Kendler, DL; Marin, F; Minisola, S; Zerbini, CAF | 1 |
| Adachi, JD; Berger, C; Bliuc, D; Center, JR; Eisman, JA; Geusens, P; Goltzman, D; Hanley, DA; Josse, RG; Kaiser, S; Kovacs, CS; Langsetmo, L; Nguyen, TV; Prior, JC; Tran, T; van den Bergh, J; van Geel, T | 1 |
| Athanasiadis, G; Ban, JK; Burden, AM; Cadarette, SM; Hayes, KN | 1 |
| Min, N; Shi, L; Wang, F; Xue, QY | 1 |
| Ebetino, FH; McClung, MR | 1 |
| Adams, A; Heidenreich, A; Jakob, T; Kuhr, K; Macherey, S; Monsef, I; Skoetz, N; Tesfamariam, YM | 1 |
| Alam, A; Boolell, M; Gauthier, G; Palacios, S; Thomasius, F; Vekeman, F | 1 |
| Bilek, LD; Flores, LE; Kupzyk, KA; Lappe, JM; Mack, LR; Waltman, N | 1 |
| Colarossi, G; Driessen, A; Eschweiler, J; Maffulli, N; Migliorini, F; Oliva, F | 1 |
| Carmona-Sarabia, L; Figueroa Guzmán, AF; Hu, C; López-Mejías, V; Peterson-Peguero, E; Santiago, AP; Vélez, GQ | 1 |
| Boolell, M; Cortet, B; Eisman, JA; Heroux, J; Ionescu-Ittu, R; Thomasius, F; Vekeman, F | 1 |
| Arístegui, I; Boolell, M; Casado, E; Rosas, J; Rubio-Rodríguez, D; Rubio-Terrés, C | 1 |
175 review(s) available for etidronate and risedronic acid
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Bisphosphonates, Old Friends of Bones and New Trends in Clinics.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases; Diphosphonates; Drug Compounding; Drug Delivery Systems; Humans | 2021 |
Bisphosphonate therapy.
Topics: Alendronate; Animals; Bone Density; Bone Resorption; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 1997 |
Risedronate.
Topics: Animals; Biological Availability; Bone Density; Bone Diseases, Metabolic; Bone Neoplasms; Bone Resorption; Etidronic Acid; Humans; Multiple Myeloma; Randomized Controlled Trials as Topic; Risedronic Acid; Tissue Distribution | 1998 |
Prediction and assessment of the response of Paget's disease to bisphosphonate treatment.
Topics: Alkaline Phosphatase; Bone Resorption; Diphosphonates; Etidronic Acid; Half-Life; Humans; Osteitis Deformans; Randomized Controlled Trials as Topic; Recurrence; Risedronic Acid; Treatment Outcome | 1999 |
The use of risedronate in Paget's disease.
Topics: Alkaline Phosphatase; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Fibrous Dysplasia, Polyostotic; Gastrointestinal Diseases; Humans; Osteitis Deformans; Pain; Risedronic Acid | 1999 |
Bisphosphonates as cancer drugs.
Topics: Antineoplastic Agents; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Neoplasm Proteins; Neoplasms; Osteolysis; Pamidronate; Parathyroid Hormone-Related Protein; Proteins; Risedronic Acid; Transforming Growth Factor beta | 1999 |
Osteoporosis: diagnosis, prevention, and treatment of established disease.
Topics: Age Factors; Aged; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Dietary Supplements; Drug Therapy, Combination; Estrogens; Etidronic Acid; Exercise; Female; Hormone Replacement Therapy; Humans; Male; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Vitamin D | 1999 |
Oral bisphosphonates: A review of clinical use in patients with bone metastases.
Topics: Alendronate; Biological Availability; Bone Density; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcium; Clodronic Acid; Diphosphonates; Double-Blind Method; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Multiple Myeloma; Pamidronate; Prostatic Neoplasms; Pyridines; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2000 |
Risedronate: a new bisphosphonate for the treatment of osteoporosis.
Topics: Adrenal Cortex Hormones; Aged; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2000 |
Prevention and treatment of osteoporosis.
Topics: Accidental Falls; Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Calcitonin; Calcium Channel Blockers; Calcium, Dietary; Case-Control Studies; Cohort Studies; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Physical Exertion; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2000 |
Gastroenterologists and choosing the right bisphosphonate.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Gastroenterology; Glucocorticoids; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2000 |
[Effect of anti-osteoporosis agents on the incidence of vertebral fractures].
Topics: Alendronate; Bone Density; Calcitonin; Calcium Channel Blockers; Densitometry; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Injuries; Spine | 2000 |
Osteoporosis: which current treatments reduce fracture risk?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2000 |
Bisphosphonates in the treatment of osteoporosis. Principles and efficacy.
Topics: Administration, Oral; Alendronate; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Controlled Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pamidronate; Papio; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Time Factors | 2000 |
Risedronate: a clinical review.
Topics: Animals; Bone and Bones; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteitis Deformans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Treatment of osteoporosis with bisphosphonates.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2001 |
Evidence-based medicine: putting theory into practice.
Topics: Alendronate; Calcium Channel Blockers; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; State Medicine; Treatment Outcome; United Kingdom | 2001 |
Consensus statement on the modern therapy of Paget's disease of bone from a Western Osteoporosis Alliance symposium. Biannual Foothills Meeting on Osteoporosis, Calgary, Alberta, Canada, September 9-10, 2000.
Topics: Alendronate; Alkaline Phosphatase; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Practice Guidelines as Topic; Risedronic Acid; Time Factors | 2001 |
Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease.
Topics: Bone and Bones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Half-Life; Humans; Intestinal Absorption; Metabolic Clearance Rate; Osteitis Deformans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2001 |
Risedronate: clinical usage.
Topics: Bone Density; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Osteitis Deformans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2001 |
[Bisphosphonate treatment prevents hip fractures in 70-79 year old women with osteoporotic vertebral fractures].
Topics: Age Factors; Aged; Alendronate; Bone Density; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Lumbar Vertebrae; Multicenter Studies as Topic; Netherlands; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2001 |
Osteoporosis in children and adolescent girls: case report of idiopathic juvenile osteoporosis and review of the literature.
Topics: Adolescent; Calcium Channel Blockers; Calcium, Dietary; Diagnosis, Differential; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Acid; Vitamin D | 2001 |
Pharmacologic therapy for the treatment and prevention of osteoporosis.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Selection; Primary Prevention; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2001 |
Bisphosphonates for osteoporosis.
Topics: Aged; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Risedronate: a new oral bisphosphonate.
Topics: Administration, Oral; Alendronate; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Humans; Male; Osteitis Deformans; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Role of alendronate and risedronate in preventing and treating osteoporosis.
Topics: Alendronate; Cost-Benefit Analysis; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; United States | 2001 |
[Alternatives to hormonal treatment for the prevention of postmenopausal osteoporosis: the bisphosphonates].
Topics: Aging; Alendronate; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Review of risedronate in the treatment of osteoporosis.
Topics: Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2001 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis: results from recent clinical trials.
Topics: Aged; Bone Density; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Endoscopy, Gastrointestinal; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Postmenopause; Proportional Hazards Models; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Safety; Steroids; Survival Analysis | 2002 |
Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid | 2002 |
Risedronate for the prevention of fractures in postmenopausal osteoporosis.
Topics: Aged; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Bone; Humans; MEDLINE; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2002 |
The underuse of therapy in the secondary prevention of hip fractures.
Topics: Accidental Falls; Alendronate; Calcium; Estrogens; Etidronic Acid; Hip Fractures; Hip Prosthesis; Humans; Parathyroid Hormone; Risedronic Acid; Risk Factors; Vitamin D | 2002 |
[Risedronate: clinical usage].
Topics: Bone Density; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Fractures, Stress; Humans; Osteitis Deformans; Osteoporosis; Prednisone; Risedronic Acid; Spinal Fractures | 2002 |
[Episcleritis secondary to risedronate].
Topics: Calcium Channel Blockers; Etidronic Acid; Female; Humans; Middle Aged; Risedronic Acid; Scleritis | 2002 |
Bone quality: getting closer to a definition.
Topics: Animals; Bone Density; Etidronic Acid; Humans; Lumbar Vertebrae; Osteoporosis; Radiography; Risedronic Acid; Spinal Fractures; Swine, Miniature; Tomography Scanners, X-Ray Computed | 2002 |
Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Digestive System; Drug Interactions; Endoscopy, Gastrointestinal; Etidronic Acid; Gastrointestinal Diseases; Humans; Risedronic Acid | 2002 |
What the gastroenterologist should know about the gastrointestinal safety profiles of bisphosphonates.
Topics: Alendronate; Anti-Inflammatory Agents, Non-Steroidal; Digestive System; Diphosphonates; Drug Interactions; Drug Tolerance; Esophagitis; Etidronic Acid; Gastric Mucosa; Humans; Irritants; Risedronic Acid; Safety | 2002 |
Meta-analyses of therapies for postmenopausal osteoporosis. III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis.
Topics: Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2002 |
Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Topics: Alendronate; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Time | 2002 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2002 |
Osteoporosis in elderly: prevention and treatment.
Topics: Aged; Alendronate; Etidronic Acid; Exercise; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2002 |
[Osteoporosis: diagnosis and treatment of vertebral fractures].
Topics: Age Factors; Aged; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Placebos; Randomized Controlled Trials as Topic; Recurrence; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Time Factors; Vitamin D | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; United States | 2002 |
Editorial: greater risk, greater benefit--true or false?
Topics: Calcium Channel Blockers; Etidronic Acid; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk Factors; Spinal Fractures | 2003 |
[Osteoporosis].
Topics: Alendronate; Bone Density; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2002 |
[Effects of bisphosphonate on trabecular microstructure].
Topics: Animals; Bone and Bones; Etidronic Acid; Female; Microradiography; Rats; Risedronic Acid | 2003 |
[Risedronate].
Topics: Aged; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Treatment of osteoporosis provided from the orthopaedic surgeon's standpoint].
Topics: Alendronate; Etidronic Acid; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid | 2003 |
[Osteoporosis in men].
Topics: Alendronate; Androgens; Calcium Channel Blockers; Diagnosis, Differential; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Hypogonadism; Male; Osteoporosis; Primary Prevention; Risedronic Acid; Risk Factors | 2003 |
Canadian consensus on osteoporosis. Preventing osteoporosis among postmenopausal women.
Topics: Aged; Alendronate; Calcium Channel Blockers; Canada; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Primary Prevention; Risedronic Acid; Risk Assessment | 2003 |
Identifying the osteopenic patient and preventing worsening of the disease.
Topics: Alendronate; Body Mass Index; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Calcitonin; Estrogen Replacement Therapy; Estrogens; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Progestins; Risedronic Acid; Risk Factors; United States | 2003 |
Prevention and treatment of osteoporosis.
Topics: Aged; Alendronate; Calcitonin; Calcium; Dietary Supplements; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Middle Aged; Osteoporosis; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2002 |
Bisphosphonates: new indications and methods of administration.
Topics: Alendronate; Animals; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Structure-Activity Relationship; Zoledronic Acid | 2003 |
Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Topics: Aged; Alendronate; Calcium Channel Blockers; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Prevalence; Risedronic Acid; Spinal Fractures | 2003 |
Risedronate for the prevention and treatment of postmenopausal osteoporosis.
Topics: Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2003 |
An update on bisphosphonates.
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Humans; Osteoclasts; Osteoporosis; Risedronic Acid; Treatment Outcome | 2004 |
An approach to postmenopausal osteoporosis treatment: a case study review.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise Therapy; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2003 |
Osteoporosis management in the new millennium.
Topics: Alendronate; Bone Density; Calcitonin; Calcium; Estrogens; Etidronic Acid; Exercise; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2003 |
[New guideline for the treatment of osteoporosis].
Topics: Alendronate; Calcitonin; Calcium; Estrogen Replacement Therapy; Etidronic Acid; Evidence-Based Medicine; Humans; Meta-Analysis as Topic; Osteoporosis; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D; Vitamin K 2 | 2004 |
[Risedronate treatment for osteoporosis].
Topics: Back Pain; Bone Density; Bone Resorption; Clinical Trials as Topic; Etidronic Acid; Femoral Neck Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal Fractures | 2004 |
[VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study].
Topics: Aged; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk; Spinal Fractures | 2004 |
[Combination therapy of bisphosphonate and estrogen for osteoporosis].
Topics: Alendronate; Bone Density; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Femur Neck; Humans; Osteoporosis; Risedronic Acid; Spine | 2004 |
Prevention and management of osteoporosis in women with breast cancer and men with prostate cancer.
Topics: Absorptiometry, Photon; Alendronate; Antineoplastic Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Drug Therapy, Combination; Estrogens; Etidronic Acid; Female; Humans; Imidazoles; Male; Osteoporosis; Prostatic Neoplasms; Quality of Life; Risedronic Acid; Risk Factors; Treatment Outcome; Vitamin D; Zoledronic Acid | 2004 |
Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Treatment Outcome | 2004 |
Prevention of glucocorticoid-induced osteoporosis.
Topics: Alendronate; Algorithms; Calcitonin; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Parathyroid Hormone; Risedronic Acid | 2004 |
Fracture protection in osteoporosis with risedronate.
Topics: Aged; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Risedronic Acid; Risk Factors | 2004 |
Pharmacologic prevention of osteoporotic fractures.
Topics: Aged; Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Selective Estrogen Receptor Modulators | 2004 |
Alendronate and risedronate for the treatment of postmenopausal osteoporosis: clinical profiles of the once-weekly and once-daily dosing formulations.
Topics: Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2004 |
Treating osteoporosis in post-menopausal women: a case approach.
Topics: Aged; Alendronate; Densitometry; Diphosphonates; Etidronic Acid; Female; Humans; Mass Screening; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Treatment Outcome | 2004 |
[Bone quality in treatment with raroxifene ].
Topics: Bone Density; Etidronic Acid; Evidence-Based Medicine; Femoral Neck Fractures; Humans; Meta-Analysis as Topic; Osteoporosis; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Regression Analysis; Reproducibility of Results; Risedronic Acid; Spinal Fractures; Testosterone | 2004 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Alendronate; Anabolic Agents; Bone Resorption; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Glucocorticoids; Humans; Ibandronic Acid; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide | 2005 |
Risedronate for prevention and treatment of osteoporosis in postmenopausal women.
Topics: Animals; Bone Density; Bone Remodeling; Chemistry, Pharmaceutical; Clinical Trials as Topic; Etidronic Acid; Female; Humans; Middle Aged; Osteoclasts; Osteoporosis, Postmenopausal; Rats; Risedronic Acid | 2005 |
[Pharmacological treatment of osteitis deformans (Paget's bone disease)].
Topics: Alendronate; Analgesics, Non-Narcotic; Antimetabolites; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Radionuclide Imaging; Risedronic Acid | 2005 |
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide | 2005 |
The use of bisphosphonates in the treatment of osteoporosis.
Topics: Alendronate; Bone Density; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Osteogenesis; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
[Paget's disease and its therapeutic management].
Topics: Administration, Oral; Alkaline Phosphatase; Biomarkers; Diphosphonates; Etidronic Acid; Follow-Up Studies; Humans; Infusions, Intravenous; Osteitis Deformans; Pamidronate; Remission Induction; Risedronic Acid; Time Factors; Treatment Outcome | 2005 |
Risedronate once a week.
Topics: Bone Density; Calcium Channel Blockers; Drug Administration Schedule; Etidronic Acid; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2003 |
Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Thiophenes | 2005 |
Use of highly potent bisphosphonates in the treatment of osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Remodeling; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2003 |
Oral antiresorptive therapy.
Topics: Administration, Oral; Aged; Alendronate; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2004 |
Glucocorticoid-induced osteoporosis: treatment options and guidelines.
Topics: Alendronate; Bone Density; Bone Resorption; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Glucocorticoids; Guideline Adherence; Humans; Male; Osteogenesis; Osteoporosis; Parathyroid Hormone; Practice Guidelines as Topic; Risedronic Acid | 2005 |
Microcracks in cortical bone: how do they affect bone biology?
Topics: Animals; Bone and Bones; Bone Matrix; Bone Remodeling; Calcium Channel Blockers; Etidronic Acid; Fractures, Bone; Humans; Osteocytes; Osteoporosis; Risedronic Acid; Stress, Mechanical | 2005 |
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Femur Neck; Fractures, Bone; Humans; Incidence; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment | 2005 |
Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Clinical Trials, Phase III as Topic; Creatine; Double-Blind Method; Etidronic Acid; Female; Humans; Kidney Function Tests; Osteoporosis, Postmenopausal; Phosphorus; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Retrospective Studies; Risedronic Acid; Treatment Outcome; Urinary Tract Infections | 2005 |
Review of treatment modalities for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Combined Modality Therapy; Diet; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fish Oils; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Teriparatide; Vitamin D; Vitamin D Deficiency | 2005 |
Prevention and treatment of glucocorticoid-induced osteoporosis in 2005.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Risedronic Acid; Risk Factors | 2005 |
Pharmacological therapy of Paget's and other metabolic bone diseases.
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Osteogenesis; Risedronic Acid; Zoledronic Acid | 2006 |
Patients with hip fracture: what can be improved?
Topics: Bone Density Conservation Agents; Etidronic Acid; Hip Fractures; Humans; Public Health; Risedronic Acid; Risk Factors | 2006 |
Strategies for the prevention and treatment of osteoporosis during early postmenopause.
Topics: Accidental Falls; Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Perimenopause; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators; Smoking; Vitamin D | 2006 |
[Application of anti-resorptive drugs for the treatment of osteoporosis].
Topics: Aged; Alendronate; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
[Your patients face the treatment of osteoporosis: How to improve the efficacy of management in clinical practice?].
Topics: Aged; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Congresses as Topic; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Exercise Therapy; Female; Fractures, Bone; France; Humans; Osteoporosis, Postmenopausal; Patient Compliance; Patient Education as Topic; Risedronic Acid | 2006 |
Oral ibandronate in the management of postmenopausal osteoporosis: review of upper gastrointestinal safety.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Bone; Gastrointestinal Diseases; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Drug injury in the upper gastrointestinal tract: effects of alendronate.
Topics: Alendronate; Bone Density Conservation Agents; Duodenum; Etidronic Acid; Gastric Mucosa; Humans; Models, Animal; Risedronic Acid | 2006 |
Preventing osteoporosis-related fractures: an overview.
Topics: Absorptiometry, Photon; Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Dietary Supplements; Diphosphonates; Etidronic Acid; Exercise; Female; Fractures, Bone; Humans; Ibandronic Acid; Motor Activity; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Selective Estrogen Receptor Modulators; Teriparatide; United States; Vitamin D | 2006 |
Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2006 |
Long-term experience with alendronate in the treatment of osteoporosis.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcitonin; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid | 2006 |
Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
[Therapeutic effects of risedronate on Paget's disease of bone].
Topics: Aged; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Acid; Humans; Male; Osteitis Deformans; Risedronic Acid | 2006 |
Fracture prevention in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Hormone Replacement Therapy; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Pamidronate; Parathyroid Hormone; Risedronic Acid; Selective Estrogen Receptor Modulators; Vitamin D | 2006 |
[Biphosphonate-associated osteonecrosis of the maxilla. Case report and review of the literature].
Topics: Administration, Oral; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Maxillary Diseases; Oroantral Fistula; Osteonecrosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
[Randomized controlled trials for the prevention and treatment of glucocorticoid-induced osteoporosis].
Topics: Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Hydroxycholecalciferols; Osteoporosis; Practice Guidelines as Topic; Primary Prevention; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Testosterone | 2006 |
Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Neoplasms; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Osteonecrosis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2006 |
How long should patients take medications for postmenopausal osteoporosis?
Topics: Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Drug Monitoring; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment; Teriparatide; Thiophenes; Time Factors; Treatment Outcome | 2007 |
Bisphosphonates.
Topics: Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2006 |
[Secondary osteoporosis. Evidence of treatment efficacy in patients with glucocorticoid-induced osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Calcitonin; Cholecalciferol; Etidronic Acid; Evidence-Based Medicine; Glucocorticoids; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Vitamin K 2 | 2007 |
Is cortical bone hip? What determines cortical bone properties?
Topics: Alendronate; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Fractures, Spontaneous; Hip; Hip Fractures; Humans; Osteoporosis; Peptide Fragments; RANK Ligand; Risedronic Acid; Teriparatide | 2007 |
The futility of current approaches to chondroprotection.
Topics: Anti-Bacterial Agents; Bone Density Conservation Agents; Cartilage, Articular; Chondrocytes; Doxycycline; Etidronic Acid; Humans; Osteoarthritis; Pain; Risedronic Acid | 2007 |
Osteochemonecrosis of jaws and bisphosphonates.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw; Osteonecrosis; Osteoporosis; Risedronic Acid; Risk Factors | 2007 |
[Treatment of osteoporosis by risedronate-- speed, efficacy and safety].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Pharmacological treatment of osteoporosis for people over 70.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Thiophenes; Vitamin D | 2007 |
Safety considerations with bisphosphonates for the treatment of osteoporosis.
Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid | 2007 |
[Osteoporosis in the patients with rheumatoid arthritis (3) : the efficacy and the selection of the osteoporosis therapeutic drug].
Topics: Alendronate; Arthritis, Rheumatoid; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2007 |
Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Female; Glucocorticoids; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; RANK Ligand; Risedronic Acid | 2007 |
Review of the safety and efficacy of risedronate for the treatment of male osteoporosis.
Topics: Adrenal Cortex Hormones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Male; Osteoporosis; Risedronic Acid; Risk Factors; Treatment Outcome | 2007 |
Evidence based medicine and effective interventions of pharmacological therapy for the prevention of osteoporotic fractures.
Topics: Alendronate; Bone Density Conservation Agents; Bone Resorption; Calcitonin; Clodronic Acid; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Selective Estrogen Receptor Modulators; Teriparatide; Thiophenes; Vitamin D | 2007 |
[HIP study--how to prevent hip fractures?].
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Stress, Mechanical; Tensile Strength | 2007 |
[FACT study].
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Evidence-Based Medicine; Female; Femur; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2007 |
[Bisphosphonates for osteoporosis].
Topics: Alendronate; Bone Density Conservation Agents; Contraindications; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Osteoporosis; Risedronic Acid | 2007 |
[Evidence of risedronate for treatment of osteoporosis].
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Evidence-Based Medicine; Female; Femoral Neck Fractures; Humans; Male; Meta-Analysis as Topic; Osteoporosis; Peptides; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2007 |
[Efficacy and tolerability of once-weekly administration of 35 mg alendronate and 17.5 mg risedronate].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials as Topic; Double-Blind Method; Etidronic Acid; Gastrointestinal Diseases; Humans; Lumbar Vertebrae; Osteoporosis; Patient Compliance; Risedronic Acid; Spinal Fractures | 2007 |
A review of Paget's disease of bone with a focus on the efficacy and safety of zoledronic acid 5 mg.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Pamidronate; Risedronic Acid; Risk Factors; Treatment Outcome; Zoledronic Acid | 2008 |
Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2008 |
[Variance of expressions of extracellular matrix components and effects of anti-osteoporotic drugs on Mönckeberg's arteriosclerosis].
Topics: Animals; Bone Density Conservation Agents; Cattle; Etidronic Acid; Extracellular Matrix; Female; Humans; Ketocholesterols; Lipoproteins, LDL; Monckeberg Medial Calcific Sclerosis; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tropoelastin | 2008 |
[Risedronate (Actonel)--from randomized clinical trials to real life].
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2007 |
Efficacy of risedronate against hip fracture in patients with neurological diseases: a meta-analysis of randomized controlled trials.
Topics: Age Distribution; Aged; Aged, 80 and over; Alzheimer Disease; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Incidence; Male; Meta-Analysis as Topic; Middle Aged; Nervous System Diseases; Osteoporosis; Parkinson Disease; Probability; Prognosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Sex Distribution; Stroke; Treatment Outcome | 2008 |
[Osteoporosis in the elderly--diagnosis and treatment].
Topics: Accidental Falls; Age Factors; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Etidronic Acid; Exercise; Female; Hip Fractures; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Sex Factors; Spinal Fractures; Vitamin D | 2005 |
Risedronate once monthly: a potential new regimen for the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid | 2008 |
Nonvertebral fracture risk reduction with nitrogen-containing bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Imidazoles; Male; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Zoledronic Acid | 2008 |
[Efficacy and tolerability of risedronate for the treatment of osteoporosis].
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Fractures, Bone; Humans; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid | 2008 |
Paget disease of bone: therapeutic options.
Topics: Alendronate; Alkaline Phosphatase; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Humans; Osteitis Deformans; Pamidronate; Retreatment; Risedronic Acid; Treatment Outcome | 2008 |
Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system.
Topics: Anthraquinones; Antirheumatic Agents; Calcitonin; Chondroitin Sulfates; Clinical Trials as Topic; Etidronic Acid; Glucosamine; Humans; Hyaluronic Acid; Organometallic Compounds; Osteoarthritis; Outcome Assessment, Health Care; Plant Extracts; Risedronic Acid; Thiophenes | 2008 |
[New development in bisphosphonate treatment. Characteristics and effectiveness of intermittent bisphophonates].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Patient Compliance; Risedronic Acid; Zoledronic Acid | 2009 |
Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Topics: Alendronate; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Organometallic Compounds; Osteoporosis; Risedronic Acid; Teriparatide; Thiophenes | 2009 |
Efficacy of bisphosphonates in reducing fracture risk in postmenopausal osteoporosis.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2009 |
Bisphosphonates for postmenopausal osteoporosis: determining duration of treatment.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Fractures, Bone; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Pamidronate; Risedronic Acid | 2009 |
Heterotopic ossification in systemic sclerosis.
Topics: Acetaminophen; Colchicine; Drug Therapy, Combination; Etidronic Acid; Humans; Knee Joint; Male; Middle Aged; Ossification, Heterotopic; Pain Measurement; Prognosis; Risedronic Acid; Risk Assessment; Scleroderma, Systemic; Severity of Illness Index; Thigh; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Follow-Up Studies; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk; Spinal Fractures; Young Adult | 2009 |
[Risedronate for treatment of osteoporosis].
Topics: Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Fractures, Bone; Fractures, Spontaneous; Humans; Osteoporosis; Risedronic Acid | 2009 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Aged; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2009 |
[Biochemical markers of bone turnover. New aspect. Biochemical markers of bone turnover in long term treatment with bisphosphonate].
Topics: Alendronate; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Osteoporosis; Risedronic Acid; Time Factors | 2009 |
Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Humans; Ibandronic Acid; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid | 2009 |
Effect of osteoporosis treatment on mortality: a meta-analysis.
Topics: Age Factors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Organometallic Compounds; Osteoporosis; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Treatment Outcome; Zoledronic Acid | 2010 |
Review of osteoporosis pharmacotherapy for geriatric patients.
Topics: Aged; Alendronate; Bone Density; Calcitonin; Calcium, Dietary; Diphosphonates; Economics, Pharmaceutical; Etidronic Acid; Exercise; Female; Humans; Ibandronic Acid; Life Style; Male; Osteonecrosis; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Vitamin D | 2009 |
Effects of risedronate on osteoarthritis of the knee.
Topics: Animals; Calcium Channel Blockers; Cartilage; Diphosphonates; Etidronic Acid; Humans; Osteoarthritis, Knee; Risedronic Acid | 2010 |
Assessment of the relationship between age and the effect of risedronate treatment in women with postmenopausal osteoporosis: a pooled analysis of four studies.
Topics: Adult; Age Distribution; Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Clinical Trials, Phase III as Topic; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Global Health; Humans; Incidence; Middle Aged; North America; Osteoporosis, Postmenopausal; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Treatment Outcome | 2010 |
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Patient Compliance; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2011 |
Challenges in clinical patient management.
Topics: Aromatase Inhibitors; Bone Density; Breast Neoplasms; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Osteoporosis; Risedronic Acid; Tamoxifen | 2010 |
[Dementia and fracture].
Topics: Accidental Falls; Bone Density; Dementia; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism, Secondary; Osteoporosis; Risedronic Acid; Risk; Risk Factors; Sunlight; Vitamin D Deficiency; Vitamin K 2; Vitamin K Deficiency | 2010 |
Osteonecrosis of the jaw and the role of macrophages.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid | 2011 |
Treatments for osteoporosis in people with a disability.
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Disabled Persons; Etidronic Acid; Humans; Osteoporosis; Parkinson Disease; Risedronic Acid; Spinal Cord Injuries; Stroke | 2011 |
Vertebral fracture efficacy during risedronate therapy in patients using proton pump inhibitors.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Gastrointestinal Diseases; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Polypharmacy; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2012 |
In brief: delayed-release risedronate (Atelvia).
Topics: Bone Density Conservation Agents; Clinical Trials as Topic; Delayed-Action Preparations; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2011 |
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Topics: Adolescent; Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Hip Joint; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteogenesis Imperfecta; Risedronic Acid; Treatment Outcome; Young Adult | 2012 |
What is the optimal duration of bisphosphonate therapy?
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Femoral Fractures; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid; Risk Factors; Time Factors | 2011 |
Stress fractures: diagnosis, treatment, and prevention.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Calcium, Dietary; Crutches; Diagnosis, Differential; Diagnostic Imaging; Electric Stimulation Therapy; Etidronic Acid; Fracture Healing; Fractures, Stress; Humans; Orthotic Devices; Pain; Risedronic Acid; Risk Factors; Ultrasonic Therapy; Vitamin D | 2011 |
Long-term treatment of osteoporosis in postmenopausal women: a review from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Risedronic Acid; Thiophenes; Vitamin D | 2012 |
Risedronate-associated scleritis: a case report and review of the literature.
Topics: Adrenal Cortex Hormones; Aged; Brain; China; Diphosphonates; Etidronic Acid; Female; Humans; Inflammation; Osteoporosis; Recurrence; Rheumatology; Risedronic Acid; Scleritis; Tomography, X-Ray Computed | 2012 |
A meta-analysis characterizing the dose-response relationships for three oral nitrogen-containing bisphosphonates in postmenopausal women.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spine | 2013 |
[Bisphosphonate related osteonecrosis of the jaw and infection with Actinomyces].
Topics: Actinomyces; Actinomycosis; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Combined Modality Therapy; Diphosphonates; Disease Susceptibility; Etidronic Acid; Female; Humans; Imidazoles; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Models, Biological; Neoplasms; Osteitis; Osteoporosis; Retrospective Studies; Risedronic Acid; Zoledronic Acid | 2012 |
[Combination of alendronate plus alfacalcidol in the treatment of osteoporosis. Rationale, preclinical data and clinical evidence].
Topics: Aged; Alendronate; Animals; Bone Density; Disease Models, Animal; Drug Combinations; Drug Interactions; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Hydroxycholecalciferols; Long-Term Care; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Rats; Risedronic Acid | 2012 |
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clodronic Acid; Diphosphonates; Disease-Free Survival; Etidronic Acid; Female; Humans; Ibandronic Acid; Pamidronate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design; Risedronic Acid; Risk; Treatment Outcome | 2013 |
[Dynamics of bone resorption analyzed by intravital imaging].
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Drug Design; Etidronic Acid; Humans; Mice; Microscopy, Fluorescence, Multiphoton; Molecular Imaging; Molecular Targeted Therapy; Osteoclasts; Osteoporosis; RANK Ligand; Risedronic Acid | 2013 |
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bis
Topics: Administration, Oral; Aged; Antibodies, Monoclonal, Humanized; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Denosumab; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Hip Joint; Humans; Ibandronic Acid; Injections, Subcutaneous; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Peptides; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors | 2014 |
[Glucocorticoid and bone].
Topics: Administration, Ophthalmic; Adult; Aged; Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Glucocorticoids; Humans; Male; Mice; Middle Aged; Osteogenesis; Osteoporosis; Practice Guidelines as Topic; Prednisolone; Risedronic Acid; Risk; Teriparatide | 2014 |
Anti-reabsorptive agents in women with osteoporosis: determining statistical equivalence according to evidence-based methods.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Female; Humans; Ibandronic Acid; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Therapeutic Equivalency | 2014 |
Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Humans; Imidazoles; Male; Middle Aged; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2015 |
Bone safety with risedronate: histomorphometric studies at different dose levels and exposure.
Topics: Aged; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2015 |
Stimulation of in-vitro angiogenesis by low concentrations of risedronate is mitigated by 1,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
Topics: 24,25-Dihydroxyvitamin D 3; Animals; Bone Density Conservation Agents; Calcitriol; Etidronic Acid; Humans; In Vitro Techniques; Neovascularization, Physiologic; Risedronic Acid | 2015 |
Bisphosphonates for Secondary Prevention of Osteoporotic Fractures: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Topics: Aged; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Network Meta-Analysis; Osteoporotic Fractures; Randomized Controlled Trials as Topic; Risedronic Acid; Secondary Prevention; Zoledronic Acid | 2019 |
History of risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Osteoporosis, Postmenopausal; Risedronic Acid | 2020 |
Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Topics: Adult; Alendronate; Antineoplastic Agents, Hormonal; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Clodronic Acid; Denosumab; Diphosphonates; Etidronic Acid; Humans; Male; Network Meta-Analysis; Pamidronate; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Zoledronic Acid | 2020 |
Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.
Topics: Adrenal Cortex Hormones; Alendronate; Bayes Theorem; Bone Density Conservation Agents; Denosumab; Etidronic Acid; Glucocorticoids; Humans; Network Meta-Analysis; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2022 |
238 trial(s) available for etidronate and risedronic acid
| Article | Year |
|---|---|
Risedronate in Paget's disease: preliminary results of a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Middle Aged; Osteitis Deformans; Risedronic Acid | 1994 |
Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
Topics: Adult; Antineoplastic Agents, Hormonal; Bone Density; Breast Neoplasms; Calcium Channel Blockers; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tamoxifen | 1997 |
A 2-year phase II study with 1-year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Femur Neck; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 1997 |
Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up.
Topics: Adult; Alkaline Phosphatase; Amino Acids; Bone Density; Calcium Channel Blockers; Creatinine; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Risedronic Acid; Time Factors | 1998 |
Risedronate gastrointestinal absorption is independent of site and rate of administration.
Topics: Area Under Curve; Calcium Channel Blockers; Dosage Forms; Duodenum; Etidronic Acid; Gastric Mucosa; Humans; Ileum; Intestinal Absorption; Male; Risedronic Acid | 1998 |
Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers; Calcium Channel Blockers; Capsules; Delayed-Action Preparations; Etidronic Acid; Female; Gelatin; Humans; Male; Middle Aged; Osteitis Deformans; Risedronic Acid | 1998 |
Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Calcium Channel Blockers; Consumer Product Safety; Dose-Response Relationship, Drug; Drug Tolerance; Etidronic Acid; Female; Follow-Up Studies; Humans; International Cooperation; Male; Middle Aged; Osteitis Deformans; Risedronic Acid; Time Factors | 1999 |
A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate/Etidronate Study Group.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Bone and Bones; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis Deformans; Pain; Recurrence; Risedronic Acid; Treatment Outcome | 1999 |
Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Capsules; Cellulose; Esophagus; Etidronic Acid; Excipients; Female; Gelatin; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Risedronic Acid; Tablets | 1999 |
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Topics: Aged; Analysis of Variance; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Radiography; Risedronic Acid; Risk; Spinal Fractures | 1999 |
Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Analysis of Variance; Biomarkers; Bone Resorption; Calcium Channel Blockers; Demography; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Middle Aged; Risedronic Acid | 1999 |
The effect of dosing regimen on the pharmacokinetics of risedronate.
Topics: Absorption; Adolescent; Adult; Age Factors; Calcium Channel Blockers; Etidronic Acid; Fasting; Female; Food-Drug Interactions; Humans; Male; Risedronic Acid; Sex Factors; Time Factors | 1999 |
Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Algorithms; Australia; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2000 |
Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers.
Topics: Administration, Oral; Adult; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Male; Risedronic Acid | 2000 |
Effect of renal function on risedronate pharmacokinetics after a single oral dose.
Topics: Administration, Oral; Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Kidney; Kidney Diseases; Kidney Function Tests; Male; Middle Aged; Risedronic Acid | 2000 |
Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Bone Density; Consumer Product Safety; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures | 2000 |
Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Europe; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Risedronic Acid; Time Factors | 2000 |
Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients.
Topics: Administration, Oral; Aged; Arthritis, Rheumatoid; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis; Prednisolone; Risedronic Acid | 2000 |
Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women.
Topics: Adult; Alendronate; Duodenoscopy; Duodenum; Endoscopy; Esophagoscopy; Esophagus; Etidronic Acid; Female; Gastroscopy; Humans; Incidence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Single-Blind Method; Stomach; Stomach Ulcer | 2000 |
Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.
Topics: Absorptiometry, Photon; Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures | 2000 |
Short-term risedronate treatment in postmenopausal women: effects on biochemical markers of bone turnover.
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Remodeling; Calcium Channel Blockers; Cohort Studies; Collagen; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Peptides; Postmenopause; Procollagen; Risedronic Acid | 2000 |
An endoscopic comparison of the effects of alendronate and risedronate on upper gastrointestinal mucosae.
Topics: Aged; Aged, 80 and over; Alendronate; Calcium Channel Blockers; Double-Blind Method; Endoscopy, Gastrointestinal; Esophagoscopy; Etidronic Acid; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Male; Middle Aged; Risedronic Acid; Time Factors | 2000 |
Placebo-controlled, randomized, evaluator-blinded endoscopy study of risedronate vs. aspirin in healthy postmenopausal women.
Topics: Adult; Aged; Aspirin; Duodenal Ulcer; Endoscopy, Gastrointestinal; Esophagus; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Stomach Ulcer | 2000 |
Effect of high doses of oral risedronate (20 mg/day) on serum parathyroid hormone levels and urinary collagen cross-link excretion in postmenopausal women with spinal osteoporosis.
Topics: Aged; Calcium Channel Blockers; Collagen; Cross-Linking Reagents; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Risedronic Acid; Spinal Diseases | 2001 |
Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Incidence; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2001 |
Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women.
Topics: Aged; Bone and Bones; Bone Density; Double-Blind Method; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.
Topics: Administration, Oral; Adult; Analysis of Variance; Area Under Curve; Calcium Channel Blockers; Cross-Over Studies; Etidronic Acid; Female; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Risedronic Acid | 2001 |
The use of scintigraphy to demonstrate the rapid esophageal transit of the oval film-coated placebo risedronate tablet compared to a round uncoated placebo tablet when administered with minimal volumes of water.
Topics: Calcium Channel Blockers; Chemistry, Pharmaceutical; Cross-Over Studies; Esophagus; Etidronic Acid; Female; Gastrointestinal Transit; Humans; Middle Aged; Postmenopause; Radionuclide Imaging; Risedronic Acid; Tablets; Water | 2001 |
Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Humans; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2001 |
Tolerability of risedronate in postmenopausal women intolerant of alendronate.
Topics: Alendronate; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Dropouts; Postmenopause; Risedronic Acid; Treatment Outcome | 2001 |
The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Resorption; Calcium Channel Blockers; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures; Stomach; Treatment Outcome | 2002 |
Risedronate reduces the risk of first vertebral fracture in osteoporotic women.
Topics: Aged; Bone Density; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk; Time Factors; Vitamin D | 2002 |
14 day endoscopy study comparing risedronate and alendronate in postmenopausal women stratified by Helicobacter pylori status.
Topics: Aged; Alendronate; Analysis of Variance; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Gastric Mucosa; Gastroscopy; Helicobacter Infections; Helicobacter pylori; Humans; Middle Aged; Osteoporosis, Postmenopausal; Probability; Reference Values; Risedronic Acid; Risk Assessment; Single-Blind Method; Stomach Ulcer; Treatment Outcome | 2002 |
A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
Topics: Adult; Aged; Biomarkers; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Risedronic Acid; Spinal Fractures | 2002 |
Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Osteogenesis; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures; Statistics, Nonparametric | 2002 |
Risedronate prevents hip fractures, but who should get therapy?
Topics: Accidental Falls; Aged; Aged, 80 and over; Alendronate; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; United States | 2002 |
Risedronate prevents new vertebral fractures in postmenopausal women at high risk.
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Incidence; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Secondary Prevention; Spinal Fractures | 2003 |
Role of gastric mucosal and gastric juice cytokine concentrations in development of bisphosphonate damage to gastric mucosa.
Topics: Administration, Oral; Aged; Alendronate; Biomarkers; Biopsy, Needle; Cytokines; Dinoprostone; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Gastric Juice; Gastric Mucosa; Gastroscopy; Humans; Interleukin-1; Interleukin-13; Interleukin-8; Middle Aged; Postmenopause; Reference Values; Risedronic Acid; Sensitivity and Specificity; Single-Blind Method | 2003 |
A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
Topics: Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2003 |
Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
Topics: Aged; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Treatment Outcome | 2003 |
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.
Topics: Aged; Biomarkers; Bone Resorption; Calcium Channel Blockers; Collagen; Collagen Type I; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Peptides; Placebos; Risedronic Acid; Risk Factors | 2003 |
Risedronate preserves bone architecture in early postmenopausal women in 1 year as measured by three-dimensional microcomputed tomography.
Topics: Absorptiometry, Photon; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Ilium; Imaging, Three-Dimensional; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tomography Scanners, X-Ray Computed | 2003 |
Comparison of change in bone resorption and bone mineral density with once-weekly alendronate and daily risedronate: a randomised, placebo-controlled study.
Topics: Aged; Aged, 80 and over; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Calcium Channel Blockers; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2003 |
Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.
Topics: Administration, Oral; Adult; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Hematologic Neoplasms; Humans; Lumbar Vertebrae; Male; Osteocalcin; Osteoporosis; Prospective Studies; Risedronic Acid; Stem Cell Transplantation; Time Factors; Treatment Outcome; Vitamin D | 2003 |
Risedronate rapidly reduces the risk for nonvertebral fractures in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Risedronic Acid; Time Factors | 2004 |
Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Topics: Aged; Amino Acids; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Incidence; Osteoporosis; Placebos; Postmenopause; Risedronic Acid; Spinal Fractures | 2004 |
Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
Topics: Administration, Oral; Adult; Area Under Curve; Calcium Channel Blockers; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Humans; Japan; Male; Middle Aged; Molecular Structure; Osteoporosis; Risedronic Acid; United Kingdom; Urine | 2004 |
Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.
Topics: Administration, Oral; Adult; Calcium Channel Blockers; Cross-Over Studies; Drug Administration Schedule; Eating; Etidronic Acid; Humans; Intestinal Absorption; Japan; Male; Osteoporosis; Risedronic Acid; Time Factors | 2004 |
Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography.
Topics: Aged; Biopsy; Bone and Bones; Etidronic Acid; Female; Humans; Imaging, Three-Dimensional; Osteoporosis, Postmenopausal; Risedronic Acid; Tomography | 2004 |
Two-year efficacy and tolerability of risedronate once a week for the treatment of women with postmenopausal osteoporosis.
Topics: Aged; Analysis of Variance; Bone Density; Double-Blind Method; Etidronic Acid; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2004 |
The effect of prophylactic treatment with risedronate on stress fracture incidence among infantry recruits.
Topics: Etidronic Acid; Fractures, Stress; Humans; Incidence; Israel; Male; Military Personnel; Risedronic Acid | 2004 |
Effects of risedronate on bone density in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Biomarkers; Bone and Bones; Bone Density; Etidronic Acid; Female; Humans; Pilot Projects; Risedronic Acid; Treatment Outcome | 2004 |
A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
Topics: Aged; Alkaline Phosphatase; Amino Acids; Biomarkers; Body Height; Bone and Bones; Collagen; Collagen Type I; Etidronic Acid; Female; Humans; Incidence; Japan; Osteoporosis, Postmenopausal; Peptides; Quality of Life; Risedronic Acid; Spinal Fractures; Surveys and Questionnaires | 2004 |
Relationship between changes in bone mineral density and vertebral fracture risk associated with risedronate: greater increases in bone mineral density do not relate to greater decreases in fracture risk.
Topics: Absorptiometry, Photon; Aged; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Risk Factors; Spinal Fractures | 2004 |
Seven years of treatment with risedronate in women with postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Radiography; Risedronic Acid; Spinal Fractures | 2004 |
Five years of treatment with risedronate and its effects on bone safety in women with postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Canada; Cohort Studies; Collagen; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Placebos; Risedronic Acid; Time Factors | 2004 |
Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old.
Topics: Aged; Aged, 80 and over; Bone Remodeling; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Risk; Spinal Fractures; Treatment Outcome | 2004 |
Comparison of the effects of alendronate and risedronate on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Topics: Aged; Alendronate; Alkaline Phosphatase; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Creatinine; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
Topics: Aged; Alendronate; Biomarkers; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States | 2005 |
Skeletal benefit after one year of risedronate therapy in patients with rheumatoid arthritis and glucocorticoid-induced osteoporosis: a prospective study.
Topics: Alkaline Phosphatase; Arthritis, Rheumatoid; Bone and Bones; C-Reactive Protein; Cross-Linking Reagents; Densitometry; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Outpatients; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Ultrasonography | 2004 |
Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Bone Density; Bone Resorption; Calcium Channel Blockers; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis; Postmenopause; Risedronic Acid; Treatment Outcome | 2004 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density; Bone Density Conservation Agents; Calcium; Double-Blind Method; Etidronic Acid; Female; Hemiplegia; Hip Fractures; Humans; Incidence; Osteoporosis; Placebos; Risedronic Acid; Stroke; Time; Treatment Outcome | 2005 |
The efficacy and tolerability of risedronate on bone mineral density and bone turnover markers in osteoporotic Chinese women: a randomized placebo-controlled study.
Topics: Asian People; Biomarkers; Bone Density; Bone Remodeling; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Statins have additive effects to vertebral bone mineral density in combination with risedronate in hypercholesterolemic postmenopausal women.
Topics: Atorvastatin; Bone Density; Bone Diseases, Metabolic; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Etidronic Acid; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Postmenopause; Pyrroles; Risedronic Acid | 2005 |
Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
Topics: Absorptiometry, Photon; Aged; Anthropometry; Bone Density; Double-Blind Method; Etidronic Acid; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Recurrence; Risedronic Acid; Risk Factors; Spinal Fractures | 2005 |
The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover.
Topics: Aged; Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Data Interpretation, Statistical; Etidronic Acid; Female; Humans; Ilium; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Synchrotrons; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2005 |
Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173].
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Etidronic Acid; Female; Humans; Knee Joint; Male; Middle Aged; Osteoarthritis, Knee; Prospective Studies; Risedronic Acid | 2005 |
Efficacy of risedronate administration in osteoporotic postmenopausal women affected by inflammatory bowel disease.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur; Femur Neck; Humans; Inflammatory Bowel Diseases; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2005 |
Vertebral fracture risk reduction with risedronate in post-menopausal women with osteoporosis: a meta-analysis of individual patient data.
Topics: Bone Density; Double-Blind Method; Etidronic Acid; Humans; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Reduction Behavior; Spinal Fractures | 2005 |
Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risedronic Acid; Spine; Vitamin D | 2006 |
Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study.
Topics: Alendronate; Alveolar Bone Loss; Analysis of Variance; Chemotherapy, Adjuvant; Dental Scaling; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractals; Humans; Male; Middle Aged; Periodontal Index; Periodontitis; Radiography; Risedronic Acid; Statistics, Nonparametric | 2005 |
Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Remodeling; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Imidazoles; Infusions, Intravenous; Male; Osteitis Deformans; Quality of Life; Risedronic Acid; Zoledronic Acid | 2005 |
Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Double-Blind Method; Endoscopy, Gastrointestinal; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Osteoarthritis, Knee; Risedronic Acid; Risk Assessment | 2005 |
Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
Topics: Absorptiometry, Photon; Adult; Amino Acids; Biomarkers; Bone Density Conservation Agents; Creatinine; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risedronic Acid; Treatment Outcome | 2005 |
A double-blind placebo-controlled study of the effects of the bisphosphonate risedronate on bone mass in patients with inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Inflammatory Bowel Diseases; Male; Middle Aged; Osteoporosis; Reference Values; Risedronic Acid; Risk Assessment; Treatment Outcome | 2006 |
Esophageal transit of the weekly film-coated risedronate (Actonel) placebo tablet in subjects with Kyphosis.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density Conservation Agents; Esophagus; Etidronic Acid; Female; Gastric Emptying; Gastrointestinal Transit; Humans; Kyphosis; Male; Middle Aged; Radionuclide Imaging; Risedronic Acid; Severity of Illness Index; Tablets, Enteric-Coated; Technetium Tc 99m Pentetate; Water | 2006 |
Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Collagen Type I; Etidronic Acid; Female; Hip; Humans; Osteocalcin; Osteoporosis; Osteoprotegerin; Postmenopause; Prospective Studies; RANK Ligand; Risedronic Acid | 2006 |
Efficacy and safety of risedronate sodium in treatment of postmenopausal osteoporosis.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Safety | 2005 |
Clinical significance of risedronate for osteoporosis in the initial treatment of male patients with Graves' disease.
Topics: Adult; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Collagen Type I; Etidronic Acid; Graves Disease; Humans; Hyperthyroidism; Japan; Male; Middle Aged; Models, Statistical; Osteoporosis; Peptides; Risedronic Acid; Thyroid Hormones; Time Factors; X-Rays | 2006 |
Effect of risedronate on bone metabolism after total hip arthroplasty: a prospective randomised study.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Bone Density; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Hip Prosthesis; Humans; Joint Instability; Male; Middle Aged; Prospective Studies; Prosthesis Failure; Reference Values; Risedronic Acid; Risk Factors; Statistics, Nonparametric; Treatment Outcome | 2006 |
Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography.
Topics: Adult; Aged; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Cohort Studies; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Premenopause; Risedronic Acid; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Femur; Femur Neck; Fractures, Bone; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2006 |
Between-meal risedronate does not alter bone turnover in nursing home residents.
Topics: Aged; Alkaline Phosphatase; Bone Density Conservation Agents; Bone Remodeling; Calcium; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Male; Nursing Homes; Peptides; Risedronic Acid; Vitamin D | 2006 |
Efficacy and acceptability of risedronate 5 mg daily compared with 35 mg once weekly for the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Acceptance of Health Care; Patient Satisfaction; Risedronic Acid; Treatment Outcome | 2006 |
Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors; Time Factors | 2006 |
A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients.
Topics: Adult; Aged; Bone Density Conservation Agents; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Humans; Knee Joint; Longitudinal Studies; Male; Middle Aged; Osteoarthritis, Knee; Osteoporosis; Radiography; Risedronic Acid; Tibia | 2007 |
Effects of risedronate on lumbar bone mineral density, bone resorption, and incidence of vertebral fracture in elderly male patients with leprosy.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Etidronic Acid; Fractures, Bone; Humans; Leprosy; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Radiography; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2006 |
Is a single infusion of zoledronic acid more effective than oral risedronate for the treatment of patients with Paget's disease?
Topics: Administration, Oral; Adult; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2006 |
Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid | 2006 |
Bone material properties in trabecular bone from human iliac crest biopsies after 3- and 5-year treatment with risedronate.
Topics: Biopsy; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Calcium; Collagen; Etidronic Acid; Female; Humans; Ilium; Osteoporosis, Postmenopausal; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Vitamin D | 2006 |
Long-term control of bone turnover in Paget's disease with zoledronic acid and risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2007 |
Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease.
Topics: Adolescent; Adult; Aged; Bone Density Conservation Agents; Bone Diseases, Metabolic; Dose-Response Relationship, Drug; Etidronic Acid; Female; Glomerulonephritis; Humans; Male; Middle Aged; Prednisolone; Prospective Studies; Risedronic Acid | 2007 |
Prevention of bone loss in survivors of breast cancer: A randomized, double-blind, placebo-controlled clinical trial.
Topics: Antineoplastic Agents; Bone Density; Bone Remodeling; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2007 |
Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Bone Density Conservation Agents; Cartilage; Disease Progression; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoarthritis, Knee; Pain; Placebos; Radiography; Risedronic Acid; Severity of Illness Index; Treatment Outcome | 2006 |
Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD).
Topics: Adult; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Kidney Diseases; Male; Prednisolone; Prospective Studies; Risedronic Acid; Vitamin D | 2007 |
Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
Topics: Aged; Alendronate; Bone Density; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2006 |
Effects of calcitonin, risedronate, and raloxifene on erythrocyte antioxidant enzyme activity, lipid peroxidation, and nitric oxide in postmenopausal osteoporosis.
Topics: Adult; Aged; Antioxidants; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcitonin; Erythrocytes; Etidronic Acid; Female; Humans; Lipid Peroxidation; Malondialdehyde; Middle Aged; Nitric Oxide; Osteoporosis, Postmenopausal; Oxidative Stress; Oxidoreductases; Raloxifene Hydrochloride; Risedronic Acid | 2007 |
Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Monitoring, Physiologic; Osteoporosis, Postmenopausal; Patient Compliance; Prospective Studies; Risedronic Acid; Treatment Refusal | 2007 |
Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women.
Topics: Aged; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Postmenopause; Raloxifene Hydrochloride; Risedronic Acid; Surveys and Questionnaires | 2007 |
Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2007 |
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease.
Topics: Aged; Aged, 80 and over; Amino Acids; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Ergocalciferols; Etidronic Acid; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Parkinson Disease; Placebo Effect; Prospective Studies; Risedronic Acid; Risk Assessment; Risk Factors; Treatment Outcome; Vitamin D Deficiency | 2007 |
[The effect of risedronate treatment on bone turnover markers in patients with hip fracture].
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Etidronic Acid; Female; Hip Fractures; Humans; Male; Osteoporosis, Postmenopausal; Peptides; Radiography; Risedronic Acid; Treatment Outcome | 2007 |
The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
Topics: Aged; Alendronate; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Etidronic Acid; Female; Humans; Kidney; Kidney Function Tests; Male; Middle Aged; Osteoporosis, Postmenopausal; Phosphorus; Raloxifene Hydrochloride; Risedronic Acid; Uric Acid | 2007 |
Monitoring of Risedronate by biochemical bone markers in clinical practice.
Topics: Alkaline Phosphatase; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Drug Monitoring; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Peptide Fragments; Procollagen; Risedronic Acid; Time Factors; Treatment Outcome; Vitamin K Deficiency | 2005 |
Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Hip Joint; Humans; Male; Middle Aged; Osteoporosis; Postoperative Complications; Risedronic Acid; Treatment Outcome | 2007 |
Weekly risedronate in kidney transplant patients with osteopenia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Glucocorticoids; Graft Rejection; Humans; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Risedronic Acid; Treatment Outcome | 2007 |
Evaluation of 41calcium as a new approach to assess changes in bone metabolism: effect of a bisphosphonate intervention in postmenopausal women with low bone mass.
Topics: Aged; Biomarkers; Bone Density; Bone Diseases, Metabolic; Calcium Radioisotopes; Diphosphonates; Etidronic Acid; Female; Humans; Kinetics; Osteoporosis, Postmenopausal; Postmenopause; Risedronic Acid; Sensitivity and Specificity | 2007 |
Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients.
Topics: Aged; Aged, 80 and over; Arthritis, Rheumatoid; Biomarkers; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome | 2007 |
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
Topics: Bone Density; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Time Factors | 2008 |
Fracture risk remains reduced one year after discontinuation of risedronate.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid; Spinal Fractures | 2008 |
Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
Topics: Aged; Bone Density Conservation Agents; Calcium; Cell Survival; Cells, Cultured; Colony-Forming Units Assay; Etidronic Acid; Female; Humans; Middle Aged; Osteoclasts; Osteoporosis, Postmenopausal; Osteoprotegerin; Postmenopause; RANK Ligand; Risedronic Acid; Stem Cells; Time Factors; Tumor Necrosis Factor-alpha; Vitamin D | 2008 |
Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Collagen Type I; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Peptides; Pilot Projects; Risedronic Acid; Treatment Outcome | 2007 |
Relationships between biochemical markers of bone and cartilage degradation with radiological progression in patients with knee osteoarthritis receiving risedronate: the Knee Osteoarthritis Structural Arthritis randomized clinical trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Collagen Type I; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoarthritis, Knee; Peptides; Radiography; Risedronic Acid | 2008 |
Effects of risedronate 5 mg/d on bone mineral density and bone turnover markers in late-postmenopausal women with osteopenia: a multinational, 24-month, randomized, double-blind, placebo-controlled, parallel-group, phase III trial.
Topics: Aged; Analysis of Variance; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Postmenopause; Risedronic Acid; White People | 2007 |
Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Androgens; Bone Density Conservation Agents; Etidronic Acid; Gonadotropin-Releasing Hormone; Humans; Male; Osteoporosis; Prostatic Neoplasms; Risedronic Acid | 2007 |
Risedronate for prevention of bone mineral density loss in patients receiving high-dose glucocorticoids: a randomized double-blind placebo-controlled trial.
Topics: Adipose Tissue; Adult; Aged; Anti-Inflammatory Agents; Body Mass Index; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Male; Middle Aged; Osteoporosis; Prednisolone; Risedronic Acid; Treatment Outcome | 2008 |
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results.
Topics: Absorptiometry, Photon; Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur Neck; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pelvic Bones; Risedronic Acid; Treatment Outcome | 2008 |
Higher efficacy of urinary bone resorption marker measurements in assessing response to treatment for osteoporosis in postmenopausal women.
Topics: Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Etidronic Acid; Female; Humans; Japan; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid | 2008 |
Osteoclast inhibitory effects of vitamin K2 alone or in combination with etidronate or risedronate in patients with rheumatoid arthritis: 2-year results.
Topics: Aged; Alkaline Phosphatase; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Cohort Studies; Collagen Type I; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoclasts; Osteoporosis; Osteoprotegerin; Peptides; Prednisolone; Prospective Studies; RANK Ligand; Risedronic Acid; Vitamin K 2 | 2008 |
Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study.
Topics: Aged; Alendronate; Anti-Inflammatory Agents; Arthritis, Rheumatoid; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Double-Blind Method; Etidronic Acid; Family Practice; Female; Fractures, Bone; Humans; Incidence; Japan; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis, Postmenopausal; Prednisolone; Pruritus; Retrospective Studies; Risedronic Acid; Time Factors | 2008 |
Serum osteoprotegerin and RANKL are not specifically altered in women with postmenopausal osteoporosis treated with teriparatide or risedronate: a randomized, controlled trial.
Topics: Aged; Biomarkers; Bone Density Conservation Agents; Calcium; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; RANK Ligand; Risedronic Acid; Teriparatide | 2008 |
A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24-month results from FACTS-International.
Topics: Absorptiometry, Photon; Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2008 |
Effect of risedronate on biochemical marker of bone resorption in postmenopausal women with osteoporosis or osteopenia.
Topics: Aged; Algorithms; Biomarkers; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid; Treatment Outcome | 2008 |
Efficacy of risedronate in Japanese male patients with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Dose-Response Relationship, Drug; Etidronic Acid; Femur Neck; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Peptides; Prospective Studies; Risedronic Acid | 2008 |
Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial.
Topics: Absorptiometry, Photon; Aged; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide | 2008 |
Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial.
Topics: Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Calcium, Dietary; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2008 |
Additive effects of glucosamine or risedronate for the treatment of osteoarthritis of the knee combined with home exercise: a prospective randomized 18-month trial.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Exercise Therapy; Female; Glucosamine; Humans; Knee Joint; Middle Aged; Osteoarthritis; Prospective Studies; Risedronic Acid | 2008 |
Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors.
Topics: Aged; Arteries; Biomarkers; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; Demography; Elasticity; Etidronic Acid; Female; Hemodynamics; Humans; Inflammation; Osteoporosis; Risedronic Acid; Risk Factors; Time Factors | 2008 |
Effect of risedronate on hip structural geometry: a 1-year, double-blind trial in chemotherapy-induced postmenopausal women.
Topics: Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Femur; Hip Joint; Humans; Middle Aged; Patient Compliance; Postmenopause; Risedronic Acid; Statistics, Nonparametric | 2008 |
Secondary osteoporosis in long-term bedridden patients with cerebral palsy.
Topics: Absorptiometry, Photon; Adolescent; Alkaline Phosphatase; Anticonvulsants; Benzodiazepines; Biomarkers; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Child, Preschool; Clobazam; Collagen Type I; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Infant; Isoxazoles; Lumbar Vertebrae; Male; Osteoporosis; Peptides; Retrospective Studies; Risedronic Acid; Severity of Illness Index; Time Factors; Treatment Outcome; Zonisamide | 2008 |
Esophageal transit and in vivo disintegration of branded risedronate sodium tablets and two generic formulations of alendronic acid tablets: a single-center, single-blind, six-period crossover study in healthy female subjects.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Cross-Over Studies; Drugs, Generic; Esophagus; Etidronic Acid; Female; Gastrointestinal Transit; Humans; Middle Aged; Posture; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Single-Blind Method; Sodium Pertechnetate Tc 99m; Tablets | 2008 |
Potential excessive suppression of bone turnover with long-term oral bisphosphonate therapy in postmenopausal osteoporotic patients.
Topics: Administration, Oral; Aged; Alendronate; Alkaline Phosphatase; Asian People; Biomarkers; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Collagen Type I; Etidronic Acid; Female; Humans; Osteogenesis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Prospective Studies; Risedronic Acid | 2008 |
Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Anabolic Agents; Bone Density Conservation Agents; Bone Remodeling; Chemotherapy, Adjuvant; Drug Resistance; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Time Factors; Treatment Outcome | 2008 |
Sustained efficacy of risedronate in men with primary and secondary osteoporosis: results of a 2-year study.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risedronic Acid; Vitamin D | 2009 |
Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Humans; Least-Squares Analysis; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Placebos; Risedronic Acid; Treatment Outcome | 2009 |
Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer.
Topics: Adult; Antineoplastic Agents; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Calcium; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Premenopause; Risedronic Acid; Vitamin D | 2009 |
LRP5 Polymorphisms and response to risedronate treatment in osteoporotic men.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Genotype; Humans; LDL-Receptor Related Proteins; Low Density Lipoprotein Receptor-Related Protein-5; Male; Middle Aged; Osteoporosis; Polymorphism, Genetic; Randomized Controlled Trials as Topic; Risedronic Acid | 2009 |
Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
Topics: Aged; Aged, 80 and over; Alendronate; Area Under Curve; Biomarkers; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Chelating Agents; Collagen Type I; Edetic Acid; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Raloxifene Hydrochloride; Risedronic Acid | 2009 |
Effects of risedronate or alfacalcidol on bone mineral density, bone turnover, back pain, and fractures in Japanese men with primary osteoporosis: results of a two-year strict observational study.
Topics: Aged; Asian People; Back Pain; Body Height; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Etidronic Acid; Fractures, Bone; Humans; Hydroxycholecalciferols; Japan; Male; Middle Aged; Osteoporosis; Phosphates; Risedronic Acid | 2009 |
Comparison of the analgesic effects of bisphosphonates: etidronate, alendronate and risedronate by electroalgometry utilizing the fall of skin impedance.
Topics: Aged; Alendronate; Analgesics; Bone and Bones; Diphosphonates; Electric Impedance; Etidronic Acid; Exercise; Female; Humans; Pain Measurement; Patient Dropouts; Risedronic Acid; Skin | 2009 |
Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study.
Topics: Administration, Oral; Adolescent; Biomarkers; Bone Density; Bone Density Conservation Agents; Child; Collagen Type I; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Lumbar Vertebrae; Male; Organ Size; Osteogenesis Imperfecta; Peptides; Risedronic Acid; Severity of Illness Index | 2009 |
Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid; Single-Blind Method | 2009 |
The effect of risedronate treatment on serum cytokines in postmenopausal osteoporosis: a 6-month randomized and controlled study.
Topics: Aged; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Calcium; Collagen Type I; Cytokines; Etidronic Acid; Female; Humans; Interleukin-1beta; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Osteoprotegerin; Peptides; RANK Ligand; Risedronic Acid; Tumor Necrosis Factor-alpha; Turkey; Vitamin D | 2009 |
Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: a phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2009 |
Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Least-Squares Analysis; Male; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome; Young Adult; Zoledronic Acid | 2009 |
Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastroesophageal Reflux; Heartburn; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2009 |
Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Chronic Disease; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Immunocompromised Host; Injections, Intravenous; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Peptides; Predictive Value of Tests; Risedronic Acid; Risk Factors; Sex Factors; Tooth Extraction | 2009 |
Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Double-Blind Method; Estradiol; Etidronic Acid; Gonadotropin-Releasing Hormone; Gynecomastia; Humans; Male; Osteoporosis; Prostatic Neoplasms; Risedronic Acid | 2010 |
Use of risedronate to prevent bone loss following a single course of glucocorticoids: findings from a proof-of-concept study in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Hip Joint; Humans; Inflammatory Bowel Diseases; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prednisolone; Risedronic Acid | 2010 |
A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta.
Topics: Absorptiometry, Photon; Administration, Oral; Adolescent; Age Determination by Skeleton; Bone Density Conservation Agents; Child; Child, Preschool; Demography; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Bone; Humans; Incidence; Osteogenesis Imperfecta; Risedronic Acid; Spine; Treatment Outcome; United Kingdom | 2010 |
Risedronate reduces intracortical porosity in women with osteoporosis.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Demography; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Periosteum; Porosity; Risedronic Acid; X-Ray Microtomography | 2010 |
Antiresorptive effects of phytoestrogen supplements compared with estradiol or risedronate in postmenopausal women using (41)Ca methodology.
Topics: Aged; Analysis of Variance; Bone Density Conservation Agents; Bone Resorption; Calcium; Calcium Radioisotopes; Cotyledon; Cross-Over Studies; Dietary Supplements; Estradiol; Etidronic Acid; Female; Genistein; Glycine max; Humans; Isoflavones; Linear Models; Medroxyprogesterone; Middle Aged; Osteoporosis, Postmenopausal; Phytoestrogens; Plant Preparations; Pueraria; Risedronic Acid; Single-Blind Method; Treatment Outcome; Trifolium | 2009 |
Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.
Topics: Aged; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Collagen Type I; Diphosphonates; Drug Interactions; Etidronic Acid; Female; Humans; Isoenzymes; Male; Middle Aged; Organ Specificity; Osteocalcin; Osteoporosis; Peptides; Risedronic Acid; Teriparatide; Time Factors | 2010 |
Biomechanical effects of teriparatide in women with osteoporosis treated previously with alendronate and risedronate: results from quantitative computed tomography-based finite element analysis of the vertebral body.
Topics: Aged; Alendronate; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female; Finite Element Analysis; Humans; Middle Aged; Osteoporosis; Risedronic Acid; Teriparatide; Tomography, X-Ray Computed | 2010 |
The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Breast Neoplasms; Calcium; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Muscle Strength; Osteoporosis, Postmenopausal; Patient Compliance; Postural Balance; Resistance Training; Risedronic Acid; Vitamin D | 2010 |
Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
Topics: Aged; Bone and Bones; Bone Density Conservation Agents; Collagen Type I; Cross-Over Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Korea; Middle Aged; Osteoporosis, Postmenopausal; Patient Preference; Peptides; Prospective Studies; Risedronic Acid | 2009 |
The effect of risedronate on hip structural geometry in chemotherapy-induced postmenopausal women with or without use of aromatase inhibitors: a 2-year trial.
Topics: Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Follow-Up Studies; Hip Joint; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Radiography; Risedronic Acid | 2010 |
Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Topics: Aged; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Clinical Protocols; Collagen Type I; Double-Blind Method; Etidronic Acid; Female; Humans; Osteoporosis; Peptides; Postmenopause; Risedronic Acid | 2009 |
Reducing hip fracture risk with risedronate in elderly women with established osteoporosis.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Reduction Behavior; Treatment Outcome | 2009 |
Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Collagen Type I; Etidronic Acid; Female; Humans; Low Back Pain; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Prospective Studies; Risedronic Acid; Spinal Fractures; Surveys and Questionnaires; Treatment Outcome | 2010 |
Prevention of aromatase inhibitor-induced bone loss using risedronate: the SABRE trial.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Hormone Replacement Therapy; Humans; Middle Aged; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Prognosis; Risedronic Acid; Survival Rate; Treatment Outcome; Triazoles | 2010 |
Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Topics: Adult; Age Factors; Aged; Alendronate; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2010 |
Efficacy, tolerability, and safety of risedronate in Japanese patients with Paget's disease of bone.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis Deformans; Risedronic Acid; Treatment Outcome | 2010 |
Effects of risedronate on bone turnover markers in osteoporotic postmenopausal women: comparison of two protocols of treatment.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Peptide Fragments; Peptides; Procollagen; Risedronic Acid | 2009 |
Response of serum carboxylated and undercarboxylated osteocalcin to risedronate monotherapy and combined therapy with vitamin K(2) in corticosteroid-treated patients: a pilot study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neuromuscular Diseases; Osteocalcin; Peptides; Pilot Projects; Prednisolone; Risedronic Acid; Treatment Outcome; Vitamin K 2 | 2010 |
Open-label trial: effect of weekly risedronate immediately after transplantation in kidney recipients.
Topics: Administration, Oral; Adult; Bone Density; Calcium; Etidronic Acid; Female; Femur Neck; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Risedronic Acid; Time Factors; Treatment Outcome; Vitamin D | 2010 |
Management of anastrozole-induced bone loss in breast cancer patients with oral risedronate: results from the ARBI prospective clinical trial.
Topics: Administration, Oral; Aged; Anastrozole; Aromatase Inhibitors; Arthralgia; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Therapy, Combination; Dyspepsia; Etidronic Acid; Female; Humans; Middle Aged; Nausea; Nitriles; Osteoporosis, Postmenopausal; Patient Dropouts; Prospective Studies; Risedronic Acid; Risk Factors; Time Factors; Treatment Outcome; Triazoles | 2010 |
Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
Topics: Aged; Androgen Antagonists; Androgens; Bone Density; Bone Density Conservation Agents; Epidemiologic Methods; Etidronic Acid; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome | 2010 |
Effects of risedronate on bone marrow adipocytes in postmenopausal women.
Topics: Adipocytes; Adipogenesis; Aged; Bone Density Conservation Agents; Bone Marrow; Bone Marrow Cells; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; PPAR gamma; Risedronic Acid | 2011 |
Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ilium; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide; Treatment Outcome | 2010 |
Effect of risedronate on osteocyte viability and bone turnover in paired iliac bone biopsies from early postmenopausal women.
Topics: Bone Density Conservation Agents; Cell Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ilium; Middle Aged; Osteocytes; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2010 |
Risedronate therapy for the prevention of steroid-induced osteoporosis in patients with minimal-change nephrotic syndrome.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Hydroxycholecalciferols; Lumbar Vertebrae; Male; Middle Aged; Nephrosis, Lipoid; Osteoporosis; Prednisolone; Prospective Studies; Risedronic Acid; Risk Factors; Young Adult | 2010 |
Beneficial effect of risedronate on arterial thickening and stiffening with a reciprocal relationship to its effect on bone mass in female osteoporosis patients: a longitudinal study.
Topics: Aged; Ankle Brachial Index; Bone Density; Bone Density Conservation Agents; Carotid Arteries; Etidronic Acid; Female; Femur Neck; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tunica Intima; Tunica Media | 2010 |
The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer.
Topics: Adipose Tissue; Aromatase Inhibitors; Body Composition; Body Mass Index; Bone Density; Breast Neoplasms; Double-Blind Method; Etidronic Acid; Female; Gonadal Hormones; Humans; Middle Aged; Placebos; Postmenopause; Risedronic Acid; Sex Hormone-Binding Globulin | 2011 |
Bone turnover markers and bone mineral density response with risedronate therapy: relationship with fracture risk and patient adherence.
Topics: Aged; Biomarkers; Bone Density; Bone Remodeling; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Patient Compliance; Risedronic Acid; Risk Factors | 2011 |
Beneficial effect of risedronate for preventing recurrent hip fracture in the elderly Japanese women.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Lumbar Vertebrae; Medication Adherence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Secondary Prevention; Treatment Outcome | 2012 |
Risedronate prevents persistent bone loss in prostate cancer patients treated with androgen deprivation therapy: results of a 2-year follow-up study.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Antineoplastic Agents; Biomarkers; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans; Lost to Follow-Up; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Prostatic Neoplasms; Radiography; Risedronic Acid | 2011 |
Comparison of the effects of elcatonin and risedronate on back and knee pain by electroalgometry using fall of skin impedance and quality of life assessment using SF-36.
Topics: Aged; Back Pain; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Female; Humans; Knee Joint; Male; Middle Aged; Osteoporosis; Pain; Quality of Life; Risedronic Acid | 2011 |
Effect of early risedronate treatment on bone mineral density and bone turnover markers after liver transplantation: a prospective single-center study.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cholecalciferol; Etidronic Acid; Female; Humans; Liver Transplantation; Male; Middle Aged; Postmenopause; Prospective Studies; Risedronic Acid; Spinal Fractures | 2011 |
Efficacy of risedronate with cholecalciferol on 25-hydroxyvitamin D level and bone turnover in Korean patients with osteoporosis.
Topics: Aged; Alkaline Phosphatase; Asian People; Bone Density; Bone Density Conservation Agents; Cholecalciferol; Collagen Type I; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Korea; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptides; Prospective Studies; Radioimmunoassay; Risedronic Acid; Treatment Outcome; Vitamin D | 2011 |
Effects of risedronate and low-dose transdermal testosterone on bone mineral density in women with anorexia nervosa: a randomized, placebo-controlled study.
Topics: Administration, Cutaneous; Adult; Androgens; Anorexia Nervosa; Bone Density; Bone Density Conservation Agents; Bone Resorption; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Risedronic Acid; Spine; Testosterone; Treatment Outcome | 2011 |
The effect of risedronate treatment on serum osteoprotegerin and bone marker levels in postmenopausal women with osteoporosis.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Femur; Follow-Up Studies; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoprotegerin; Risedronic Acid; Vitamin D | 2011 |
Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin.
Topics: Aged; Amino Acids; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoprotegerin; Postmenopause; Risedronic Acid; Vitamin D | 2011 |
Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists.
Topics: Adolescent; Adult; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Hip Joint; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteogenesis Imperfecta; Risedronic Acid; Treatment Outcome; Young Adult | 2012 |
The prevention of hip fracture with menatetrenone and risedronate plus calcium supplementation in elderly patients with Alzheimer disease: a randomized controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Hemostatics; Hip Fractures; Humans; Hyperparathyroidism; Male; Osteoporosis; Risedronic Acid; Vitamin D; Vitamin K; Vitamin K 2 | 2011 |
Once-weekly risedronate for prevention of hip fracture in women with Parkinson's disease: a randomised controlled trial.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium; Drug Administration Schedule; Drug Therapy, Combination; Ergocalciferols; Etidronic Acid; Female; Hip Fractures; Humans; Parkinson Disease; Risedronic Acid | 2011 |
Multicentre trial of weekly risedronate on bone density in adults with cystic fibrosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Cystic Fibrosis; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Risedronic Acid; Single-Blind Method | 2011 |
Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Disability Evaluation; Disease Progression; Etidronic Acid; Europe; Female; Humans; Knee Joint; Male; Middle Aged; North America; Osteoarthritis, Knee; Radiography; Risedronic Acid; Severity of Illness Index; Time Factors | 2011 |
Effects of pharmaceutical care on adherence and persistence to bisphosphonates in postmenopausal osteoporotic women.
Topics: Alendronate; Biomarkers, Pharmacological; Bone and Bones; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Medication Adherence; Menopause; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Pharmaceutical Services; Postmenopause; Risedronic Acid; Sample Size; Time Factors; Treatment Outcome | 2011 |
Efficacy and safety of a novel delayed-release risedronate 35 mg once-a-week tablet.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tablets, Enteric-Coated; Treatment Outcome | 2012 |
Efficacy of different therapeutic regimens on hepatic osteodystrophy in chronic viral liver disease.
Topics: Absorptiometry, Photon; Adult; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcitonin; Chronic Disease; Etidronic Acid; Female; Hepatitis, Viral, Human; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Risedronic Acid; Treatment Outcome; Vitamin D | 2011 |
Post hoc analysis of a single IV infusion of zoledronic acid versus daily oral risedronate on lumbar spine bone mineral density in different subgroups with glucocorticoid-induced osteoporosis.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Lumbar Vertebrae; Male; Menopause; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Prednisone; Risedronic Acid; Sex Factors; Vitamin D; Young Adult; Zoledronic Acid | 2012 |
Regional bone metabolism at the lumbar spine and hip following discontinuation of alendronate and risedronate treatment in postmenopausal women.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Femur; Fluorodeoxyglucose F18; Hip; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Positron-Emission Tomography; Radiopharmaceuticals; Risedronic Acid; Treatment Outcome | 2012 |
The effect of weekly risedronate on periprosthetic bone resorption following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.
Topics: Absorptiometry, Photon; Administration, Oral; Adult; Aged; Analysis of Variance; Arthroplasty, Replacement, Hip; Bone Density; Bone Density Conservation Agents; Bone Resorption; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Periprosthetic Fractures; Postoperative Complications; Reference Values; Risedronic Acid; Risk Assessment; Sweden; Treatment Outcome | 2011 |
Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Femur Neck; Glucocorticoids; Hip Joint; Humans; Imidazoles; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Risedronic Acid; Young Adult; Zoledronic Acid | 2012 |
Long-term outcomes of children and adolescents who had cerebral palsy with secondary osteoporosis.
Topics: Adolescent; Alkaline Phosphatase; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Child, Preschool; Collagen Type I; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Hydroxycholecalciferols; Infant; Male; Osteoporosis; Peptides; Risedronic Acid; Treatment Outcome | 2012 |
The effect of teriparatide compared with risedronate on reduction of back pain in postmenopausal women with osteoporotic vertebral fractures.
Topics: Aged; Back Pain; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Femur Neck; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Pain Measurement; Quality of Life; Risedronic Acid; Spinal Fractures; Teriparatide; Treatment Outcome | 2012 |
Effects of alendronate and risedronate on bone material properties in actively forming trabecular bone surfaces.
Topics: Aged; Alendronate; Bone and Bones; Bone Density; Cross-Sectional Studies; Etidronic Acid; Female; Humans; Risedronic Acid; Spectrum Analysis, Raman; Time Factors | 2012 |
Pharmaceutical care issues encountered by post-menopausal osteoporotic women prescribed bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Health Knowledge, Attitudes, Practice; Humans; Malaysia; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care; Patient Satisfaction; Pharmaceutical Services; Quality of Life; Risedronic Acid | 2012 |
Risedronate improves bone mineral density in Crohn's disease: a two year randomized controlled clinical trial.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Calcium Carbonate; Crohn Disease; Dietary Supplements; Double-Blind Method; Etidronic Acid; Female; Femur Neck; Hip; Humans; Intention to Treat Analysis; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Risedronic Acid; Spine; Statistics, Nonparametric; Vitamin D; Young Adult | 2012 |
Successful treatment of calcific uraemic arteriolopathy with bisphosphonates.
Topics: Aged; Alendronate; Alkaline Phosphatase; Arterioles; Calciphylaxis; Calcium; Comorbidity; Diphosphonates; Disease Progression; Etidronic Acid; Female; Humans; Hyperparathyroidism, Secondary; Ibandronic Acid; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Parathyroidectomy; Phosphates; Prospective Studies; Renal Dialysis; Risedronic Acid; Skin; Uremia | 2012 |
Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Bone Neoplasms; Castration; Disease Progression; Docetaxel; Etidronic Acid; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Netherlands; Norway; Pain; Prednisone; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Risedronic Acid; Risk Assessment; Risk Factors; Taxoids; Time Factors; Treatment Outcome | 2012 |
Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures?
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Fracture Fixation, Internal; Fracture Healing; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Postoperative Period; Prospective Studies; Risedronic Acid; Secondary Prevention | 2012 |
Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
Topics: Bone Density; Bone Density Conservation Agents; Demography; Double-Blind Method; Etidronic Acid; Female; Humans; Least-Squares Analysis; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Placebos; Risedronic Acid; Time Factors; Treatment Outcome | 2012 |
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Administration, Oral; Aged; Biomarkers; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2013 |
Lipid profiles within the SABRE trial of anastrozole with and without risedronate.
Topics: Adult; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Density Conservation Agents; Breast Neoplasms; Cholesterol, HDL; Cholesterol, LDL; Etidronic Acid; Female; Humans; Lipids; Middle Aged; Nitriles; Risedronic Acid; Treatment Outcome; Triazoles; Triglycerides | 2012 |
Elcatonin in combination with risedronate is more effective than risedronate alone for relieving back pain in postmenopausal women with osteoporosis.
Topics: Aged; Aged, 80 and over; Analgesics; Back Pain; Bone Density; Bone Density Conservation Agents; Calcitonin; Collagen Type I; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Pain Measurement; Peptides; Risedronic Acid | 2012 |
Effect of risedronate on bone in renal transplant recipients.
Topics: Adult; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Double-Blind Method; Etidronic Acid; Female; Glomerular Filtration Rate; Gonadal Steroid Hormones; Humans; Immunosuppression Therapy; Kidney Transplantation; Male; Middle Aged; Parathyroid Hormone; Prospective Studies; Risedronic Acid | 2012 |
Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Transplantation; Decompression, Surgical; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ilium; Injections, Subcutaneous; Japan; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Pain, Postoperative; Prospective Studies; Risedronic Acid; Spinal Fusion; Teriparatide; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years.
Topics: Administration, Oral; Aged; Bone Density; Bone Density Conservation Agents; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Femur; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2013 |
Combination therapy with risedronate and teriparatide in male osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Therapy, Combination; Etidronic Acid; Femur Neck; Humans; Injections, Subcutaneous; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Placebos; Risedronic Acid; Teriparatide | 2013 |
The effects of risedronate administered in combination with a proton pump inhibitor for the treatment of osteoporosis.
Topics: Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporotic Fractures; Proton Pump Inhibitors; Risedronic Acid | 2013 |
Midterm outcome of risedronate therapy for patients with Paget's disease of bone in the central part of Japan.
Topics: Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Density Conservation Agents; Etidronic Acid; Female; Follow-Up Studies; Humans; Japan; Male; Middle Aged; Osteitis Deformans; Prospective Studies; Risedronic Acid; Treatment Outcome | 2013 |
A novel monthly dosing regimen of risedronate for the treatment of postmenopausal osteoporosis: 2-year data.
Topics: Aged; Bone and Bones; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Patient Safety; Research Design; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2013 |
Effects of bisphosphonate treatment on circulating osteogenic endothelial progenitor cells in postmenopausal women.
Topics: Biomarkers; Bone Density; Bone Density Conservation Agents; C-Reactive Protein; Calcium; Creatinine; Double-Blind Method; Down-Regulation; Endothelium; Enzyme-Linked Immunosorbent Assay; Etidronic Acid; Female; Flow Cytometry; Gene Expression Regulation; Humans; Interleukin-8; Middle Aged; Osteoblasts; Osteogenesis; Osteoporosis, Postmenopausal; Osteoprotegerin; Phosphorus; Placebos; RANK Ligand; Risedronic Acid; Stem Cells; Treatment Outcome; Vitamin D | 2013 |
Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Femur; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Placebo Effect; Prostatic Neoplasms; Risedronic Acid | 2013 |
Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Europe; Female; Follow-Up Studies; Glucocorticoids; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Radiography; Risedronic Acid; Spinal Fractures; Teriparatide | 2013 |
Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective.
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Screws; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Prospective Studies; Risedronic Acid; Spinal Fusion; Teriparatide; Treatment Outcome | 2013 |
Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Male; Middle Aged; Osteoporosis; Prednisone; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2013 |
Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Infusions, Intravenous; Japan; Male; Middle Aged; Osteoporosis; Proportional Hazards Models; Risedronic Acid; Spinal Fractures; Time Factors; Treatment Outcome | 2013 |
Early changes in biochemical markers of bone formation during teriparatide therapy correlate with improvements in vertebral strength in men with glucocorticoid-induced osteoporosis.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Femur Neck; Finite Element Analysis; Glucocorticoids; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteogenesis; Osteoporosis; Peptide Fragments; Procollagen; Risedronic Acid; Teriparatide; Treatment Outcome | 2013 |
Early changes in 25-hydroxyvitamin D levels and bone markers after monthly risedronate with cholecalciferol in Korean patients with osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alkaline Phosphatase; Biomarkers; Bone Density Conservation Agents; Chi-Square Distribution; Cholecalciferol; Collagen Type I; Double-Blind Method; Drug Combinations; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Prospective Studies; Republic of Korea; Risedronic Acid; Treatment Outcome; Vitamin D | 2013 |
Oral risedronate sodium improves bone mineral density in non-ambulatory patients: a randomized, double-blind, placebo controlled trial.
Topics: Absorptiometry, Photon; Adolescent; Adult; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Cerebral Palsy; Child; Collagen Type I; Double-Blind Method; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Male; Osteocalcin; Peptides; Risedronic Acid; Treatment Outcome; Young Adult | 2013 |
Design of a randomized clinical trial of concurrent treatment with vitamin K2 and risedronate compared to risedronate alone in osteoporotic patients: Japanese Osteoporosis Intervention Trial-03 (JOINT-03).
Topics: Aged; Body Mass Index; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Glomerular Filtration Rate; Humans; Osteocalcin; Osteoporosis; Prospective Studies; Risedronic Acid; Spinal Fractures; Vitamin D; Vitamin K 2 | 2014 |
Effects of risedronate alone or combined with vitamin K2 on serum undercarboxylated osteocalcin and osteocalcin levels in postmenopausal osteoporosis.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Incidence; Osteocalcin; Osteoporosis, Postmenopausal; Prospective Studies; Risedronic Acid; Spinal Fractures; Vitamin K 2 | 2014 |
Risedronate in children with osteogenesis imperfecta: a randomised, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Alkaline Phosphatase; Analysis of Variance; Bone Density; Bone Density Conservation Agents; Child; Child, Preschool; Collagen; Double-Blind Method; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Osteogenesis Imperfecta; Risedronic Acid; Treatment Outcome | 2013 |
Comparison of non-vertebral fracture between minodronate and risedronate therapy in elderly female patients with Alzheimer disease.
Topics: Accidental Falls; Aged; Alzheimer Disease; Body Mass Index; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Risedronic Acid | 2013 |
Bioequivalence study of two risedronate sodium film-coated tablet formulations in healthy volunteers.
Topics: Adolescent; Adult; Biological Availability; Bone Density Conservation Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Cross-Over Studies; Etidronic Acid; Female; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Risedronic Acid; Single-Blind Method; Solubility; Tablets; Therapeutic Equivalency; Young Adult | 2014 |
Risedronate slows or partly reverses cortical and trabecular microarchitectural deterioration in postmenopausal women.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Collagen Type I; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Peptides; Postmenopause; Risedronic Acid; Tibia; Tomography, X-Ray Computed | 2014 |
Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Topics: Aged; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Collagen Type I; Demography; Denosumab; Etidronic Acid; Female; Humans; Medication Adherence; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid; Treatment Outcome | 2014 |
Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
Topics: Absorptiometry, Photon; Adult; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Crohn Disease; Dietary Supplements; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Lumbar Vertebrae; Male; Middle Aged; Prospective Studies; Risedronic Acid; Treatment Outcome; Vitamin D | 2014 |
Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen.
Topics: Aged; Asian People; Biomarkers; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Japan; Lumbar Vertebrae; Male; Osteoporosis; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2014 |
Increased bone mineral density with monthly intravenous ibandronate contributes to fracture risk reduction in patients with primary osteoporosis: three-year analysis of the MOVER study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Injections, Intravenous; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2014 |
Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial.
Topics: Adult; Aged; Anastrozole; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Follow-Up Studies; Humans; International Agencies; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Prognosis; Risedronic Acid; Triazoles | 2014 |
Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.
Topics: Aged; Antibodies, Monoclonal, Humanized; Bone Density; Bone Density Conservation Agents; Denosumab; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Satisfaction; Risedronic Acid; Treatment Outcome | 2015 |
[Comparative analysis of programs of complete correction osteogenic in patients with chronic pancreatitis].
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Pancreatitis, Chronic; Risedronic Acid | 2014 |
Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: A multicenter, prospective, parallel group study.
Topics: Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Cross-Over Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Preference; Peptides; Poland; Risedronic Acid; Treatment Outcome; Turkey | 2015 |
Bone-loading exercises versus risedronate for the prevention of osteoporosis in postmenopausal women with low bone mass: a randomized controlled trial.
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Postmenopause; Risedronic Acid | 2022 |
566 other study(ies) available for etidronate and risedronic acid
| Article | Year |
|---|---|
An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
Topics: Alkyl and Aryl Transferases; Animals; Bone Resorption; Crystallography, X-Ray; Dictyostelium; Diphosphonates; Enzyme Inhibitors; Geranyltranstransferase; Humans; Inhibitory Concentration 50; Models, Molecular; Quantitative Structure-Activity Relationship; Rats | 2002 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure.
Topics: Aging; Animals; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Dinoprostone; Etidronic Acid; Female; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1992 |
BM 21.0955, a potent new bisphosphonate to inhibit bone resorption.
Topics: Alendronate; Animals; Benzoates; Bone Resorption; Calcium; Clodronic Acid; Diphosphonates; Etidronic Acid; Ibandronic Acid; Injections, Intravenous; Osteoclasts; Pamidronate; Rats; Retinoids; Risedronic Acid; Spectrophotometry, Atomic; Tetracycline; Thyroxine | 1991 |
Inhibitory effects of a bisphosphonate (risedronate) on experimental periodontitis in rats.
Topics: Alveolar Bone Loss; Analysis of Variance; Animals; Bone Density; Calcium Channel Blockers; Cell Count; Drug Evaluation, Preclinical; Etidronic Acid; Male; Osteoclasts; Periodontitis; Rats; Rats, Wistar; Regression Analysis; Risedronic Acid | 1995 |
Extra cancellous bone induced by combined prostaglandin E2 and risedronate administration is maintained after their withdrawal in older female rats.
Topics: Aging; Analysis of Variance; Animals; Body Weight; Bone Development; Bone Resorption; Calcium Channel Blockers; Dinoprostone; Disease Models, Animal; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Muscle, Skeletal; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
Topics: Animals; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cachexia; Diphosphonates; Etidronic Acid; Humans; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Risedronic Acid; Survival Analysis; Transplantation, Heterologous | 1995 |
Parathyroid hormone monotherapy and cotherapy with antiresorptive agents restore vertebral bone mass and strength in aged ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Calcium Channel Blockers; Disease Models, Animal; Drug Therapy, Combination; Estradiol; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1995 |
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site.
Topics: Administration, Oral; Animals; Bone Density; Bone Development; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Calcium Channel Blockers; Cell Wall; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Ilium; Kinetics; Models, Biological; Models, Theoretical; Osteoblasts; Osteoporosis, Postmenopausal; Risedronic Acid | 1995 |
Direct stereological estimation of three-dimensional connectivity in rat vertebrae: effect of estrogen, etidronate and risedronate following ovariectomy.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Estradiol; Etidronic Acid; Female; Humans; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1995 |
The anabolic effects of parathyroid hormone on cortical bone mass, dimensions and strength--assessed in a sexually mature, ovariectomized rat model.
Topics: Analysis of Variance; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Calcium Channel Blockers; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Estradiol; Etidronic Acid; Female; Femur; Ovariectomy; Parathyroid Hormone; Peptide Fragments; Rats; Rats, Sprague-Dawley; Risedronic Acid; Teriparatide | 1995 |
Response of cortical bone to antiresorptive agents and parathyroid hormone in aged ovariectomized rats.
Topics: Animals; Biomarkers; Bone Density; Bone Development; Bone Resorption; Calcitonin; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Estradiol; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Ovariectomy; Parathyroid Hormone; Peptide Fragments; Rats; Rats, Sprague-Dawley; Risedronic Acid; Spectrophotometry, Ultraviolet; Teriparatide; Tibia | 1995 |
Effects of topical administration of a bisphosphonate (risedronate) on orthodontic tooth movements in rats.
Topics: Administration, Topical; Alveolar Bone Loss; Alveolar Process; Analysis of Variance; Animals; Bone Density; Calcium Channel Blockers; Dose-Response Relationship, Drug; Etidronic Acid; Male; Orthodontics, Corrective; Osteoclasts; Rats; Rats, Wistar; Risedronic Acid; Tooth Mobility; Tooth Root | 1994 |
Effect of the bisphosphonate risedronate on bone metastases in a rat mammary adenocarcinoma model system.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Body Weight; Bone and Bones; Bone Neoplasms; Bone Resorption; Calcium; Cell Division; Etidronic Acid; Female; Mammary Neoplasms, Experimental; Rats; Risedronic Acid | 1994 |
Risedronate activity in the fetal and neonatal mouse.
Topics: Analysis of Variance; Animals; Animals, Newborn; Calcium; Calcium Channel Blockers; Culture Techniques; Diphosphonates; Etidronic Acid; Female; Fetus; Lactation; Maternal-Fetal Exchange; Mice; Osteoclasts; Parathyroid Hormone; Pregnancy; Prenatal Exposure Delayed Effects; Risedronic Acid; Skull | 1993 |
Skeletal effects of withdrawal of estrogen and diphosphonate treatment in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Diseases, Metabolic; Disease Models, Animal; Estradiol; Etidronic Acid; Female; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1993 |
The positive effect of parathyroid hormone on femoral neck bone strength in ovariectomized rats is more pronounced than that of estrogen or bisphosphonates.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Calcium Channel Blockers; Drug Interactions; Estradiol; Etidronic Acid; External Fixators; Female; Femur; Ovariectomy; Parathyroid Hormone; Peptide Fragments; Rats; Rats, Sprague-Dawley; Reference Values; Risedronic Acid; Tensile Strength; Teriparatide | 1994 |
Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Analysis of Variance; Bone Resorption; Calcium; Etidronic Acid; Female; Homeostasis; Humans; Hydroxyproline; Hyperparathyroidism; Kidney Tubules; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Postmenopause; Risedronic Acid | 1993 |
Risedronate pretreatment does not hamper the anabolic effects of prostaglandin E2 in ovx rats.
Topics: Aging; Animals; Dinoprostone; Drug Evaluation, Preclinical; Drug Interactions; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Reference Values; Risedronic Acid; Tibia | 1995 |
Co-treatment of PGE2 and risedronate is better than PGE2 alone in the long-term treatment of ovariectomized-induced osteopenic rats.
Topics: Aging; Animals; Body Weight; Bone Development; Bone Diseases, Metabolic; Dinoprostone; Drug Therapy, Combination; Etidronic Acid; Factor Analysis, Statistical; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1995 |
Intermittent treatment of prostaglandin E2 with risedronate is more anabolic than prostaglandin E2 alone in the proximal tibial metaphysis of ovariectomized rats.
Topics: Analysis of Variance; Animals; Dinoprostone; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Intermittent treatments of prostaglandin E2 plus risedronate and prostaglandin E2 alone are equally anabolic on tibial shaft of ovariectomized rats.
Topics: Animals; Bone Development; Bone Marrow; Dinoprostone; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Risedronate plus prostaglandin E2 is superior to prostaglandin E2 alone in maintaining the added bone after withdrawal in a non-growing bone site in ovariectomized rats.
Topics: Analysis of Variance; Animals; Bone Diseases, Metabolic; Dinoprostone; Disease Models, Animal; Drug Therapy, Combination; Etidronic Acid; Female; Ovariectomy; Ovary; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1995 |
Partial maintenance of extra cancellous bone mass by antiresorptive agents after discontinuation of human parathyroid hormone (1-38) in right hindlimb immobilized rats.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcitonin; Disease Models, Animal; Estradiol; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Parathyroid Hormone; Peptide Fragments; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1995 |
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo.
Topics: Animals; Apoptosis; Bone Neoplasms; Cell Survival; Cells, Cultured; Diphosphonates; Etidronic Acid; Male; Mice; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Nude; Necrosis; Osteoclasts; Risedronic Acid | 1995 |
Inhibitory effect of the topical administration of a bisphosphonate (risedronate) on root resorption incident to orthodontic tooth movement in rats.
Topics: Administration, Topical; Analysis of Variance; Animals; Depression, Chemical; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Etidronic Acid; Male; Osteoclasts; Rats; Rats, Wistar; Risedronic Acid; Root Resorption; Time Factors; Tooth Movement Techniques; Tooth Root | 1996 |
Prostaglandin E2 (PGE2) and risedronate was superior to PGE2 alone in maintaining newly added bone in the cortical bone site after withdrawal in older intact rats.
Topics: Age Factors; Aging; Animals; Bone and Bones; Bone Density; Calcium Channel Blockers; Dinoprostone; Drug Synergism; Drug Therapy, Combination; Etidronic Acid; Female; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1997 |
Nonclinical model for assessing gastric effects of bisphosphonates.
Topics: Alendronate; Animals; Chelating Agents; Diphosphonates; Edetic Acid; Egtazic Acid; Etidronic Acid; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach | 1997 |
No loss of biomechanical effects after withdrawal of short-term PTH treatment in an aged, osteopenic, ovariectomized rat model.
Topics: Aging; Animals; Biomechanical Phenomena; Bone and Bones; Bone Diseases, Metabolic; Calcium Channel Blockers; Drug Administration Schedule; Etidronic Acid; Female; Ovariectomy; Ovary; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid; Time Factors | 1997 |
Effects of intermittent hPTH(1-34) alone and in combination with 1,25(OH)(2)D(3) or risedronate on endosteal bone remodeling in canine cancellous and cortical bone.
Topics: Animals; Bone and Bones; Bone Remodeling; Calcitriol; Calcium; Calcium Channel Blockers; Dogs; Drug Therapy, Combination; Etidronic Acid; Humans; Risedronic Acid; Teriparatide | 1996 |
Intermittent on/off prostaglandin E2 and risedronate are equally anabolic as daily PGE2 alone treatment in cortical bone of ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Calcium Channel Blockers; Dinoprostone; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Osteoporosis; Ovariectomy; Ovary; Oxytocics; Rats; Rats, Sprague-Dawley; Risedronic Acid; Time Factors; Weight Gain | 1997 |
Paget's disease of bone: reduction of disease activity with oral risedronate.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alkaline Phosphatase; Calcium; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis Deformans; Pain; Phosphates; Risedronic Acid; Treatment Outcome | 1998 |
Changes in bone mineral density in patients with Paget's disease treated with risedronate.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Bone Density; Bone Remodeling; Calcium Channel Blockers; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteitis Deformans; Risedronic Acid | 1997 |
TRK-530 inhibits accumulation of superoxide anions derived from human polymorphonuclear leukocytes and bone resorption induced by activated osteoclasts.
Topics: Animals; Animals, Suckling; Antioxidants; Bone Resorption; Calcitriol; Calcium Channel Blockers; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Hindlimb; Humans; Mice; N-Formylmethionine Leucyl-Phenylalanine; Neutrophil Activation; Neutrophils; Osteoclasts; Risedronic Acid; Superoxides | 1998 |
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.
Topics: Alendronate; Animals; Apoptosis; Bone Resorption; Cells, Cultured; Clodronic Acid; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Ibandronic Acid; Lovastatin; Macrophages; Mevalonic Acid; Mice; Osteoclasts; Protein Prenylation; Protein Processing, Post-Translational; ras Proteins; Risedronic Acid; Structure-Activity Relationship | 1998 |
Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.
Topics: Alendronate; Animals; Calcium Channel Blockers; Dose-Response Relationship, Drug; Etidronic Acid; Female; Gastric Mucosa; Rats; Rats, Sprague-Dawley; Risedronic Acid | 1998 |
Risedronate released for Paget's disease.
Topics: Calcium Channel Blockers; Drug Approval; Etidronic Acid; Humans; Osteitis Deformans; Risedronic Acid; United States; United States Food and Drug Administration | 1998 |
Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease.
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Calcitriol; Calcium; Calcium Channel Blockers; Creatinine; Etidronic Acid; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteitis Deformans; Parathyroid Hormone; Phosphorus; Risedronic Acid | 1998 |
Withdrawal of parathyroid hormone treatment causes rapid resorption of newly formed vertebral cancellous and endocortical bone in old rats.
Topics: Absorptiometry, Photon; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Calcium Channel Blockers; Elasticity; Etidronic Acid; Lumbar Vertebrae; Male; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid; Substance Withdrawal Syndrome; Weight-Bearing | 1998 |
Evaluation of the effects of risedronate on hepatic microsomal drug metabolizing enzyme activities following administration to rats for 14 days: lack of an induction response.
Topics: Animals; Enzyme Induction; Etidronic Acid; Female; Male; Microsomes, Liver; Organ Size; Rats; Rats, Sprague-Dawley; Risedronic Acid; Time Factors; Xenobiotics | 1998 |
Risedronate for Paget's disease of bone.
Topics: Administration, Oral; Aged; Bone Resorption; Calcium Channel Blockers; Clinical Trials as Topic; Diarrhea; Double-Blind Method; Drug Administration Schedule; Drug Interactions; Esophagitis; Etidronic Acid; Humans; Intestinal Absorption; Middle Aged; Nausea; Osteitis Deformans; Risedronic Acid | 1998 |
Esophageal irritation due to alendronate sodium tablets: possible mechanisms.
Topics: Alendronate; Animals; Bone Resorption; Diphosphonates; Dogs; Esophagus; Etidronic Acid; Mucous Membrane; Risedronic Acid | 1998 |
Binding and antiresorptive properties of heterocycle-containing bisphosphonate analogs: structure-activity relationships.
Topics: Alendronate; Animals; Bone and Bones; Bone Resorption; Calcification, Physiologic; Calcium; Culture Techniques; Etidronic Acid; Female; Mice; Pregnancy; Risedronic Acid; Structure-Activity Relationship | 1998 |
Skeletal effects of constant and terminated use of risedronate on cortical bone in ovariectomized rats.
Topics: Animals; Bone and Bones; Bone Remodeling; Disease Models, Animal; Drug Administration Schedule; Etidronic Acid; Female; Osteoporosis; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Time Factors | 1999 |
Skeletal effects of constant and terminated use of sodium risedronate in ovariectomized rats.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 1998 |
New drugs 99, Part III.
Topics: Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Humans; Infliximab; Leprostatic Agents; Osteitis Deformans; Oxazines; Rifampin; Risedronic Acid; Thalidomide; Thionucleotides; Trastuzumab | 1999 |
Risedronic acid. NE 58095, risedronate sodium, Actonel.
Topics: Aged; Animals; Drugs, Investigational; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Rats; Risedronic Acid | 1999 |
Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase.
Topics: Alendronate; Animals; Apoptosis; Calcium Channel Blockers; Caspase Inhibitors; Caspases; Clodronic Acid; Diphosphonates; Diterpenes; Enzyme Activation; Etidronic Acid; Macrophage Colony-Stimulating Factor; Male; MAP Kinase Kinase Kinases; Mevalonic Acid; Mice; Mice, Inbred BALB C; Osteoclasts; Protein Prenylation; Protein Serine-Threonine Kinases; Risedronic Acid; Signal Transduction; Staurosporine; Time Factors | 1999 |
Iatrogenic osteoporosis.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Glucocorticoids; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 1999 |
Conference report--scientific and clinical developments in osteoporosis.
Topics: Bone Density; Bone Remodeling; Calcium Channel Blockers; Diphosphonates; Estrogen Receptor beta; Estrogens, Non-Steroidal; Etidronic Acid; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isoflavones; Osteoporosis, Postmenopausal; Phytoestrogens; Plant Preparations; Receptors, Estrogen; Risedronic Acid | 1999 |
Improvement of pagetic bone lesions with risedronate treatment: a radiologic study.
Topics: Aged; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteitis Deformans; Radiography; Risedronic Acid | 2000 |
Bisphosphonate therapy and vascular calcification.
Topics: Blood Vessels; Calcification, Physiologic; Calcinosis; Calcium Channel Blockers; Cardiovascular Diseases; Diphosphonates; Etidronic Acid; Humans; Risedronic Acid | 2000 |
Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.
Topics: Alendronate; Animals; Bone Remodeling; Calcium Channel Blockers; Dogs; Etidronic Acid; Female; Radiography; Ribs; Risedronic Acid | 2000 |
The intracellular target for the antiresorptive aminobisphosphonate drugs in Dictyostelium discoideum is the enzyme farnesyl diphosphate synthase.
Topics: Alendronate; Alkyl and Aryl Transferases; Amino Acid Sequence; Animals; Base Sequence; Bone Resorption; Dictyostelium; Diphosphonates; DNA Primers; Etidronic Acid; Farnesyl-Diphosphate Farnesyltransferase; Geranyltranstransferase; Molecular Sequence Data; Risedronic Acid; RNA, Messenger; Sequence Homology, Amino Acid | 2000 |
Mandibular bone formation rates in aged ovariectomized rats treated with anti-resorptive agents alone and in combination with intermittent parathyroid hormone.
Topics: Analysis of Variance; Animals; Bone Resorption; Calcitonin; Calcium Channel Blockers; Diphosphonates; Disease Models, Animal; Disease Progression; Drug Combinations; Estrogens; Etidronic Acid; Female; Follow-Up Studies; Humans; Humerus; Mandible; Mandibular Diseases; Minerals; Osteogenesis; Osteoporosis; Ovariectomy; Parathyroid Hormone; Periosteum; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
[A new bisphosphonate. A vertebral body fracture seldom remains alone].
Topics: Etidronic Acid; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Spinal Fractures | 2000 |
New developments in osteoporosis treatment.
Topics: Alendronate; Anticholesteremic Agents; Drug Administration Schedule; Etidronic Acid; Humans; Osteoporosis; Parathyroid Hormone; Risedronic Acid | 2000 |
Gastric damage in the rat with nitrogen-containing bisphosphonates depends on pH.
Topics: Administration, Oral; Alendronate; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Indomethacin; Male; Pamidronate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach; Structure-Activity Relationship | 2000 |
Drugs for prevention and treatment of postmenopausal osteoporosis.
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Bone Resorption; Breast Neoplasms; Calcitonin; Calcium; Calcium Channel Blockers; Clinical Trials as Topic; Densitometry; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Vitamin D | 2000 |
Effect of bisphosphonates on surface hydrophobicity and phosphatidylcholine concentration of rodent gastric mucosa.
Topics: Alendronate; Animals; Anti-Inflammatory Agents; Diphosphonates; Etidronic Acid; Gastric Mucosa; Indomethacin; Male; Pamidronate; Phosphatidylcholines; Rats; Rats, Sprague-Dawley; Risedronic Acid; Surface Properties | 2000 |
Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats.
Topics: Alendronate; Animals; Body Weight; Etidronic Acid; Female; Femur; Hindlimb Suspension; Osteoporosis; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
Topics: Alendronate; Alkyl and Aryl Transferases; Animals; Bone Resorption; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Geranyltranstransferase; Hydroxymethylglutaryl CoA Reductases; Ibandronic Acid; Male; Mevalonic Acid; Osteoclasts; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2000 |
Pharmacological interventions for the prevention of vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: does site-specificity exist?
Topics: Aged; Alendronate; Calcitriol; Calcium Channel Agonists; Calcium Channel Blockers; Estrogen Antagonists; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2000 |
Oesophageal transit, disintegration and gastric emptying of a film-coated risedronate placebo tablet in gastro-oesophageal reflux disease and normal control subjects.
Topics: Aged; Aged, 80 and over; Esophagus; Etidronic Acid; Female; Gastric Emptying; Gastroesophageal Reflux; Humans; Male; Middle Aged; Risedronic Acid | 2001 |
Maintenance of cortical bone in human parathyroid hormone(1-84)-treated ovariectomized rats.
Topics: Animals; Bone Marrow; Cross-Sectional Studies; Estradiol; Etidronic Acid; Female; Femur; Humans; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2001 |
Once-a-week alendronate (Fosamax).
Topics: Alendronate; Bone Resorption; Calcium Channel Blockers; Chemistry, Pharmaceutical; Clinical Trials as Topic; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
Hip fractures: do preventive drugs work for all?
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Osteoporosis; Risedronic Acid; Risk Factors | 2001 |
The role of combination treatment for osteoporosis.
Topics: Aged; Drug Therapy, Combination; Estrogen Replacement Therapy; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2001 |
The effect of risedronate on the risk of hip fracture in elderly women.
Topics: Aged; Calcium Channel Blockers; Data Interpretation, Statistical; Etidronic Acid; Female; Follow-Up Studies; Hip Fractures; Humans; Incidence; Risedronic Acid | 2001 |
The effect of risedronate on the risk of hip fracture in elderly women.
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Hip Fractures; Humans; Risedronic Acid; Risk Factors | 2001 |
The effect of risedronate on the risk of hip fracture in elderly women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Femur Neck; Hip Fractures; Humans; Risedronic Acid; Risk Factors | 2001 |
Absolute vs. relative numbers in evaluating drug therapy.
Topics: Alendronate; Data Interpretation, Statistical; Etidronic Acid; Female; Fractures, Bone; Humans; Informed Consent; Osteoporosis, Postmenopausal; Patient Education as Topic; Patient Selection; Risedronic Acid; Risk Assessment; Risk Factors | 2001 |
[Bisphosphonates in osteoporosis. Significantly reduces risk of fracture].
Topics: Aged; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2001 |
(31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth.
Topics: Animals; Antiparasitic Agents; Cell Division; Cryptosporidiosis; Cryptosporidium parvum; Diphosphates; Etidronic Acid; Magnetic Resonance Spectroscopy; Mice; Mice, Nude; Phosphorus Radioisotopes; Plasmodium berghei; Rabbits; Risedronic Acid; Toxoplasma; Transplantation, Heterologous | 2001 |
Re: Lanza et al.--Endoscopic comparison of alendronate and risedronate.
Topics: Alendronate; Etidronic Acid; Gastroscopy; Humans; Risedronic Acid; Stomach Ulcer | 2001 |
The in-vitro porcine adhesion model is not predictive of the esophageal transit of risedronate tablets in humans.
Topics: Animals; Calcium Channel Blockers; Cell Adhesion; Chemistry, Pharmaceutical; Esophagus; Etidronic Acid; Humans; Models, Biological; Predictive Value of Tests; Risedronic Acid; Swine; Tablets | 2001 |
Osteoporosis in men.
Topics: Alendronate; Calcium Channel Blockers; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid | 2001 |
Bisphosphonates are potent inhibitors of Trypanosoma cruzi farnesyl pyrophosphate synthase.
Topics: Alkyl and Aryl Transferases; Amino Acid Motifs; Amino Acid Sequence; Amino Acids; Animals; Binding Sites; Birds; Blotting, Northern; Blotting, Southern; Calcium Channel Blockers; Cations; Cells, Cultured; Cloning, Molecular; Crystallography, X-Ray; Diphosphonates; Dose-Response Relationship, Drug; Escherichia coli; Etidronic Acid; Geranyltranstransferase; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Molecular Sequence Data; Polyisoprenyl Phosphates; Protein Binding; Recombinant Proteins; Risedronic Acid; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Sesquiterpenes; Trypanosoma cruzi | 2001 |
[Fluorides and bisphosphonates in the treatment of osteoporosis].
Topics: Aged; Bone Density; Bone Resorption; Calcium, Dietary; Clinical Trials as Topic; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Fluorides; Humans; Middle Aged; Osteoblasts; Osteoporosis; Osteoporosis, Postmenopausal; Pilot Projects; Risedronic Acid; Spinal Fractures; Time Factors; Vitamin D | 2001 |
Vgamma2Vdelta2 T-cell receptor-mediated recognition of aminobisphosphonates.
Topics: Alendronate; Antigens; Cell Line, Transformed; Cytotoxicity, Immunologic; Diphosphonates; Etidronic Acid; Gene Rearrangement, delta-Chain T-Cell Antigen Receptor; Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor; Humans; Interferon-gamma; Interleukin-2; Jurkat Cells; Lymphocyte Activation; Monocytes; Multiple Myeloma; Neoplasms; Neoplastic Stem Cells; Osteoclasts; Osteoporosis; Pamidronate; Receptors, Antigen, T-Cell, gamma-delta; Recombinant Fusion Proteins; Risedronic Acid; Structure-Activity Relationship; T-Lymphocyte Subsets; Transfection | 2001 |
[Optimizing treatment of osteoporosis. Rapidly effective therapy lowers fracture risk in 1 year up to 70%].
Topics: Aged; Aged, 80 and over; Clinical Trials, Phase III as Topic; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2001 |
[Risedronate now also approved for hip fractures. Study discloses significant risk reduction in proximal femoral neck fractures].
Topics: Aged; Clinical Trials as Topic; Drug Approval; Etidronic Acid; Female; Femoral Neck Fractures; Fractures, Spontaneous; Germany; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2001 |
Maintenance of cancellous bone in ovariectomized, human parathyroid hormone [hPTH(1-84)]-treated rats by estrogen, risedronate, or reduced hPTH.
Topics: Animals; Bone Density; Bone Diseases, Metabolic; Calcium Channel Blockers; Diphosphonates; Estrogens; Etidronic Acid; Female; Femur; Humans; Osteogenesis; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid; Survival Rate; Tibia | 2001 |
[Osteoporosis. Fracture as alarm signal].
Topics: Aged; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2001 |
Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis.
Topics: Actins; Alendronate; Animals; Apoptosis; Bone Resorption; Cytoskeleton; Etidronic Acid; Mice; Osteoclasts; Risedronic Acid | 2001 |
A method to assess the proportion of treatment effect explained by a surrogate endpoint.
Topics: Biometry; Endpoint Determination; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2001 |
Bisphosphonate treatment suppresses not only stochastic remodeling but also the targeted repair of microdamage.
Topics: Alendronate; Animals; Bone Density; Bone Regeneration; Diphosphonates; Dogs; Etidronic Acid; Female; Fractures, Bone; Rib Fractures; Risedronic Acid; Stochastic Processes | 2001 |
[Economic aspects of osteoporosis therapy. What does a prevented fracture cost?].
Topics: Aged; Alendronate; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Humans; National Health Programs; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures | 2001 |
[Therapy of osteoporosis. Risk factors alone are not an indication].
Topics: Aged; Aged, 80 and over; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2001 |
[Risedronate, a new diphosphonate in osteoporosis and Paget's disease].
Topics: Aged; Calcium Channel Blockers; Cortisone; Costs and Cost Analysis; Double-Blind Method; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteitis Deformans; Osteoporosis; Osteoporosis, Postmenopausal; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Time Factors | 2002 |
The cost utility of bisphosphonate treatment in established osteoporosis.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans; Models, Econometric; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid; Time Factors | 2002 |
[When osteoporosis first manifests itself. Without therapy the next fracture threatens].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; Osteoporosis; Risedronic Acid | 2002 |
Comparison insight dual X-ray absorptiometry (DXA), histomorphometry, ash weight, and morphometric indices for bone evaluation in an animal model (the orchidectomized rat) of male osteoporosis.
Topics: Absorptiometry, Photon; Animals; Body Weight; Bone and Bones; Bone Density; Climacteric; Disease Models, Animal; Etidronic Acid; Hypogonadism; Male; Orchiectomy; Organ Size; Osteoporosis; Predictive Value of Tests; Rats; Rats, Wistar; Risedronic Acid; Statistics as Topic; Tibia | 2001 |
Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Topics: Aged; Alendronate; Calcium Channel Blockers; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2002 |
Sequential treatment with basic fibroblast growth factor and PTH is more efficacious than treatment with PTH alone for increasing vertebral bone mass and strength in osteopenic ovariectomized rats.
Topics: Aging; Animals; Biomechanical Phenomena; Bone Density; Bone Diseases, Metabolic; Bone Resorption; Calcium; Drug Synergism; Estrogens; Etidronic Acid; Female; Fibroblast Growth Factor 2; Organ Size; Ovariectomy; Parathyroid Hormone; Phosphorus; Rats; Rats, Sprague-Dawley; Risedronic Acid; Spine | 2002 |
Risedronate: a new oral bisphosphonate.
Topics: Aged; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Postmenopause; Risedronic Acid | 2002 |
Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography.
Topics: Animals; Biomechanical Phenomena; Calcium Channel Blockers; Etidronic Acid; Female; Lumbar Vertebrae; Ovariectomy; Radiography; Risedronic Acid; Swine, Miniature; Tomography Scanners, X-Ray Computed | 2002 |
Prevention of bone loss in ovariectomized rats by combined treatment with risedronate and 1alpha,25-dihydroxyvitamin D3.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone Density; Calcitriol; Etidronic Acid; Female; Osteoporosis; Ovariectomy; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2002 |
[Patients with fractures are in the front line for osteoporosis treatment but how to treat?].
Topics: Alendronate; Bone Density; Calcitonin; Etidronic Acid; Fractures, Bone; Health Services Accessibility; Humans; Osteoporosis; Physician's Role; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2001 |
[Osteoporosis therapy. A comparison of bisphosphonates].
Topics: Aged; Alendronate; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2002 |
Assessment of mortality in patients enrolled in a risedronate clinical trial program: a retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Calcium Channel Blockers; Cause of Death; Clinical Trials, Phase III as Topic; Cohort Studies; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Middle Aged; North America; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Survival Rate | 2002 |
Commentary on: Bone mineral density and fracture prevalence in long-term kidney graft recipients.
Topics: Bone Density; Etidronic Acid; Fractures, Bone; Humans; Kidney Transplantation; Osteoporosis; Prevalence; Risedronic Acid | 2002 |
Bisphosphonates and the upper gastrointestinal tract: skeletal gain without visceral pain?
Topics: Alendronate; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Osteoporosis, Postmenopausal; Risedronic Acid | 2002 |
[Treatment of osteoporosis. Not only measurements count].
Topics: Biopsy; Bone and Bones; Bone Density; Clinical Trials as Topic; Etidronic Acid; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2002 |
Once-a-week risedronate (actonel).
Topics: Administration, Oral; Digestive System; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2002 |
Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
Topics: Angiogenesis Inhibitors; Animals; Bone and Bones; Cell Division; Cells, Cultured; Clodronic Acid; Diphosphonates; Endothelium, Vascular; Epithelial Cells; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Male; Neovascularization, Physiologic; Orchiectomy; Osteitis Deformans; Prostate; Rats; Rats, Sprague-Dawley; Risedronic Acid; Testosterone; Tissue Distribution; Zoledronic Acid | 2002 |
Effects of risedronate, alendronate, and etidronate on the viability and activity of rat bone marrow stromal cells in vitro.
Topics: Alendronate; Animals; Bone and Bones; Bone Marrow Cells; Cell Survival; Diphosphonates; Diterpenes; Etidronic Acid; Farnesol; Fibroblasts; Models, Animal; Rats; Rats, Wistar; Risedronic Acid; Stromal Cells | 2003 |
[Osteoporosis: diagnosis, prevention and treatment].
Topics: Adult; Aged; Calcitonin; Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Injections, Intramuscular; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
[Weeks of pain, vertebral body fractures during sleep, invalidism. Save your osteoporosis patients from this fate].
Topics: Activities of Daily Living; Age Factors; Alendronate; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Disabled Persons; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Pain; Raloxifene Hydrochloride; Risedronic Acid; Sex Factors; Spinal Fractures | 2002 |
Medications for postmenopausal osteoporosis prevention.
Topics: Alendronate; Bone Density; Estrogen Antagonists; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors; Selective Estrogen Receptor Modulators | 2002 |
[Economic assessment based on a clinical study of risedronate. Fracture prevention in elderly women with osteoporosis is cost-effective].
Topics: Aged; Cost of Illness; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Health Care Costs; Humans; Middle Aged; Models, Economic; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Sweden | 2003 |
Three hydrates of the bisphosphonate risedronate, consisting of one molecular and two ionic structures.
Topics: Alanine; Crystallography, X-Ray; Etidronic Acid; Gadolinium; Hydrogen Bonding; Models, Molecular; Proline; Risedronic Acid | 2003 |
[Vertebral body fracture as incidental finding in thoracic radiography. Family physician usually does not learn about it].
Topics: Bone Density; Diphosphonates; Double-Blind Method; Etidronic Acid; Family Practice; Female; Follow-Up Studies; Humans; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Radiography, Thoracic; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Spinal Fractures; Time Factors | 2003 |
Bone density changes with once weekly risedronate in postmenopausal women.
Topics: Aged; Aged, 80 and over; Bone Density; Calcium; Digestive System; Diphosphonates; Drug Tolerance; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Retrospective Studies; Risedronic Acid; Vitamin D | 2003 |
Involvement of vacuolar H+ -ATPase in incorporation of risedronate into osteoclasts.
Topics: Actins; Animals; Bone Resorption; Cells, Cultured; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Extracellular Fluid; Male; Mice; Microscopy, Immunoelectron; Osteoclasts; Risedronic Acid; Vacuolar Proton-Translocating ATPases | 2003 |
Tolerability and compliance with risedronate in clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Patient Dropouts; Risedronic Acid | 2003 |
[For patients with osteoporosis-induced fracture the emergency brake must be pulled. Every 4th patient as a recurrence in the following year].
Topics: Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Secondary Prevention; Spinal Fractures | 2003 |
[To treat effectively without delay. The data on fractures decisive].
Topics: Aged; Calcium Channel Blockers; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Prospective Studies; Risedronic Acid; Risk Factors; Spinal Fractures; Time Factors | 2003 |
[Therapy of osteoporosis with bisphosphonate. Bone quality maintained over years].
Topics: Aged; Bone Density; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Long-Term Care; Osteoporosis, Postmenopausal; Risedronic Acid; Spinal Fractures | 2003 |
[Evidence-based therapy of osteoporosis--comment on DMW 17/2003].
Topics: Alendronate; Budgets; Drug Costs; Etidronic Acid; Evidence-Based Medicine; Germany; Humans; National Health Programs; Osteoporosis; Risedronic Acid | 2003 |
Determination of risedronate in human urine by column-switching ion-pair high-performance liquid chromatography with ultraviolet detection.
Topics: Chromatography, High Pressure Liquid; Etidronic Acid; Humans; Ions; Reference Standards; Reproducibility of Results; Risedronic Acid; Sensitivity and Specificity; Spectrophotometry, Ultraviolet | 2003 |
Show us the numbers.
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Drug Industry; Etidronic Acid; Humans; Incidence; Osteoporosis; Reproducibility of Results; Research Design; Risedronic Acid; Risk Assessment | 2003 |
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Topics: Animals; Bone and Bones; Bone Morphogenetic Protein 2; Bone Morphogenetic Proteins; Bone Resorption; Calcium; Calcium Channel Blockers; Carrier Proteins; Etidronic Acid; Glycoproteins; Male; Membrane Glycoproteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Osteocalcin; Osteogenesis; Osteoprotegerin; Phosphorus; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Risedronic Acid; Transforming Growth Factor beta | 2003 |
Canine cancellous bone microarchitecture after one year of high-dose bisphosphonates.
Topics: Alendronate; Animals; Bone Development; Compressive Strength; Dogs; Etidronic Acid; Female; Growth Plate; Imaging, Three-Dimensional; Lumbar Vertebrae; Radiography; Risedronic Acid; Stress, Mechanical; Treatment Outcome | 2003 |
Spectrophotometric determination of some drugs for osteoporosis.
Topics: Alendronate; Etidronic Acid; Osteoporosis; Risedronic Acid; Spectrophotometry | 2003 |
A prospective study of risedronate on regional bone metabolism and blood flow at the lumbar spine measured by 18F-fluoride positron emission tomography.
Topics: Absorptiometry, Photon; Aged; Bone and Bones; Bone Density; Calcium Channel Blockers; Etidronic Acid; Female; Fluorides; Fluorine Radioisotopes; Humans; Lumbar Vertebrae; Metabolic Clearance Rate; Middle Aged; Radiopharmaceuticals; Regional Blood Flow; Risedronic Acid; Tomography, Emission-Computed | 2003 |
Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs.
Topics: Alendronate; Animals; Bone Density; Bone Remodeling; Calcification, Physiologic; Carbonates; Collagen; Crystallography; Diphosphonates; Dogs; Etidronic Acid; Female; Microscopy, Electron, Scanning; Osteogenesis; Osteoporosis; Phosphates; Proteins; Ribs; Risedronic Acid; Scattering, Radiation; Spectrophotometry, Infrared; Thoracic Vertebrae; Tomography, X-Ray Computed; X-Ray Diffraction | 2003 |
Patent news.
Topics: Animals; Antineoplastic Agents; Benzamides; Carbazoles; Drug Industry; Etidronic Acid; Gastroesophageal Reflux; Humans; Imatinib Mesylate; Patents as Topic; Piperazines; Pyrimidines; Risedronic Acid; Serotonin Receptor Agonists; Tryptamines; United Kingdom | 2003 |
The effects of binge alcohol exposure on bone resorption and biomechanical and structural properties are offset by concurrent bisphosphonate treatment.
Topics: Amino Acids; Animals; Biomechanical Phenomena; Bone Density; Bone Resorption; Diphosphonates; Ethanol; Etidronic Acid; Male; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2004 |
Osteoblast proliferation and maturation by bisphosphonates.
Topics: Adaptation, Physiological; Alendronate; Cell Differentiation; Cell Division; Cell Line; Cell Survival; Cells, Cultured; Diphosphonates; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Etidronic Acid; Extracellular Matrix Proteins; Humans; Osteoblasts; Risedronic Acid | 2004 |
Mucosal irritative and healing impairment action of risedronate in rat stomachs: comparison with alendronate.
Topics: Acetic Acid; Alendronate; Animals; Diphosphonates; Etidronic Acid; Gastric Mucosa; Male; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach Ulcer; Wound Healing | 2004 |
[Bisphosphonates in the prevention of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis].
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2003 |
Bisphosphonate treatment affects trabecular bone apparent modulus through micro-architecture rather than matrix properties.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Matrix; Calcification, Physiologic; Dogs; Etidronic Acid; Female; Risedronic Acid | 2004 |
[Osteoporosis therapy. Bisphosphonates compared].
Topics: Alendronate; Bone Density; Clinical Trials as Topic; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Risedronic Acid; Time Factors | 2003 |
Efficacy of risedronate on clinical vertebral fractures within six months.
Topics: Body Height; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Radiography; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures | 2004 |
Risedronate and pamidronate treatment in the clinical management of patients with severe Paget's disease of bone and acquired resistance to bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Calcitriol; Clodronic Acid; Diphosphonates; Drug Tolerance; Etidronic Acid; Female; Humans; Injections, Intravenous; Male; Middle Aged; Osteitis Deformans; Pain; Pamidronate; Parathyroid Hormone; Risedronic Acid; Treatment Outcome | 2004 |
Selective in vitro effects of the farnesyl pyrophosphate synthase inhibitor risedronate on Trypanosoma cruzi.
Topics: Alkyl and Aryl Transferases; Animals; Cells, Cultured; Chagas Disease; Chlorocebus aethiops; Enzyme Inhibitors; Etidronic Acid; Geranyltranstransferase; Mice; Microscopy, Electron; Myocytes, Cardiac; Risedronic Acid; Sterols; Trypanocidal Agents; Trypanosoma cruzi; Vero Cells | 2004 |
Antiparasitic activity of risedronate in a murine model of acute Chagas' disease.
Topics: Acute Disease; Alkyl and Aryl Transferases; Animals; Chagas Disease; Disease Models, Animal; Enzyme Inhibitors; Etidronic Acid; Female; Geranyltranstransferase; Heart; Mice; Myocardium; Parasitemia; Risedronic Acid; Trypanocidal Agents | 2004 |
Contribution of Complementarity-Determining Region 3 of the T-Cell Receptor Vδ2 Chain to the Recognition of Aminobisphosphonates by Human γδ T-Cells.
Topics: Amino Acid Sequence; Amino Acids, Neutral; Cells, Cultured; Complementarity Determining Regions; Diphosphonates; Etidronic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Lymphocyte Activation; Receptors, Antigen, T-Cell, gamma-delta; Risedronic Acid; T-Lymphocytes | 2004 |
Pharmacoeconomic analysis of osteoporosis treatment with risedronate.
Topics: Aged; Calcium Channel Blockers; Cost-Benefit Analysis; Etidronic Acid; Evidence-Based Medicine; Female; Germany; Hip Fractures; Humans; Incidence; Markov Chains; Middle Aged; Mortality; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risedronic Acid | 2003 |
Antiresorptive therapy conserves some periarticular bone and ligament mechanical properties after anterior cruciate ligament disruption in the rabbit knee.
Topics: Animals; Anterior Cruciate Ligament; Biomechanical Phenomena; Bone Density; Etidronic Acid; Osteoarthritis; Rabbits; Risedronic Acid | 2004 |
[Consistent therapeutic success in osteoporosis].
Topics: Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Fractures, Spontaneous; Humans; Osteoporosis; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2004 |
Regulation of mineral-to-matrix ratio of lumbar trabecular bone in ovariectomized rats treated with risedronate in combination with or without vitamin K2.
Topics: Absorptiometry, Photon; Amino Acids; Animals; Biomechanical Phenomena; Body Weight; Bone Density; Bone Matrix; Etidronic Acid; Female; Femur; Lumbar Vertebrae; Osteocalcin; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Tomography, X-Ray Computed; Vitamin K 2 | 2004 |
[Data comparison of osteoporosis patients demonstrates nasal administration is not optimal].
Topics: Administration, Intranasal; Administration, Oral; Aerosols; Aged; Alendronate; Calcitonin; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Treatment Outcome | 2004 |
New treatments for brittle bones.
Topics: Alendronate; Animals; Bone Density; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2004 |
Coming to grips with bone loss.
Topics: Alendronate; Animals; Bone and Bones; Bone Density; Bone Remodeling; Carrier Proteins; Estrenes; Estrogens; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Membrane Glycoproteins; Osteoblasts; Osteoclasts; Osteoporosis; Osteoporosis, Postmenopausal; Parathyroid Hormone; Parathyroid Hormone-Related Protein; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Receptors, Estrogen; Risedronic Acid; Signal Transduction; Teriparatide; Vitamin D | 2004 |
[Risk of osteoporosis in postmenopausal women. When is bone density measurement indicated?].
Topics: Absorptiometry, Photon; Aged; Alendronate; Bone Density; Etidronic Acid; Evidence-Based Medicine; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Selective Estrogen Receptor Modulators; Spinal Fractures | 2004 |
[Faster and long-lasting protection with risedronate. With strengthened bones longer self-sufficient].
Topics: Age Factors; Aged; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Retrospective Studies; Risedronic Acid; Risk Factors; Spinal Fractures; Time Factors | 2004 |
[Risedronate affects bone strength, too. Faster protective effect on microarchitecture].
Topics: Bone and Bones; Calcium Channel Blockers; Collagen; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Time Factors | 2004 |
[Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
Topics: Alendronate; Bone Density; Drug Administration Schedule; Etidronic Acid; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2004 |
[Stability also depends on other parameters. Bone density--not a good indicator for fracture prevention].
Topics: Absorptiometry, Photon; Bone and Bones; Bone Density; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2004 |
[Are there differences in bisphosphonates? (interview by Dr. Beate Schumacher)].
Topics: Alendronate; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Fractures, Spontaneous; Humans; Meta-Analysis as Topic; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Treatment Outcome | 2004 |
Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Germany; Hip Fractures; Humans; Incidence; Insurance, Pharmaceutical Services; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2004 |
Pharmaceutical care and community pharmacists' understanding of bisphosphonate dosing information.
Topics: Alendronate; Community Pharmacy Services; Diphosphonates; Drug Administration Schedule; Drug Information Services; Education, Pharmacy, Continuing; Etidronic Acid; Female; Humans; Knowledge; Male; Pharmacists; Risedronic Acid; Surveys and Questionnaires | 2004 |
Extemporaneous procedures for dissolving risedronate tablets for oral administration and for feeding tubes.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Drug Compounding; Enteral Nutrition; Etidronic Acid; Pharmaceutical Solutions; Risedronic Acid; Solubility; Tablets | 2005 |
Preparation and evaluation of floating risedronate sodium Gelucire 39/01 matrices.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Drug Delivery Systems; Drug Evaluation, Preclinical; Etidronic Acid; Humans; Hydrophobic and Hydrophilic Interactions; Male; Microscopy, Electron, Scanning; Microscopy, Polarization; Polyethylene Glycols; Radionuclide Imaging; Risedronic Acid; Technology, Pharmaceutical; Time Factors; Triglycerides | 2004 |
Trochanteric hip fracture in an elderly patient with leprosy during osteoporosis treatment with risedronate and alfacalcidol.
Topics: Aged; Aged, 80 and over; Bone Density; Etidronic Acid; Femur; Hip Fractures; Humans; Hydroxycholecalciferols; Leprosy; Male; Mycobacterium leprae; Osteoporosis; Radiography; Risedronic Acid | 2005 |
Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis.
Topics: Animals; Bone Resorption; Calcium Channel Blockers; Diphosphonates; Dogs; Drug Resistance; Etidronic Acid; Forelimb; Immobilization; Osteoporosis; Risedronic Acid | 2005 |
[Update 2004. Osteoporosis--management--current status].
Topics: Aged; Aged, 80 and over; Alendronate; Calcium, Dietary; Cross-Sectional Studies; Etidronic Acid; Female; Fractures, Spontaneous; Germany; Health Surveys; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Practice Guidelines as Topic; Raloxifene Hydrochloride; Risedronic Acid; Spinal Fractures; Vitamin D | 2004 |
[Routine osteoporosis therapy].
Topics: Administration, Intranasal; Aged; Alendronate; Calcitonin; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Germany; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid; Risk; United States | 2004 |
Bisphosphonates induce inflammation and rupture of atherosclerotic plaques in apolipoprotein-E null mice.
Topics: Alendronate; Animals; Aorta; Apolipoproteins E; Arteriosclerosis; Carotid Stenosis; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Female; Mice; Mice, Inbred C57BL; Mice, Knockout; Risedronic Acid; Treatment Outcome | 2005 |
[FACT study: benefits of alendronate].
Topics: Aged; Alendronate; Bone Density; Calcium Channel Blockers; Double-Blind Method; Etidronic Acid; Female; Humans; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Time Factors | 2005 |
Alendronate and risedronate: reports of severe bone, joint, and muscle pain.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alendronate; Arthralgia; Bone and Bones; Child; Etidronic Acid; Female; Humans; Male; Middle Aged; Pain; Risedronic Acid | 2005 |
Effects of risedronate on trabecular microstructure and biomechanical properties in ovariectomized rat tibia.
Topics: Animals; Biomechanical Phenomena; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Etidronic Acid; Female; Finite Element Analysis; Imaging, Three-Dimensional; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Tomography, X-Ray Computed | 2005 |
Structural and analytical characterization of three hydrates and an anhydrate form of risedronate.
Topics: Absorption; Crystallography, X-Ray; Differential Thermal Analysis; Etidronic Acid; Excipients; Magnetic Resonance Spectroscopy; Models, Molecular; Risedronic Acid; Spectrophotometry, Infrared; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman | 2005 |
Interleukin-6 and osteoprotegerin systems in Paget's disease of bone: relationship to risedronate treatment.
Topics: Aged; Etidronic Acid; Female; Glycoproteins; Humans; Interleukin-6; Male; Middle Aged; Osteitis Deformans; Osteoprotegerin; Receptors, Cytoplasmic and Nuclear; Receptors, Tumor Necrosis Factor; Risedronic Acid | 2005 |
Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Topics: Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2005 |
Bisphosphonates stimulate an endogenous nonselective cation channel in Xenopus oocytes: potential mechanism of action.
Topics: Alendronate; Animals; Diphosphonates; Electric Impedance; Etidronic Acid; Ion Channels; Membrane Potentials; Oocytes; Rats; Risedronic Acid; Xenopus | 2005 |
[Evaluation of the effects of treatment of osteoporosis].
Topics: Aged; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Factors | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Bone Density; Bone Remodeling; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Maxillary Diseases; Middle Aged; Osteonecrosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Risedronate in the treatment of Murine Chagas' disease.
Topics: Animals; Chagas Cardiomyopathy; Chagas Disease; Disease Models, Animal; Etidronic Acid; Mice; Mice, Inbred C57BL; Myocardium; Risedronic Acid; Survival Analysis; Trypanocidal Agents; Trypanosoma cruzi | 2005 |
Current pharmacological treatment for fibrous dysplasia and perspectives for the future.
Topics: Calcium Channel Blockers; Diphosphonates; Etidronic Acid; Fibrous Dysplasia of Bone; Humans; Randomized Controlled Trials as Topic; Risedronic Acid | 2005 |
Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B.
Topics: Apoptosis; Cytochalasin B; Etidronic Acid; Extracellular Signal-Regulated MAP Kinases; Humans; Intracellular Membranes; Membrane Potentials; Mitochondria; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; ras Proteins; Risedronic Acid; Signal Transduction; Trifluoperazine; U937 Cells | 2005 |
[Calcium gaps in osteoporosis patients close. Blister pack simplifies comedication of calcium and bisphosphonates].
Topics: Alendronate; Calcitonin; Calcium; Clinical Trials as Topic; Cohort Studies; Drug Packaging; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Time Factors | 2005 |
[Excellent adjustment with greater action. To pay attention to improving compliance].
Topics: Aged; Calcium; Clinical Trials as Topic; Cross-Over Studies; Diphosphonates; Drug Packaging; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid; Time Factors | 2005 |
Risedronate-induced intravascular haemolysis complicated by acute tubular necrosis.
Topics: Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Furosemide; Hemolysis; Humans; Isotonic Solutions; Kidney Tubular Necrosis, Acute; Middle Aged; Risedronic Acid; Sodium Chloride; Treatment Outcome | 2005 |
[Marketing--alendronate versus risedronate].
Topics: Alendronate; Bone Density; Drug Information Services; Etidronic Acid; Humans; Marketing; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
[To increase bone density faster and stronger].
Topics: Alendronate; Bone Density; Bone Resorption; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Osteoporosis, Postmenopausal; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Tablets; Time Factors | 2005 |
Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability.
Topics: Chemistry, Pharmaceutical; Desiccation; Drug Compounding; Drug Stability; Etidronic Acid; Humidity; Pharmaceutical Preparations; Quality Control; Risedronic Acid; Spectrum Analysis, Raman; Tablets; Technology, Pharmaceutical; Temperature; Water | 2005 |
Risedronate induced BOOP complicated with sarcoidosis.
Topics: Aged; Calcium Channel Blockers; Cryptogenic Organizing Pneumonia; Etidronic Acid; Female; Humans; Muscular Diseases; Osteoporosis; Risedronic Acid; Sarcoidosis; Sarcoidosis, Pulmonary | 2005 |
Chronic diffuse sclerosing osteomyelitis treated with risedronate.
Topics: Adult; Calcium Channel Blockers; Chronic Disease; Etidronic Acid; Female; Humans; Osteomyelitis; Pain; Risedronic Acid | 2005 |
High-dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse.
Topics: Animals; Bone and Bones; Bone Density; Dogs; Etidronic Acid; Female; Immobilization; Risedronic Acid | 2005 |
Alendronate (Fosamax) and risedronate (Actonel) revisited.
Topics: Alendronate; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid | 2005 |
Osteoclast responses to lipopolysaccharide, parathyroid hormone and bisphosphonates in neonatal murine calvaria analyzed by laser scanning confocal microscopy.
Topics: Acid Phosphatase; Actins; Alkaline Phosphatase; Animals; Animals, Newborn; Bone Density; Bone Resorption; Clodronic Acid; Collagen Type I; Diphosphonates; Etidronic Acid; Fluorescent Dyes; Integrin beta3; Integrin-Binding Sialoprotein; Isoenzymes; Lipopolysaccharides; Mice; Organ Culture Techniques; Osteoclasts; Osteopontin; Parathyroid Hormone; Risedronic Acid; Sialoglycoproteins; Skull; Tartrate-Resistant Acid Phosphatase | 2005 |
Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; Bone Diseases; Cause of Death; Cohort Studies; Dyspepsia; England; Etidronic Acid; Family Practice; Female; Gastrointestinal Diseases; Humans; Incidence; Male; Nausea; Osteitis Deformans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome; Vomiting | 2005 |
Hospitalization-related bone loss and the protective effect of risedronate.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Female; Femur; Hospitalization; Humans; Lumbar Vertebrae; Osteoporosis; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Treatment Outcome | 2006 |
Madarosis from mitochondriopathy.
Topics: Aged; Alopecia Areata; Aspirin; Bisoprolol; Drug Therapy, Combination; Etidronic Acid; Eyelashes; Female; Humans; Mitochondrial Myopathies; Molsidomine; Nitroglycerin; Risedronic Acid | 2005 |
A bright future for osteoporosis treatment.
Topics: Adrenergic beta-Antagonists; Animals; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Ibandronic Acid; Lithium Compounds; Osteogenesis; Osteoporosis; Receptor, Cannabinoid, CB1; Risedronic Acid | 2005 |
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Insurance Claim Review; Insurance, Pharmaceutical Services; Managed Care Programs; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care; Patient Compliance; Proportional Hazards Models; Risedronic Acid; Self Administration; United States | 2005 |
Effects of risedronate on femoral bone mineral density and bone strength in sciatic neurectomized young rats.
Topics: Animals; Biomechanical Phenomena; Bone Density; Etidronic Acid; Femur; Male; Rats; Rats, Sprague-Dawley; Risedronic Acid; Sciatic Nerve | 2005 |
Bone remodeling at the iliac crest can predict the changes in remodeling dynamics, microdamage accumulation, and mechanical properties in the lumbar vertebrae of dogs.
Topics: Administration, Oral; Alendronate; Animals; Biomechanical Phenomena; Bone Remodeling; Calcium Channel Blockers; Dogs; Etidronic Acid; Female; Ilium; Lumbar Vertebrae; Risedronic Acid | 2005 |
[Risedronate: a possible treatment for extraosseous calcification].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; CREST Syndrome; Etidronic Acid; Female; Glucocorticoids; Humans; Joint Diseases; Middle Aged; Ossification, Heterotopic; Osteoporosis; Prednisolone; Risedronic Acid; Shoulder Joint | 2005 |
Risedronate therapy for prevention of hip fracture after stroke in elderly women.
Topics: Accidental Falls; Aged; Bone Density Conservation Agents; Causality; Clinical Trials as Topic; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Selection; Radiography; Reproducibility of Results; Risedronic Acid; Selection Bias; Spinal Fractures; Stroke | 2005 |
[Practical approaches to the osteoporosis treatment--instructions for drug use that draws the effect of the medicine].
Topics: Adult; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Patient Education as Topic; Risedronic Acid | 2005 |
[Antiresorptive treatment after proximal femur fracture].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Hip Fractures; Humans; Retrospective Studies; Risedronic Acid; Vitamin D | 2005 |
Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design.
Topics: Alendronate; Amino Acid Sequence; Animals; Drug Design; Etidronic Acid; Geranyltranstransferase; Magnesium; Models, Molecular; Molecular Sequence Data; Protein Structure, Secondary; Protozoan Proteins; Risedronic Acid; Sequence Alignment; Sequence Homology, Amino Acid; Trypanocidal Agents; Trypanosoma cruzi | 2006 |
[Examination and treatment of orthopedic-surgery patients with osteoporosis-related fragility fractures].
Topics: Adult; Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fracture Healing; Fractures, Spontaneous; Hip Fractures; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Care Planning; Patient Education as Topic; Risedronic Acid; Vitamin D | 2005 |
Preparation and evaluation of floating risedronate sodium-Gelucire 43/01 formulations.
Topics: Bone Density Conservation Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Stability; Etidronic Acid; Excipients; Microscopy, Electron, Scanning; Radionuclide Imaging; Risedronic Acid; Thermodynamics; Triglycerides | 2005 |
One drug tackles two diseases.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Periodontal Diseases; Risedronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alendronate; Cost-Benefit Analysis; Diphosphonates; Drug Administration Schedule; Drug Costs; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2005 |
Paget's disease and bisphosphonates.
Topics: Administration, Oral; Alkaline Phosphatase; Diphosphonates; Disease Progression; Etidronic Acid; Humans; Imidazoles; Osteitis Deformans; Remission Induction; Risedronic Acid; Zoledronic Acid | 2005 |
Symptomatic hypocalcemia due to oral risedronate therapy.
Topics: Adult; Bone Density Conservation Agents; Celiac Disease; Etidronic Acid; Humans; Hypocalcemia; Male; Osteoporosis; Risedronic Acid | 2005 |
[Optimizing therapy in Paget disease].
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Follow-Up Studies; Humans; Imidazoles; Infusions, Intravenous; Osteitis Deformans; Randomized Controlled Trials as Topic; Risedronic Acid; Zoledronic Acid | 2005 |
Ophthalmological events in patients receiving risedronate: summary of information gained through follow-up in a prescription-event monitoring study in England.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Bone Density Conservation Agents; Drug Prescriptions; England; Etidronic Acid; Eye Diseases; Female; Humans; Male; Middle Aged; Risedronic Acid | 2006 |
Profound refractory hypocalcemia after thyroidectomy in a patient receiving chronic oral bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Goiter, Nodular; Humans; Hypocalcemia; Risedronic Acid; Thyroidectomy | 2005 |
Potential adverse effects.
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Jaw Diseases; Osteonecrosis; Periodontal Diseases; Risedronic Acid | 2006 |
Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Topics: Alendronate; Databases as Topic; Diphosphonates; Drug Prescriptions; Drug Utilization; Etidronic Acid; Female; Glucocorticoids; Health Care Surveys; Humans; Male; Middle Aged; Osteoporosis; Patient Compliance; Pharmacies; Process Assessment, Health Care; Quality of Health Care; Risedronic Acid; Self Disclosure; Time Factors | 2006 |
[What do we need to know--what can we do?].
Topics: Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Calcium Channel Blockers; Clinical Trials as Topic; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid | 2005 |
Osteoporosis drug may protect joints.
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoarthritis, Knee; Risedronic Acid | 2006 |
Enthalpy versus entropy-driven binding of bisphosphonates to farnesyl diphosphate synthase.
Topics: Animals; Diphosphonates; Etidronic Acid; Geranyltranstransferase; Hydrophobic and Hydrophilic Interactions; Ibandronic Acid; Kinetics; Risedronic Acid; Static Electricity; Thermodynamics; Trypanosoma brucei brucei | 2006 |
Osteoporosis management in a Medicaid population after the Women's Health Initiative study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Drug Utilization; Estrogen Receptor Modulators; Estrogens; Etidronic Acid; Female; Humans; Medicaid; Middle Aged; Osteoporosis, Postmenopausal; Outcome Assessment, Health Care; Pennsylvania; Practice Patterns, Physicians'; Risedronic Acid; Women's Health Services | 2006 |
The cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Health Care Costs; Humans; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Spinal Fractures; Stochastic Processes | 2006 |
Effects of a prostaglandin EP4 agonist, ONO-4819, and risedronate on trabecular microstructure and bone strength in mature ovariectomized rats.
Topics: Aging; Animals; Bone Density; Etidronic Acid; Female; Heptanoates; Ovariectomy; Prostaglandins E; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Tibia | 2006 |
Chemical makeup of microdamaged bone differs from undamaged bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Carbonates; Collagen; Dogs; Etidronic Acid; Lumbar Vertebrae; Phosphates; Proteins; Random Allocation; Risedronic Acid; Spectrophotometry, Infrared; Synchrotrons; Time Factors | 2006 |
Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells.
Topics: Alkyl and Aryl Transferases; Apoptosis; Bone Density Conservation Agents; DNA Replication; Etidronic Acid; Humans; Multiple Myeloma; Protein Prenylation; Risedronic Acid; S Phase; Tumor Cells, Cultured | 2006 |
Is the increase in osteoporosis prevention a result of the audit?
Topics: Adrenal Cortex Hormones; Alendronate; Bone Density Conservation Agents; Calcium; Clinical Trials as Topic; Etidronic Acid; Humans; Medical Audit; Neurology; Osteoporosis; Practice Guidelines as Topic; Risedronic Acid; United Kingdom; Vitamin D | 2006 |
Differential effects of bisphosphonates on breast cancer cell lines.
Topics: Alendronate; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clodronic Acid; Cyclin D1; Diphosphonates; DNA Fragmentation; Etidronic Acid; Female; Flow Cytometry; Humans; Ibandronic Acid; Imidazoles; Pamidronate; Risedronic Acid; RNA, Messenger; Zoledronic Acid | 2007 |
Comparative effects of risedronate and calcitriol on cancellous bone in rats with glucocorticoid-induced osteopenia.
Topics: Animals; Biomechanical Phenomena; Body Weight; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Bone Remodeling; Bone Resorption; Calcitriol; Calcium; Etidronic Acid; Female; Femur; Phosphorus; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Tomography, X-Ray Computed | 2006 |
Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo.
Topics: Animals; Cell Division; Cell Line, Tumor; Diphosphonates; Disease Models, Animal; Etidronic Acid; Imidazoles; Mesothelioma; Mice; Phosphorylation; Risedronic Acid; Zoledronic Acid | 2006 |
Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Databases, Factual; Drug Administration Schedule; Drug Prescriptions; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Middle Aged; Multivariate Analysis; Netherlands; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid | 2006 |
The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs.
Topics: Animals; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Models, Molecular; Molecular Sequence Data; Molecular Structure; Nitrogen; Protein Binding; Protein Conformation; Recombinant Proteins; Risedronic Acid; Zoledronic Acid | 2006 |
Osteoporosis in older people: a tale of two studies (and three treatments).
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Male; Osteoporosis; Risedronic Acid; Teriparatide; Vitamin D | 2006 |
Bisphosphonates activate nucleotide receptors signaling and induce the expression of Hsp90 in osteoblast-like cell lines.
Topics: Adenosine Triphosphate; Alendronate; Apyrase; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Survival; Diphosphonates; Etidronic Acid; HSP90 Heat-Shock Proteins; Humans; Mass Spectrometry; Mitogen-Activated Protein Kinase Kinases; Models, Biological; Osteoblasts; Receptors, Purinergic P2; Risedronic Acid; Signal Transduction; Suramin | 2006 |
Sequential treatment of ovariectomized mice with bFGF and risedronate restored trabecular bone microarchitecture and mineralization.
Topics: Animals; Biomarkers; Calcification, Physiologic; Etidronic Acid; Female; Femur; Fibroblast Growth Factor 2; Lumbar Vertebrae; Mice; Ovariectomy; Risedronic Acid; Stress, Mechanical; Tomography, Emission-Computed; Transforming Growth Factor beta | 2006 |
Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Glucocorticoids; Humans; Logistic Models; Male; Middle Aged; Osteoporosis; Patient Compliance; Proportional Hazards Models; Risedronic Acid | 2006 |
[Only bone densitometry answers this question. How stable are your patients' bones?].
Topics: Absorptiometry, Photon; Aged; Bone Density; Diphosphonates; Etidronic Acid; Femoral Neck Fractures; Fractures, Spontaneous; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2006 |
Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Calcification, Physiologic; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Risedronic Acid; Time Factors | 2006 |
Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone.
Topics: Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Hypocalcemia; Middle Aged; Osteitis Deformans; Radiography; Risedronic Acid | 2006 |
Serum NTX is a practical marker for assessing antiresorptive therapy for glucocorticoid treated patients with chronic kidney disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Body Mass Index; Bone Density; Bone Density Conservation Agents; Bone Resorption; Chronic Disease; Collagen Type I; Creatinine; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Glucocorticoids; Humans; Kidney Diseases; Male; Middle Aged; Peptides; Risedronic Acid | 2006 |
Anti-inflammatory and anti-nociceptive activity of risedronate in experimental pain models in rats and mice.
Topics: Acetic Acid; Analgesics; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Inflammation; Leukotriene B4; Male; Mice; Pain; Pain Measurement; Rats; Rats, Wistar; Risedronic Acid; Tumor Necrosis Factor-alpha; Zymosan | 2006 |
Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Male; Managed Care Programs; Middle Aged; Osteoporosis; Patient Compliance; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Bisphosphonates suppress periosteal osteoblast activity independently of resorption in rat femur and tibia.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Diphosphonates; Etidronic Acid; Female; Femur; Injections, Subcutaneous; Osteoblasts; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Tibia | 2006 |
Cost-effectiveness of alternative treatments for women with osteoporosis in Canada.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Decision Support Techniques; Etidronic Acid; Female; Humans; Markov Chains; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid | 2006 |
Farnesyl diphosphate synthase is a cytosolic enzyme in Leishmania major promastigotes and its overexpression confers resistance to risedronate.
Topics: Animals; Cytosol; Drug Resistance; Etidronic Acid; Geranyltranstransferase; Leishmania major; Recombinant Proteins; Risedronic Acid; Selection, Genetic; Tissue Distribution; Transfection | 2006 |
[Substance properties of zoledronate make it possible: bisphosphonate therapy only once yearly].
Topics: Aged; Aged, 80 and over; Alendronate; Biological Availability; Bone Density Conservation Agents; Diphosphonates; Double-Blind Method; Etidronic Acid; Female; Geranyltranstransferase; Humans; Imidazoles; Male; Multicenter Studies as Topic; Osteitis Deformans; Osteoporosis, Postmenopausal; Patient Compliance; Placebos; Randomized Controlled Trials as Topic; Risedronic Acid; Surveys and Questionnaires; Time Factors; Zoledronic Acid | 2006 |
Madarosis from mitochondriopathy.
Topics: Alopecia Areata; Aspirin; Bisoprolol; Drug Therapy, Combination; Etidronic Acid; Eyelashes; Humans; Mitochondrial Myopathies; Molsidomine; Nitroglycerin; Risedronic Acid | 2006 |
Therapeutic effect of risedronate on cancellous and cortical bone in ovariectomized osteopenic rats: a comparison with the effects of alfacalcidol.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Models, Animal; Etidronic Acid; Female; Hydroxycholecalciferols; Osteogenesis; Ovariectomy; Random Allocation; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2006 |
Preventive effects of risedronate and calcitriol on cancellous osteopenia in rats treated with high-dose glucocorticoid.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Calcitriol; Etidronic Acid; Female; Glucocorticoids; Methylprednisolone; Osteogenesis; Random Allocation; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2006 |
Antioxidant effect of bisphosphonates and simvastatin on chondrocyte lipid peroxidation.
Topics: Animals; Antioxidants; Boron Compounds; Cattle; Cells, Cultured; Chondrocytes; Clodronic Acid; Diphosphonates; Edetic Acid; Etidronic Acid; Ferrous Compounds; Flow Cytometry; Hydrogen Peroxide; Lipid Peroxidation; Pamidronate; Risedronic Acid; Simvastatin; tert-Butylhydroperoxide | 2006 |
Dehydration of risedronate hemi-pentahydrate: analytical and physical characterization.
Topics: Bone Density Conservation Agents; Calorimetry, Differential Scanning; Crystallization; Desiccation; Drug Compounding; Etidronic Acid; Hot Temperature; Magnetic Resonance Spectroscopy; Particle Size; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Thermogravimetry; Water; X-Ray Diffraction | 2006 |
Importance of calcium co-medication in bisphosphonate therapy of osteoporosis: an approach to improving correct intake and drug adherence.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Calcium, Dietary; Dietary Supplements; Drug Packaging; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2006 |
Fracture incidence and characterization in patients on osteoporosis treatment: the ICARO study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Italy; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Factors; Vitamin D | 2006 |
Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men.
Topics: Aged; Aged, 80 and over; Alendronate; Arthritis, Rheumatoid; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Florida; Glucocorticoids; Hospitals, Veterans; Humans; Male; Middle Aged; Osteoporosis; Prevalence; Retrospective Studies; Risedronic Acid; Sex Factors | 2006 |
Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Matrix; Bone Remodeling; Dogs; Etidronic Acid; Female; Osteoblasts; Periosteum; Raloxifene Hydrochloride; Ribs; Risedronic Acid | 2006 |
A general approach for the quantitative analysis of bisphosphonates in human serum and urine by high-performance liquid chromatography/tandem mass spectrometry.
Topics: Alendronate; Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Diazomethane; Etidronic Acid; Humans; Risedronic Acid; Sensitivity and Specificity; Tandem Mass Spectrometry | 2006 |
[A young woman with headaches and skull anomalies: a long road to the diagnosis 'Paget's disease'].
Topics: Adult; Alkaline Phosphatase; Bone Density Conservation Agents; Diagnosis, Differential; Etidronic Acid; Female; Headache; Humans; Magnetic Resonance Imaging; Osteitis Deformans; Radiography; Radionuclide Imaging; Risedronic Acid; Skull; Treatment Outcome | 2006 |
Skeletal effects of short-term exposure to dexamethasone and response to risedronate treatment studied in vivo in rabbits by magnetic resonance micro-imaging and spectroscopy.
Topics: Animals; Bone Density; Bone Diseases; Dexamethasone; Etidronic Acid; Glucocorticoids; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Male; Rabbits; Radionuclide Imaging; Risedronic Acid; Time Factors | 2006 |
Effect of pre- and post-surgery treatment with risedronate on trabecular bone loss in ovariectomized rats.
Topics: Absorptiometry, Photon; Animals; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Resorption; Disease Models, Animal; Drug Administration Schedule; Etidronic Acid; Female; Femur; Fluoresceins; Image Processing, Computer-Assisted; Ovariectomy; Postoperative Care; Preoperative Care; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 2006 |
Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Evaluation; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Incidence; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Treatment Outcome; United States | 2007 |
Beneficial effect of pretreatment and treatment continuation with risedronate and vitamin K2 on cancellous bone loss after ovariectomy in rats: a bone histomorphometry study.
Topics: Absorptiometry, Photon; Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Etidronic Acid; Female; Femur; Ovariectomy; Premedication; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Time Factors; Treatment Outcome; Vitamin K 2; Vitamins | 2006 |
Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Dental Implantation, Endosseous; Etidronic Acid; Female; Humans; Jaw Diseases; Middle Aged; Oroantral Fistula; Osteonecrosis; Risedronic Acid | 2007 |
Risedronate and alendronate suppress osteocyte apoptosis following cyclic fatigue loading.
Topics: Alendronate; Animals; Apoptosis; Biomechanical Phenomena; Bone Density Conservation Agents; Etidronic Acid; Female; Osteocytes; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Ulna | 2007 |
Effect of administration site in the gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal.
Topics: Animals; Biological Availability; Etidronic Acid; Food-Drug Interactions; Gastrointestinal Transit; Infusions, Intravenous; Intestinal Absorption; Intestinal Mucosa; Male; Molecular Structure; Naphthalenes; Propionates; Rats; Rats, Wistar; Risedronic Acid; Trientine | 2007 |
European women's preference for osteoporosis treatment: influence of clinical effectiveness and dosing frequency.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Europe; Female; Humans; Interviews as Topic; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid | 2006 |
Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Ibandronic Acid; Interviews as Topic; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Patient Satisfaction; Risedronic Acid; United States | 2006 |
Effect of risedronate on the cortical and cancellous bone mass and mechanical properties in ovariectomized rats: a comparison with the effects of alfacalcidol.
Topics: Analysis of Variance; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Dose-Response Relationship, Drug; Etidronic Acid; Female; Femur; Hydroxycholecalciferols; Ovariectomy; Phosphorus; Random Allocation; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stress, Mechanical; Tibia | 2006 |
Risedronate-induced Hepatitis.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Liver Diseases; Liver Function Tests; Long-Term Care; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment; Severity of Illness Index; Transaminases | 2007 |
Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Topics: Aged; Aged, 80 and over; Alendronate; Attitude to Health; Bone Density; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Cross-Over Studies; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Fractures, Spontaneous; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Patient Compliance; Proportional Hazards Models; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk Assessment; Severity of Illness Index; Treatment Outcome; United States | 2007 |
Risedronate for the prevention of hip fractures: concern about validity of trials.
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Follow-Up Studies; Hip Fractures; Humans; Male; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Risedronic Acid; Treatment Outcome | 2007 |
Development and validation of a reversed-phase ion-pair high-performance liquid chromatographic method for the determination of risedronate in pharmaceutical preparations.
Topics: Calcium Channel Blockers; Chromatography, High Pressure Liquid; Etidronic Acid; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Reproducibility of Results; Risedronic Acid; Spectrophotometry, Ultraviolet; Tablets | 2007 |
Additive effect of vitamin K2 and risedronate on long bone mass in hypophysectomized young rats.
Topics: Alkaline Phosphatase; Amino Acids; Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Drug Synergism; Etidronic Acid; Female; Femur; Hypophysectomy; Image Processing, Computer-Assisted; Insulin-Like Growth Factor I; Random Allocation; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Vitamin K 2; Vitamins | 2007 |
Bisphosphonates. A cornerstone of osteoporosis treatment.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Estrogen Replacement Therapy; Etidronic Acid; Female; Humans; Ibandronic Acid; Mandibular Diseases; Osteonecrosis; Osteoporosis; Risedronic Acid | 2007 |
Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
Topics: Absorptiometry, Photon; Aged; Biopsy; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Calcification, Physiologic; Calcium; Etidronic Acid; Female; Humans; Ilium; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2007 |
[Men also need bone protection].
Topics: Bone Density; Bone Density Conservation Agents; Double-Blind Method; Etidronic Acid; Female; Humans; Male; Middle Aged; Multicenter Studies as Topic; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Sex Factors | 2006 |
[Correlation between studies and general practice].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Etidronic Acid; Family Practice; Female; Fractures, Spontaneous; Humans; Male; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid; Treatment Outcome | 2006 |
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction | 2007 |
[Osteoporosis compounds in general practice. That is REAL: in routine practice the better choice].
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Etidronic Acid; Female; Fractures, Spontaneous; Hip Fractures; Humans; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Spinal Fractures | 2007 |
A case of pachydermoperiostosis treated by oral administration of a bisphosphonate and arthroscopic synovectomy.
Topics: Adult; Arthroscopy; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Orthopedic Procedures; Osteoarthropathy, Primary Hypertrophic; Risedronic Acid; Synovectomy | 2007 |
Yearly zoledronic acid in postmenopausal osteoporosis.
Topics: Administration, Oral; Aged; Alendronate; Atrial Fibrillation; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Osteoporosis, Postmenopausal; Risedronic Acid; Zoledronic Acid | 2007 |
Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Humans; Logistic Models; Male; Osteoporosis; Patient Compliance; Quality of Life; Risedronic Acid; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2007 |
Risedronate has no adverse effects on mouse haematopoiesis.
Topics: Animals; Bone Density Conservation Agents; Bone Marrow Cells; Bone Marrow Transplantation; Calcium; Etidronic Acid; Hematopoiesis; Leukocytes; Male; Mice; Mice, Inbred C57BL; Organ Size; Phosphates; Risedronic Acid; Seminal Vesicles | 2007 |
Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Compressive Strength; Diphosphonates; Dogs; Etidronic Acid; Female; Lumbar Vertebrae; Models, Animal; Risedronic Acid | 2008 |
Risedronate did not block the maximal anabolic effect of PTH in aged rats.
Topics: Absorptiometry, Photon; Age Factors; Anabolic Agents; Animals; Etidronic Acid; Female; Parathyroid Hormone; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tomography, X-Ray Computed | 2007 |
Correlation between bone lesion changes and cartilage volume loss in patients with osteoarthritis of the knee as assessed by quantitative magnetic resonance imaging over a 24-month period.
Topics: Analysis of Variance; Bone and Bones; Bone Cysts; Cartilage, Articular; Diphosphonates; Disease Progression; Edema; Etidronic Acid; Female; Femur; Fibrocartilage; Follow-Up Studies; Humans; Linear Models; Magnetic Resonance Imaging; Male; Middle Aged; Osteoarthritis, Knee; Patella; Risedronic Acid | 2008 |
Implant placement with or without simultaneous tooth extraction in patients taking oral bisphosphonates: postoperative healing, early follow-up, and the incidence of complications in two private practices.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Dental Care for Chronically Ill; Dental Implantation, Endosseous; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Jaw Diseases; Middle Aged; Osseointegration; Osteonecrosis; Retrospective Studies; Risedronic Acid; Tooth Extraction; Wound Healing | 2007 |
Hip fractures in users of first- vs. second-generation bisphosphonates.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Hospitalization; Humans; Ontario; Osteoporosis, Postmenopausal; Retrospective Studies; Risedronic Acid; Social Class | 2007 |
Aromatase inhibitor-induced bone mineral loss and its prevention by bisphosphonate administration in postmenopausal breast cancer patients.
Topics: Aged; Anastrozole; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Breast Neoplasms; Drug Interactions; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Postmenopause; Risedronic Acid; Triazoles | 2007 |
Osteoporosis: non-hormonal treatment.
Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcitonin; Calcium, Dietary; Denosumab; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Organometallic Compounds; Osteoporosis, Postmenopausal; Parathyroid Hormone; Raloxifene Hydrochloride; Randomized Controlled Trials as Topic; RANK Ligand; Risedronic Acid; Thiophenes; Vitamin D; Women's Health | 2007 |
Patient compliance with alendronate, risedronate and raloxifene for the treatment of osteoporosis in postmenopausal women.
Topics: Alendronate; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Compliance; Postmenopause; Prospective Studies; Raloxifene Hydrochloride; Risedronic Acid | 2007 |
Isoprenoid-independent pathway is involved in apoptosis induced by risedronate, a bisphosphonate, in which Bim plays a critical role in breast cancer cell line MCF-7.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density Conservation Agents; Breast Neoplasms; Calcium Channel Blockers; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Membrane Proteins; Proto-Oncogene Proteins; Pyridines; Risedronic Acid; RNA, Small Interfering; Signal Transduction; Terpenes; Tumor Cells, Cultured | 2007 |
High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.
Topics: Absorptiometry, Photon; Accidental Falls; Administration, Oral; Biopsy; Bone and Bones; Bone Density; Bone Density Conservation Agents; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Injections, Intravenous; Lumbar Vertebrae; Middle Aged; Pamidronate; Risedronic Acid; Spinal Fractures; Thoracic Vertebrae; Time Factors; Treatment Outcome | 2007 |
Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis.
Topics: Access to Information; Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Data Interpretation, Statistical; Etidronic Acid; Fractures, Bone; Humans; Risedronic Acid; Risk | 2007 |
[Osteoporosis treatment: choices and options].
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Etidronic Acid; Humans; Osteoporosis; Risedronic Acid; Treatment Outcome | 2007 |
Effects of risedronate on fracture risk in postmenopausal women with osteopenia.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Postmenopause; Randomized Controlled Trials as Topic; Regression Analysis; Risedronic Acid; Risk Factors | 2008 |
The aminobisphosphonate risedronate preserves localized mineral and material properties of bone in the presence of glucocorticoids.
Topics: Animals; Biomechanical Phenomena; Biopsy; Bone Density Conservation Agents; Calcification, Physiologic; Drug Interactions; Elasticity; Etidronic Acid; Glucocorticoids; Humans; Ilium; Lumbar Vertebrae; Male; Mice; Microscopy, Electron, Transmission; Prednisolone; Risedronic Acid; Tomography, X-Ray | 2007 |
Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate.
Topics: Alkyl and Aryl Transferases; Animals; Bone Density Conservation Agents; Cell Line; Cell Proliferation; Cell Survival; Chromatography, Liquid; Diphosphonates; Durapatite; Etidronic Acid; Geranyltranstransferase; Mice; Organophosphonates; Propionates; Protein Prenylation; Pyridines; Risedronic Acid; Structure-Activity Relationship | 2007 |
Risedronate prevents the loss of microarchitecture in glucocorticoid-induced osteoporosis in rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Etidronic Acid; Female; Glucocorticoids; Osteoblasts; Osteogenesis; Osteoporosis; Random Allocation; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2007 |
Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans; Models, Biological; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Severity of Illness Index | 2008 |
Oral bisphosphonate-induced osteonecrosis: risk factors, prediction of risk using serum CTX testing, prevention, and treatment.
Topics: Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Jaw Diseases; Middle Aged; Osteonecrosis; Peptides; Prospective Studies; Risedronic Acid; Time Factors | 2007 |
Effects of risedronate in a rat model of osteopenia due to orchidectomy and disuse: densitometric, histomorphometric and microtomographic studies.
Topics: Absorptiometry, Photon; Animals; Body Composition; Bone and Bones; Bone Density; Bone Diseases, Metabolic; Botulinum Toxins; Etidronic Acid; Hindlimb; Male; Orchiectomy; Rats; Rats, Wistar; Risedronic Acid; Testosterone; Tomography, X-Ray Computed | 2008 |
Preservation of periarticular cancellous morphology and mechanical stiffness in post-traumatic experimental osteoarthritis by antiresorptive therapy.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Computer Simulation; Disease Models, Animal; Elasticity; Etidronic Acid; Female; Femur; Models, Biological; Osteoarthritis; Rabbits; Radiography; Risedronic Acid; Stress, Mechanical; Treatment Outcome | 2008 |
Bisphosphonates alter trabecular bone collagen cross-linking and isomerization in beagle dog vertebra.
Topics: Alendronate; Amino Acids; Animals; Arginine; Bone Density Conservation Agents; Bone Remodeling; Collagen; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Lumbar Vertebrae; Lysine; Raloxifene Hydrochloride; Risedronic Acid | 2008 |
The cost-effectiveness of risedronate treatment in Japanese women with osteoporosis.
Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Bone; Humans; Japan; Middle Aged; Osteoporosis; Prevalence; Quality-Adjusted Life Years; Risedronic Acid | 2008 |
NMR investigations of the static and dynamic structures of bisphosphonates on human bone: a molecular model.
Topics: Alendronate; Biochemistry; Bone and Bones; Bone Density Conservation Agents; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Hydrogen; Imidazoles; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Pamidronate; Protein Structure, Tertiary; Risedronic Acid; Zoledronic Acid | 2008 |
[Patient's preference for the daily and weekly bisphosphonate--evaluation from questionnaire of osteoporosis patients].
Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Patient Satisfaction; Risedronic Acid; Surveys and Questionnaires | 2008 |
[Guide for the prevention and treatment of glucocorticoid-induced osteoporosis of the Spanish Society of Internal Medicine].
Topics: Etidronic Acid; Glucocorticoids; Humans; Osteoporosis; Risedronic Acid | 2008 |
[Clinical significance of risedronate for patients with prostate cancer receiving androgen deprivation therapy].
Topics: Aged; Androgen Antagonists; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Prospective Studies; Prostatic Neoplasms; Risedronic Acid | 2008 |
[Radius shaft fracture in a 31-year old man].
Topics: Adult; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Osteitis Deformans; Radiography; Radius Fractures; Risedronic Acid | 2008 |
Osteoporosis treatment and fracture incidence: the ICARO longitudinal study.
Topics: Adult; Age Factors; Aged; Alendronate; Body Mass Index; Bone Density Conservation Agents; Etidronic Acid; Female; Fractures, Bone; Humans; Italy; Longitudinal Studies; Middle Aged; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Treatment Failure | 2008 |
Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Line, Tumor; Cell Survival; Coculture Techniques; Dentin; Diphosphonates; Endocytosis; Etidronic Acid; Extracellular Matrix Proteins; Macrophages; Mice; Microscopy, Fluorescence; Osteoblasts; Osteoclasts; Protein Prenylation; Rabbits; rap1 GTP-Binding Proteins; Risedronic Acid; Skull | 2008 |
In vitro disintegration and dissolution studies of once-weekly copies of alendronate sodium tablets (70 mg) and in vivo implications.
Topics: Alendronate; Biological Availability; Bone Density Conservation Agents; Canada; Diphosphonates; Drugs, Generic; Etidronic Acid; Germany; Humans; In Vitro Techniques; Netherlands; Risedronic Acid; Tablets; Technology, Pharmaceutical; Time Factors; United Kingdom | 2008 |
Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis.
Topics: Aged; Alendronate; Analysis of Variance; Bone Density; Cohort Studies; Databases, Factual; Diphosphonates; Dose-Response Relationship, Drug; Drug Administration Schedule; Etidronic Acid; Female; Humans; Logistic Models; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Patient Compliance; Probability; Prognosis; Retrospective Studies; Risedronic Acid; Risk Factors; Severity of Illness Index; Treatment Outcome; Treatment Refusal | 2008 |
Osteonecrosis of the jaw: new developments in an old disease.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Jaw Diseases; Osteonecrosis; Risedronic Acid; Risk Factors | 2008 |
Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies.
Topics: Algorithms; Binding Sites; Bone Density Conservation Agents; Carcinoma; Computer Simulation; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Farnesyltranstransferase; Humans; Imidazoles; Inhibitory Concentration 50; Magnesium; Models, Chemical; Organophosphonates; Pyridines; Risedronic Acid; Stereoisomerism; Structure-Activity Relationship; Zoledronic Acid | 2008 |
Summaries for patients. Drug therapy for osteoporosis.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Topics: Administration, Inhalation; Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Male; New Jersey; Osteoporosis; Osteoporosis, Postmenopausal; Pennsylvania; Raloxifene Hydrochloride; Risedronic Acid; Risk Factors | 2008 |
Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Epidemiologic Methods; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Risedronic Acid; Risk Factors; Treatment Refusal | 2008 |
Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2008 |
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats.
Topics: Alendronate; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Etidronic Acid; Female; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2008 |
Effects of vitamin K(2) and risedronate on bone formation and resorption, osteocyte lacunar system, and porosity in the cortical bone of glucocorticoid-treated rats.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Bone Resorption; Disease Models, Animal; Drug Combinations; Etidronic Acid; Female; Glucocorticoids; Osteocytes; Osteogenesis; Osteoporosis; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia; Vitamin K 2 | 2008 |
Effect of risedronate on bone mass, remodelling and biomechanical strength in orchidectomized rats.
Topics: Animals; Bone and Bones; Bone Density; Bone Remodeling; Etidronic Acid; Male; Orchiectomy; Rats; Rats, Wistar; Risedronic Acid | 2008 |
Vitamin D status and response to treatment in post-menopausal osteoporosis.
Topics: Activities of Daily Living; Aged; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Resorption; Calcium; Confounding Factors, Epidemiologic; Dietary Supplements; Etidronic Acid; Female; Fractures, Bone; Humans; Incidence; Logistic Models; Middle Aged; Odds Ratio; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Risk; Treatment Outcome; Vitamin D; Vitamin D Deficiency | 2009 |
Can a disorder of the vestibular system underlie an etiology for migraine?
Topics: Bone Density Conservation Agents; Calcium Channel Blockers; Electronystagmography; Etidronic Acid; Humans; Male; Middle Aged; Migraine Disorders; Risedronic Acid; Tinnitus; Vestibular Diseases | 2008 |
Kinetic study on hemipenta hydrate risedronate monosodium in batch crystallization by cooling mode.
Topics: Algorithms; Crystallization; Etidronic Acid; Kinetics; Risedronic Acid; Solvents; Temperature; X-Ray Diffraction | 2008 |
Determination of the microscopic equilibrium dissociation constants for risedronate and its analogues reveals two distinct roles for the nitrogen atom in nitrogen-containing bisphosphonate drugs.
Topics: Animals; Bone Density Conservation Agents; Dictyostelium; Diphosphonates; Etidronic Acid; Hydrogen-Ion Concentration; Microscopy; Nitrogen; Proteome; Risedronic Acid; Spectrometry, Mass, Electrospray Ionization; Spectrometry, Mass, Fast Atom Bombardment | 2008 |
Identification of material parameters based on Mohr-Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density Conservation Agents; Computer Simulation; Diphosphonates; Dogs; Etidronic Acid; Hardness Tests; Nanotechnology; Risedronic Acid; Shear Strength; Stress, Mechanical | 2008 |
Urinary osteocalcin and other markers of bone metabolism: the effect of risedronate therapy.
Topics: Aged; Biomarkers; Bone Density; Etidronic Acid; Female; Humans; Middle Aged; Osteocalcin; Osteoporosis, Postmenopausal; Risedronic Acid; Time Factors | 2008 |
Maximizing effectiveness of bisphosphonate therapy for osteoporosis.
Topics: Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Imidazoles; Medication Adherence; Osteoporosis; Physician-Patient Relations; Risedronic Acid; Risk Factors; Zoledronic Acid | 2008 |
Effect of temporal changes in bone turnover on the bone mineralization density distribution: a computer simulation study.
Topics: Bone and Bones; Bone Density; Bone Remodeling; Computer Simulation; Etidronic Acid; Female; Humans; Kinetics; Menopause; Models, Statistical; Models, Theoretical; Osteoporosis; Risedronic Acid; Time Factors | 2008 |
Bisphosphonate therapy ameliorates hearing loss in mice lacking osteoprotegerin.
Topics: Animals; Bone Density Conservation Agents; Cochlea; Diphosphonates; Etidronic Acid; Evoked Potentials, Auditory, Brain Stem; Female; Hearing; Hearing Loss; Mice; Mice, Inbred C57BL; Mice, Transgenic; Osteoprotegerin; Risedronic Acid; Time Factors | 2009 |
Osteoporosis in men.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Osteoporosis; Risedronic Acid; Spinal Fractures; Teriparatide | 2008 |
IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole.
Topics: Adult; Aged; Anastrozole; Aromatase Inhibitors; Bone Density Conservation Agents; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Chemotherapy, Adjuvant; Double-Blind Method; Etidronic Acid; Female; Humans; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Nitriles; Osteoporosis, Postmenopausal; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Triazoles | 2008 |
A new dinuclear platinum complex with a nitrogen-containing geminal bisphosphonate as potential anticancer compound specifically targeted to bone tissues.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Crystallization; Crystallography, X-Ray; Diphosphonates; Etidronic Acid; Humans; Organoplatinum Compounds; Risedronic Acid | 2008 |
Monthly risedronate (Actonel) for postmenopausal osteoporosis.
Topics: Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Fees, Pharmaceutical; Female; Humans; Osteoporosis; Postmenopause; Risedronic Acid; Treatment Outcome; United States | 2008 |
Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Budgets; Cost-Benefit Analysis; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Ibandronic Acid; Markov Chains; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Risk Factors; United States | 2008 |
Cutaneous vasculitis induced by risedronate.
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Risedronic Acid; Skin Diseases, Vascular; Vasculitis | 2008 |
DXA-based hip structural analysis of once-weekly bisphosphonate-treated postmenopausal women with low bone mass.
Topics: Absorptiometry, Photon; Alendronate; Bone Density; Diphosphonates; Etidronic Acid; Female; Femur; Fractures, Bone; Hip; Humans; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Risk Assessment | 2009 |
Effects of risedronate on alveolar bone loss and angiogenesis: a stereologic study in rats.
Topics: Alveolar Bone Loss; Alveolar Process; Animals; Blood Vessels; Bone Density; Bone Density Conservation Agents; Bone Marrow; Cell Count; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Etidronic Acid; Image Processing, Computer-Assisted; Male; Neovascularization, Physiologic; Osteoblasts; Osteoclasts; Osteogenesis; Osteonecrosis; Periodontal Attachment Loss; Periodontitis; Periodontium; Placebos; Random Allocation; Rats; Rats, Wistar; Risedronic Acid; Time Factors | 2008 |
Osteoporotic fracture management in India: a survey of orthopaedic surgeons.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Disease Progression; Etidronic Acid; Fractures, Bone; Health Care Surveys; Humans; India; Orthopedics; Osteoporosis; Risedronic Acid | 2008 |
The potential effects on fracture outcomes of improvements in persistence and compliance with bisphosphonates.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Hip Fractures; Humans; Male; Middle Aged; Patient Compliance; Risedronic Acid | 2009 |
Changes in urinary NTX levels in patients with primary osteoporosis undergoing long-term bisphosphonate treatment.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Risedronic Acid | 2008 |
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate.
Topics: Alendronate; Animals; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Bone Matrix; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Glycation End Products, Advanced; Models, Animal; Osteoporosis; Risedronic Acid | 2009 |
[Severe oesophagus injury as a complication during treatment with risedronic acid].
Topics: Aged; Bone Density Conservation Agents; Esophagus; Etidronic Acid; Gastrointestinal Motility; Humans; Male; Osteoporosis; Risedronic Acid | 2008 |
Effect of risedronate in a minipig cartilage defect model with allograft.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cartilage, Articular; Chondrocytes; Collagen Type I; Collagen Type II; Etidronic Acid; Female; Male; Risedronic Acid; Swine; Swine, Miniature; Transplantation, Homologous | 2009 |
Geranylgeranyl transferase type II inhibition prevents myeloma bone disease.
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Cell Count; Diphosphonates; Disease Models, Animal; Enzyme Inhibitors; Etidronic Acid; Male; Mice; Mice, Inbred C57BL; Multiple Myeloma; Osteoclasts; Osteoporosis; Protein Prenylation; Pyridines; Risedronic Acid; Transferases; Tumor Burden | 2008 |
Effects of combined administration of alfacalcidol and risedronate on cancellous and cortical bone mass of the tibia in glucocorticoid-treated young rats.
Topics: Animals; Bone Density; Bone Density Conservation Agents; Dose-Response Relationship, Drug; Drug Synergism; Etidronic Acid; Female; Glucocorticoids; Hydroxycholecalciferols; Osteogenesis; Osteoporosis; Rats; Rats, Sprague-Dawley; Risedronic Acid; Tibia | 2008 |
RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Medication Adherence; Osteoporosis; Postmenopause; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Reduction Behavior; Spinal Fractures; Treatment Outcome | 2009 |
Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo.
Topics: Animals; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Drug Therapy, Combination; Enzyme-Linked Immunosorbent Assay; Etidronic Acid; Female; Humans; Mice; Pyridines; Risedronic Acid; Structure-Activity Relationship | 2008 |
Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and risedronate on different pathways for bone formation and mineralization.
Topics: Animals; Calcification, Physiologic; Etidronic Acid; Gene Expression; Glucocorticoids; Immunohistochemistry; Male; Mice; Osteocalcin; Osteogenesis; Parathyroid Hormone; Prednisolone; Reverse Transcriptase Polymerase Chain Reaction; Risedronic Acid; Tomography, X-Ray Computed; Wnt Proteins | 2008 |
[Treatment of osteoporosis in the elderly: what is the evidence?].
Topics: Age Factors; Aged; Aged, 80 and over; Aging; Alendronate; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Evidence-Based Medicine; Female; Fractures, Bone; Humans; Male; Osteoporosis; Osteoporosis, Postmenopausal; Raloxifene Hydrochloride; Risedronic Acid; Teriparatide; Treatment Outcome | 2008 |
Compatibility of risedronate sodium tablets with food thickeners.
Topics: Bone Density Conservation Agents; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Incompatibility; Drug Stability; Etidronic Acid; Food Additives; Risedronic Acid; Tablets | 2008 |
[Non traumatic tooth extraction in patients treated by bisphosphonate].
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Mandibular Diseases; Orthodontic Extrusion; Osteonecrosis; Risedronic Acid; Tooth Extraction | 2008 |
Differences in persistence among different weekly oral bisphosphonate medications.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Drugs, Generic; Epidemiologic Methods; Etidronic Acid; Female; Fractures, Bone; Humans; Length of Stay; Male; Medication Adherence; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Patient Acceptance of Health Care; Quebec; Risedronic Acid; Sex Factors | 2009 |
[Differences among bisfosfonates--specificity of risedronate (Actonel)].
Topics: Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Fractures, Spontaneous; Humans; Osteoporosis; Risedronic Acid | 2008 |
Fluorescently labeled risedronate and related analogues: "magic linker" synthesis.
Topics: Animals; Etidronic Acid; Fluorescent Dyes; Magnetic Resonance Spectroscopy; Osteoclasts; Rabbits; Risedronic Acid; Temperature | 2008 |
Evaluation by digital subtraction radiography of induced changes in the bone density of the female rat mandible.
Topics: Animals; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Etidronic Acid; Female; Image Processing, Computer-Assisted; Mandible; Mandibular Diseases; Methylprednisolone; Methylprednisolone Acetate; Radiographic Image Enhancement; Random Allocation; Rats; Rats, Wistar; Risedronic Acid; Subtraction Technique; Time Factors | 2008 |
Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Confidence Intervals; Etidronic Acid; Female; Fractures, Bone; Health Care Costs; Humans; Male; Osteoporosis; Risedronic Acid; Risk Factors | 2009 |
[New bisphosphonates and trends in drug therapy for osteoporosis: preface].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Humans; Imidazoles; Osteoporosis; Risedronic Acid; Zoledronic Acid | 2009 |
[Examination of beneficial effects of risedronate in improving quality of life during long-term treatment of primary osteoporosis].
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Collagen Type I; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Peptides; Quality of Life; Retrospective Studies; Risedronic Acid; Surveys and Questionnaires; Time Factors; Treatment Outcome | 2009 |
Medical treatment of otosclerosis: rationale for use of bisphosphonates.
Topics: Aged; Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Cell Death; Combined Modality Therapy; Diphosphonates; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ear, Inner; Ear, Middle; Etidronic Acid; Follow-Up Studies; Hearing Aids; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Osteoclasts; Osteoprotegerin; Otosclerosis; Risedronic Acid; Speech Discrimination Tests; Speech Reception Threshold Test; Stapes Surgery; Tinnitus | 2008 |
Dental implants in a patient with Paget disease under bisphosphonate treatment: a case report.
Topics: Administration, Oral; Bone Density Conservation Agents; Dental Implantation, Endosseous; Dental Prosthesis, Implant-Supported; Denture, Partial, Fixed; Etidronic Acid; Female; Humans; Jaw, Edentulous, Partially; Maxilla; Middle Aged; Osteitis Deformans; Risedronic Acid | 2009 |
Monaural diplacusis with tinnitus, aural fullness, hyperacusis, and sensorineural hearing loss.
Topics: Bone Density Conservation Agents; Diabetes Mellitus, Type 2; Etidronic Acid; Hearing Loss, Sensorineural; Humans; Hyperacusis; Hyperparathyroidism; Male; Middle Aged; Otosclerosis; Risedronic Acid; Tinnitus | 2009 |
Transcriptome and proteome analysis of osteocytes treated with nitrogen-containing bisphosphonates.
Topics: Animals; Bone Density Conservation Agents; Cells, Cultured; Chromatography, Liquid; Diphosphonates; Electrophoresis, Gel, Two-Dimensional; Etidronic Acid; Gene Expression Profiling; Isotope Labeling; Osteocytes; Proteome; Risedronic Acid; RNA, Messenger; Spectrometry, Mass, Electrospray Ionization | 2009 |
Oral bisphosphonates and risk of atrial fibrillation and flutter in women: a self-controlled case-series safety analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Atrial Fibrillation; Atrial Flutter; Bone Density Conservation Agents; Case-Control Studies; Databases, Factual; Diphosphonates; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Humans; Incidence; Middle Aged; Risedronic Acid; Risk; Time Factors | 2009 |
Comparative gastrointestinal safety of weekly oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Epidemiologic Methods; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Hemorrhage; Hospitalization; Humans; Male; Osteoporosis; Pennsylvania; Risedronic Acid; Treatment Outcome | 2009 |
Treating osteoporosis in Canada: what clinical efficacy data should be considered by policy decision makers?
Topics: Aged; Bone Density Conservation Agents; Canada; Decision Making; Epidemiologic Methods; Etidronic Acid; Female; Humans; Meta-Analysis as Topic; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Treatment Outcome | 2009 |
Prior treatment with vitamin K(2) significantly improves the efficacy of risedronate.
Topics: Animals; Body Weight; Bone Density Conservation Agents; Drug Administration Schedule; Drug Evaluation, Preclinical; Drug Therapy, Combination; Etidronic Acid; Female; Femur; Mice; Mice, Inbred ICR; Osteoporosis; Ovariectomy; Risedronic Acid; Vitamin K 2 | 2009 |
Theoretical analysis of alendronate and risedronate effects on canine vertebral remodeling and microdamage.
Topics: Alendronate; Animals; Computer Simulation; Disease Models, Animal; Dogs; Etidronic Acid; Fractures, Bone; Risedronic Acid; Spine; Substrate Specificity | 2009 |
Unusual mid-shaft fractures during long-term bisphosphonate therapy.
Topics: Adult; Aged; Alendronate; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2010 |
Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate.
Topics: Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Risk Factors | 2009 |
Bone microdamage.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Bone; Humans; Risedronic Acid | 2009 |
Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Nails; Casts, Surgical; Etidronic Acid; External Fixators; Female; Follow-Up Studies; Fracture Fixation, Internal; Fracture Healing; Fractures, Spontaneous; Humans; Male; Middle Aged; Multivariate Analysis; Osteoporosis; Radiography; Radius Fractures; Risedronic Acid; Time Factors; Wrist Injuries | 2009 |
Value of a new fixed-combination pack of bisphosphonate, calcium and vitamin D in the therapy of osteoporosis: results of two quantitative patient research studies.
Topics: Bone Density Conservation Agents; Calcium Compounds; Data Collection; Diphosphonates; Drug Combinations; Drug Packaging; Drug Therapy, Combination; Etidronic Acid; Female; France; Health Knowledge, Attitudes, Practice; Humans; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Patient Education as Topic; Patient Satisfaction; Risedronic Acid; Vitamin D | 2009 |
Glucocorticoid-induced osteoporosis: hope on the HORIZON.
Topics: Administration, Oral; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Glucocorticoids; Humans; Imidazoles; Infusions, Intravenous; Osteoblasts; Osteoporosis; Research Design; Risedronic Acid; Treatment Outcome; Zoledronic Acid | 2009 |
Risedronate recovers bone loss in patients with prostate cancer undergoing androgen-deprivation therapy.
Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density Conservation Agents; Bone Resorption; Etidronic Acid; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Risedronic Acid | 2009 |
Comparative effects of risedronate, atorvastatin, estrogen and SERMs on bone mass and strength in ovariectomized rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Bone Density; Bone Density Conservation Agents; Clomiphene; Estrogens; Etidronic Acid; Female; Femur; Heptanoic Acids; Osteoporosis; Ovariectomy; Pyrroles; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid; Selective Estrogen Receptor Modulators; Tibia | 2009 |
Osteonecrosis associated with short-term oral administration of bisphosphonate.
Topics: Administration, Oral; Aged; Bone Density Conservation Agents; Denture, Partial, Removable; Etidronic Acid; Female; Humans; Mandible; Mandibular Diseases; Oral Ulcer; Osteonecrosis; Risedronic Acid; Wound Healing | 2009 |
Comparison of the effect of vitamin K(2) and risedronate on trabecular bone in glucocorticoid-treated rats: a bone histomorphometry study.
Topics: Animals; Bone and Bones; Bone Density; Etidronic Acid; Female; Glucocorticoids; Random Allocation; Rats; Risedronic Acid; Vitamin K; Vitamins | 2009 |
Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis.
Topics: Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium; Diphosphonates; Drugs, Generic; Etidronic Acid; Female; Hip Joint; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Radiography; Retrospective Studies; Risedronic Acid; Therapeutic Equivalency; Vitamin D | 2009 |
Cancer-induced bone loss and associated pain-related behavior is reduced by risedronate but not its phosphonocarboxylate analog NE-10790.
Topics: Acid Phosphatase; Animals; Behavior, Animal; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Cell Proliferation; Cells, Cultured; Diphosphonates; Etidronic Acid; Fibroblasts; Glial Fibrillary Acidic Protein; Humans; Immunoenzyme Techniques; Isoenzymes; Male; Mice; Mice, Nude; Pain; Pyridines; Risedronic Acid; Tartrate-Resistant Acid Phosphatase; Xenograft Model Antitumor Assays | 2009 |
Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
Topics: Age Factors; Aged; Aged, 80 and over; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Female; Hip Fractures; Humans; Markov Chains; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Risk Assessment; Sensitivity and Specificity; Spinal Fractures; Switzerland | 2008 |
Re "Effect of long-term treatment with risedronate on arterial compliance in osteoporotic patients with cardiovascular risk factors" by A. Luckish et al.
Topics: Apolipoproteins; Arteries; Bone Density Conservation Agents; Cardiovascular Diseases; Compliance; Etidronic Acid; Female; Humans; Lipid Metabolism; Osteoporosis; Risedronic Acid; Triglycerides | 2009 |
[Postmenopausal osteoporosis. Bisphosphonates are not all equal].
Topics: Alendronate; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Drugs, Generic; Etidronic Acid; Female; Germany; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Practice Guidelines as Topic; Retrospective Studies; Risedronic Acid; Time Factors | 2009 |
[Patient compliance program aids therapy success].
Topics: Alendronate; Bone Density Conservation Agents; Calcium; Cholecalciferol; Clinical Trials as Topic; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis, Postmenopausal; Patient Compliance; Risedronic Acid; Time Factors | 2009 |
Risedronate on two consecutive days per month.
Topics: Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Humans; Medication Adherence; Osteoporosis, Postmenopausal; Randomized Controlled Trials as Topic; Risedronic Acid | 2009 |
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
Topics: Alendronate; Animals; Apoptosis; Atorvastatin; Bone Density Conservation Agents; Caspases; Cell Line; Diphosphonates; DNA Fragmentation; Drug Synergism; Enzyme Activation; Etidronic Acid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myoblasts, Skeletal; Pyrroles; Rats; Rhabdomyolysis; Risedronic Acid | 2009 |
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis.
Topics: Animals; Biomarkers; Biomechanical Phenomena; Bone Density; Bone Density Conservation Agents; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Durapatite; Etidronic Acid; Female; Femur; Humans; Hydroxycholecalciferols; Lumbar Vertebrae; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Wistar; Risedronic Acid; Stress, Mechanical; Treatment Outcome; Weight-Bearing; X-Ray Diffraction; X-Ray Microtomography | 2009 |
Weekly versus monthly drug regimens: 1-year compliance and persistence with bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Diphosphonates; Drug Prescriptions; Etidronic Acid; Female; Humans; Ibandronic Acid; Longitudinal Studies; Male; Middle Aged; Osteoporosis; Patient Compliance; Retrospective Studies; Risedronic Acid | 2009 |
The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX.
Topics: Age Factors; Aged; Aged, 80 and over; Algorithms; Bone Density Conservation Agents; Cost-Benefit Analysis; Drug Costs; Epidemiologic Methods; Etidronic Acid; Female; Health Care Costs; Humans; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; Risedronic Acid; United Kingdom | 2010 |
Risedronate directly inhibits osteoclast differentiation and inflammatory bone loss.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Cell Differentiation; Cell Line; Cell Survival; Etidronic Acid; Humans; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred ICR; NFATC Transcription Factors; Osteoclasts; Osteoporosis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-fos; RANK Ligand; Risedronic Acid | 2009 |
[Acute exacerbation of a chronic esophagitis].
Topics: Acute Disease; Anti-Bacterial Agents; Bone Density Conservation Agents; Clindamycin; Diagnosis, Differential; Drug Therapy, Combination; Esophagitis; Etidronic Acid; Female; Gastroesophageal Reflux; Humans; Middle Aged; Osteoporosis, Postmenopausal; Parenteral Nutrition; Risedronic Acid | 2009 |
Risedronate inhibits human osteosarcoma cell invasion.
Topics: Antineoplastic Agents; Bone Density Conservation Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Etidronic Acid; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Osteosarcoma; Risedronic Acid; RNA, Messenger | 2009 |
Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention.
Topics: Animals; Antinematodal Agents; beta-Cyclodextrins; Bone Neoplasms; Drug Delivery Systems; Etidronic Acid; Female; Mice; Mice, Inbred BALB C; Nanostructures; Neoplasm Metastasis; Risedronic Acid; Spectrum Analysis, Raman | 2009 |
Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years.
Topics: Aged; Bone Density Conservation Agents; Cost-Benefit Analysis; Etidronic Acid; Female; Humans; Models, Statistical; Organometallic Compounds; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Thiophenes | 2010 |
Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Topics: Age Factors; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Epidemiologic Methods; Etidronic Acid; Female; Hip Fractures; Humans; Ibandronic Acid; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; United States | 2010 |
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection.
Topics: Alendronate; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cell Movement; Diphosphonates; DNA Breaks, Double-Stranded; DNA Damage; Etidronic Acid; Gene Deletion; Humans; Ibandronic Acid; Microscopy, Confocal; Microscopy, Electron; Microtubules; Mutation; Polyisoprenyl Phosphates; Risedronic Acid; RNA Interference; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins | 2009 |
Corticosteroids: no drug prevention of fractures needed.
Topics: Adrenal Cortex Hormones; Alendronate; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diphosphonates; Etidronic Acid; Fractures, Bone; Humans; Imidazoles; Osteoporosis; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Factors; Steroids; Teriparatide; Vitamin D; Zoledronic Acid | 2009 |
Risedronate prevents early radiation-induced osteoporosis in mice at multiple skeletal locations.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Etidronic Acid; Female; Mice; Mice, Inbred C57BL; Osteoporosis; Risedronic Acid; Tomography, X-Ray Computed; Whole-Body Irradiation | 2010 |
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Jaw Diseases; Male; Osteonecrosis; Prevalence; Risedronic Acid; Surveys and Questionnaires; Tooth Extraction | 2010 |
A retrospective clinical and radiographic study on healing of periradicular lesions in patients taking oral bisphosphonates.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Composite Resins; Diphosphonates; Etidronic Acid; Follow-Up Studies; Gutta-Percha; Humans; Ibandronic Acid; Middle Aged; Periapical Diseases; Radiography; Retrospective Studies; Risedronic Acid; Root Canal Filling Materials; Root Canal Preparation; Single-Blind Method; Treatment Outcome; Wound Healing | 2009 |
Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Imidazoles; Osteogenesis; Osteoporosis; Ovariectomy; Rats; Risedronic Acid; Zoledronic Acid | 2010 |
Differences between bisphosphonates in binding affinities for hydroxyapatite.
Topics: Bone Density Conservation Agents; Chromatography, Liquid; Diphosphonates; Durapatite; Etidronic Acid; Imidazoles; Risedronic Acid; Spectrophotometry, Ultraviolet; Zoledronic Acid | 2010 |
Bisphosphonate treatment modifies canine bone mineral and matrix properties and their heterogeneity.
Topics: Alendronate; Animals; Bone Density; Bone Matrix; Calcification, Physiologic; Diphosphonates; Dogs; Etidronic Acid; Female; Risedronic Acid; Treatment Outcome | 2010 |
Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Biomarkers; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Peptide Fragments; Peptides; Procollagen; Risedronic Acid | 2009 |
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone.
Topics: Alendronate; Animals; Bone and Bones; Bone Density Conservation Agents; Bone Resorption; Cell Aggregation; Cell Proliferation; Diphosphonates; Dogs; Dose-Response Relationship, Drug; Etidronic Acid; Female; Humans; Models, Animal; Osteoclasts; Osteoporosis, Postmenopausal; Risedronic Acid; Treatment Outcome | 2010 |
Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Diseases, Metabolic; Cyclic AMP Response Element-Binding Protein; Diphosphonates; Endoplasmic Reticulum; Etidronic Acid; Immunoblotting; Mice; Mice, Knockout; Microscopy, Electron; Nerve Tissue Proteins; Risedronic Acid | 2010 |
Osteonecrosis of the jawbones in 2 osteoporosis patients treated with nitrogen-containing bisphosphonates: osteonecrosis reduction replacing NBP with non-NBP (etidronate) and rationale.
Topics: Aged; Aged, 80 and over; Binding, Competitive; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Humans; Inflammation Mediators; Lipopolysaccharides; Mandibular Diseases; Nitrogen; Osteomyelitis; Osteonecrosis; Osteoporosis, Postmenopausal; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium Compounds; Tooth Extraction | 2010 |
Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cost-Benefit Analysis; Costs and Cost Analysis; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Italy; Male; Osteoporosis; Quality of Life; Risedronic Acid | 2010 |
Inhibition of necrotic actions of nitrogen-containing bisphosphonates (NBPs) and their elimination from bone by etidronate (a non-NBP): a proposal for possible utilization of etidronate as a substitution drug for NBPs.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Resorption; Diphosphonates; Ear, External; Etidronic Acid; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imidazoles; Inflammation Mediators; Injections, Intraperitoneal; Injections, Subcutaneous; Interleukin-1; Male; Mice; Mice, Inbred BALB C; Necrosis; Osteonecrosis; Osteosclerosis; Pamidronate; Pravastatin; Radionuclide Imaging; Radiopharmaceuticals; Risedronic Acid; Technetium; Tibia; Time Factors; Zoledronic Acid | 2010 |
An in vitro assay to measure targeted drug delivery to bone mineral.
Topics: Alendronate; Anabolic Agents; Bone and Bones; Bone Density Conservation Agents; Diphosphonates; Drug Delivery Systems; Durapatite; Etidronic Acid; Humans; Ibandronic Acid; Imidazoles; Nuclear Magnetic Resonance, Biomolecular; Pamidronate; Risedronic Acid; Zoledronic Acid | 2010 |
Analysis of risedronate and related substances by ion-pair reversed-phase high-performance liquid chromatography with evaporative light-scattering detection.
Topics: Acetates; Calibration; Chromatography, High Pressure Liquid; Etidronic Acid; Light; Linear Models; Phosphates; Phosphites; Pyridines; Reproducibility of Results; Risedronic Acid; Scattering, Radiation | 2010 |
High level of serum undercarboxylated osteocalcin in patients with incident fractures during bisphosphonate treatment.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Middle Aged; Osteocalcin; Osteoporosis; Risedronic Acid; Risk Factors | 2010 |
Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid.
Topics: Alkyl and Aryl Transferases; Bone Density Conservation Agents; Bone Resorption; Cell Line; Cell Survival; Chromatography, High Pressure Liquid; Enzyme Inhibitors; Etidronic Acid; Humans; Lactates; Organophosphonates; Organophosphorus Compounds; Osteoporosis; Protein Prenylation; rab GTP-Binding Proteins; Risedronic Acid; Stereoisomerism | 2010 |
Effects of treatment with risedronate and alfacalcidol on progression of atherosclerosis in postmenopausal women with type 2 diabetes mellitus accompanied with osteoporosis.
Topics: Aged; Aorta, Abdominal; Atherosclerosis; Body Mass Index; Bone Density Conservation Agents; Calcinosis; Carotid Arteries; Diabetes Mellitus, Type 2; Etidronic Acid; Female; Humans; Hydroxycholecalciferols; Osteoporosis, Postmenopausal; Postmenopause; Prospective Studies; Radiography; Risedronic Acid; Ultrasonography | 2010 |
Risedronate-induced arthritis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Middle Aged; Osteoarthritis; Osteoporosis, Postmenopausal; Risedronic Acid | 2010 |
Fluorescent risedronate analogues reveal bisphosphonate uptake by bone marrow monocytes and localization around osteocytes in vivo.
Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Bone Marrow Cells; Diphosphonates; Etidronic Acid; Female; Fluorescent Dyes; Mice; Mice, Inbred C57BL; Monocytes; Osteocytes; Prenylation; Rabbits; rap1 GTP-Binding Proteins; Risedronic Acid | 2010 |
Intravenous zoledronic acid: what are the indications for male osteoporosis?
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Clinical Trials as Topic; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Male; Osteoporosis; Parathyroid Hormone; Risedronic Acid; Risk Factors; Testosterone; Zoledronic Acid | 2010 |
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors | 2010 |
Atypical femoral fractures and bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Osteoporosis; Risedronic Acid; Risk Factors | 2010 |
Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Frozen bone with remodelling at the crack.
Topics: Alendronate; Bone Density Conservation Agents; Bone Nails; Bone Resorption; Etidronic Acid; Female; Femoral Fractures; Fracture Fixation, Intramedullary; Fractures, Stress; Humans; Middle Aged; Radiography; Risedronic Acid | 2010 |
Risedronate improves proximal femur bone density and geometry in patients with osteoporosis or osteopenia and clinical risk factors of fractures: a practice-based observational study.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Fractures, Bone; Humans; Male; Middle Aged; Osteoporosis; Risedronic Acid | 2011 |
In vivo microfocal computed tomography and micro-magnetic resonance imaging evaluation of antiresorptive and antiinflammatory drugs as preventive treatments of osteoarthritis in the rat.
Topics: Alendronate; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bone Density Conservation Agents; Disease Models, Animal; Drug Therapy, Combination; Epiphyses; Etidronic Acid; Female; Femur; Magnetic Resonance Imaging; Meloxicam; Osteoarthritis, Knee; Osteophyte; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stifle; Thiazines; Thiazoles; Tibia; Tomography, X-Ray Computed; Water | 2010 |
Immediate loading in mandible full-arch: pilot study in patients with osteoporosis in bisphosphonate therapy.
Topics: Aged; Alendronate; Bone Density; Bone Density Conservation Agents; Dental Arch; Dental Prosthesis, Implant-Supported; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Immediate Dental Implant Loading; Male; Mandible; Middle Aged; Osteoporosis; Pilot Projects; Radiography, Panoramic; Risedronic Acid; Tooth Extraction; Tooth Socket; Treatment Outcome | 2012 |
[Incidence of hip fractures due to osteoporosis in relation to the prescription of drugs for their prevention and treatment in Galicia, Spain].
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Prescriptions; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Male; Middle Aged; Organometallic Compounds; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Spain; Thiophenes | 2011 |
Particulate adducts based on sodium risedronate and titanium dioxide for the bioavailability enhancement of oral administered bisphosphonates.
Topics: Administration, Oral; Animals; Biological Availability; Chromatography, High Pressure Liquid; Diphosphonates; Etidronic Acid; Male; Microscopy, Electron, Scanning; Rats; Rats, Wistar; Risedronic Acid; Titanium; X-Ray Diffraction | 2010 |
Greater magnitude of turnover suppression occurs earlier after treatment initiation with risedronate than alendronate.
Topics: Alendronate; Animals; Bone Density Conservation Agents; Bone Remodeling; Diaphyses; Etidronic Acid; Female; Fluorescent Dyes; Rabbits; Risedronic Acid; Spine; Tibia; Time Factors | 2011 |
How do bisphosphonates inhibit bone metastasis in vivo?
Topics: Animals; Bone Density Conservation Agents; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Cell Line, Tumor; Diphosphonates; Etidronic Acid; Female; Humans; Lung Neoplasms; Melanoma, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Pyridines; Risedronic Acid; Xenograft Model Antitumor Assays | 2010 |
[Osteoporosis management in general practice. Preventing spontaneous bone fractures].
Topics: Bone Density Conservation Agents; Calcium; Drug Therapy, Combination; Etidronic Acid; Fractures, Spontaneous; Humans; Risedronic Acid; Spinal Fractures; Vitamin D | 2010 |
The effect of risedronate on osteogenic lineage is mediated by cyclooxygenase-2 gene upregulation.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Bone Marrow Cells; Cell Line; Cell Survival; Cells, Cultured; Cyclooxygenase 2; Etidronic Acid; Female; Gene Expression Regulation, Enzymologic; Glucocorticoids; Osteocytes; Osteogenesis; Rats; Rats, Sprague-Dawley; Risedronic Acid; Up-Regulation | 2010 |
A reliable predictive factorial model for entrapment optimization of a sodium bisphosphonate into biodegradable microspheres.
Topics: Analysis of Variance; Bone Density Conservation Agents; Drug Compounding; Etidronic Acid; Lactic Acid; Microspheres; Models, Statistical; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Risedronic Acid | 2011 |
Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase.
Topics: Binding Sites; Computer Simulation; Diphosphonates; Enzyme Inhibitors; Etidronic Acid; Geranylgeranyl-Diphosphate Geranylgeranyltransferase; Hemiterpenes; Humans; Organophosphorus Compounds; Polyisoprenyl Phosphates; Protein Binding; Risedronic Acid; Structure-Activity Relationship | 2010 |
Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Databases, Factual; Drug Substitution; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Retrospective Studies; Risedronic Acid; Risk Assessment; United Kingdom; Upper Gastrointestinal Tract | 2010 |
Effect of risedronate on bone resorption during consolidation phase of distraction osteogenesis: a rabbit model.
Topics: Animals; Bone Density Conservation Agents; Bone Regeneration; Bone Resorption; Disease Models, Animal; Dose-Response Relationship, Drug; Etidronic Acid; Follow-Up Studies; Injections, Intralesional; Intraoperative Care; Male; Osteogenesis, Distraction; Rabbits; Radiography; Retrospective Studies; Risedronic Acid; Tibia; Treatment Outcome | 2010 |
[Jaw osteonecrosis induced by oral biphosphonates: 12 cases].
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Alendronate; Autoimmune Diseases; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chronic Disease; Delayed Diagnosis; Diphosphonates; Drug Therapy, Combination; Etidronic Acid; Female; Follow-Up Studies; Humans; Jaw Diseases; Male; Mandibular Diseases; Middle Aged; Osteonecrosis; Osteoporosis; Risedronic Acid; Time Factors; Tooth Extraction; Treatment Outcome | 2010 |
Risedronate metal complexes potentially active against Chagas disease.
Topics: Animals; Chagas Disease; Coordination Complexes; Etidronic Acid; Geranyltranstransferase; Models, Chemical; Risedronic Acid; Trypanosoma cruzi; X-Ray Diffraction | 2010 |
Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase.
Topics: Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Chick Embryo; Chorioallantoic Membrane; Diphosphonates; Endothelial Cells; Etidronic Acid; Geranyltranstransferase; Humans; Imidazoles; Male; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Risedronic Acid; Zoledronic Acid | 2011 |
Cost-effectiveness of Denosumab for the treatment of postmenopausal osteoporosis.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Etidronic Acid; Female; Humans; Markov Chains; Middle Aged; Organometallic Compounds; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Patient Compliance; Quality-Adjusted Life Years; RANK Ligand; Risedronic Acid; Thiophenes | 2011 |
The effects of risedronate and exercise on osteoporotic lumbar rat vertebrae and their sensory innervation.
Topics: Afferent Pathways; Animals; Back Pain; Bone Density Conservation Agents; Cells, Cultured; Disease Models, Animal; Etidronic Acid; Female; Lumbar Vertebrae; Nociceptors; Osteoporosis; Physical Conditioning, Animal; Rats; Rats, Sprague-Dawley; Risedronic Acid; Sensory Receptor Cells | 2010 |
Characterization of a new solvate of risedronate.
Topics: Bone Density Conservation Agents; Buffers; Crystallization; Etidronic Acid; Powder Diffraction; Risedronic Acid; Solubility; Transition Temperature; Water | 2011 |
How to prevent glucocorticoid-induced osteoporosis.
Topics: Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Humans; Organometallic Compounds; Osteoporosis; Risedronic Acid; Thiophenes | 2010 |
Hip structure analysis of bisphosphonate-treated Japanese postmenopausal women with osteoporosis.
Topics: Aged; Alendronate; Asian People; Diphosphonates; Etidronic Acid; Female; Hip; Humans; Japan; Osteoporosis, Postmenopausal; Radiography; Risedronic Acid | 2011 |
Response of postpoliomyelitis patients to bisphosphonate treatment.
Topics: Administration, Oral; Alendronate; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Etidronic Acid; Female; Fractures, Bone; Humans; Linear Models; Male; Middle Aged; Postpoliomyelitis Syndrome; Retrospective Studies; Risedronic Acid | 2010 |
Outcome of patients with early breast cancer receiving nitrogen-containing bisphosphonates: a comparative analysis from the Metropolitan Detroit Cancer Surveillance System.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Michigan; Middle Aged; Neoplasm Staging; Population Surveillance; Registries; Retrospective Studies; Risedronic Acid; Survival Analysis; Treatment Outcome; Zoledronic Acid | 2010 |
Diagnosis of Paget's disease of the pelvis using F-18 FDG PET/CT.
Topics: Asymptomatic Diseases; Bone Density Conservation Agents; Diagnosis, Differential; Etidronic Acid; Female; Fluorodeoxyglucose F18; Humans; Ilium; Incidental Findings; Middle Aged; Osteitis Deformans; Positron-Emission Tomography; Predictive Value of Tests; Radiopharmaceuticals; Risedronic Acid; Sclerosis; Tomography, X-Ray Computed; Whole Body Imaging | 2010 |
When do bisphosphonates make the most sense?
Topics: Bone Density Conservation Agents; Bone Resorption; Clinical Trials as Topic; Diphosphonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Etidronic Acid; Female; Fractures, Bone; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; United States; Women's Health | 2011 |
Prospective evaluation of free radicals and antioxidant activity following 6-month risedronate treatment in patients with postmenopausal osteoporosis.
Topics: Aged; Antioxidants; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Free Radicals; Humans; Middle Aged; Osteoporosis, Postmenopausal; Oxidative Stress; Risedronic Acid | 2012 |
Longitudinal change in hip fracture incidence after starting risedronate or raloxifene: an observational study.
Topics: Aged; Aged, 80 and over; Bone Density Conservation Agents; Case-Control Studies; Etidronic Acid; Female; Hip Fractures; Humans; Longitudinal Studies; Raloxifene Hydrochloride; Risedronic Acid | 2011 |
A case of Marinesco-Sjögren syndrome: MRI observations of skeletal muscles, bone metabolism, and treatment with testosterone and risedronate.
Topics: Adult; Bone and Bones; Drug Therapy, Combination; Etidronic Acid; Humans; Magnetic Resonance Imaging; Male; Muscle, Skeletal; Risedronic Acid; Spinocerebellar Degenerations; Testosterone; Treatment Outcome | 2011 |
Osteoporosis medication and reduced mortality risk in elderly women and men.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Bone Density Conservation Agents; Cohort Studies; Comorbidity; Etidronic Acid; Female; Follow-Up Studies; Humans; Male; Middle Aged; Mortality; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; Risk Factors | 2011 |
Dose-dependent differential effects of risedronate on gene expression in osteoblasts.
Topics: Animals; Bone Density Conservation Agents; Cell Line; Dose-Response Relationship, Drug; Etidronic Acid; Gene Expression; Gene Expression Profiling; Osteoblasts; Osteogenesis; Rats; Reverse Transcriptase Polymerase Chain Reaction; Risedronic Acid | 2011 |
Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
Topics: Adaptor Proteins, Signal Transducing; Aged; Aged, 80 and over; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Morphogenetic Proteins; Bone Remodeling; Etidronic Acid; Female; Genetic Markers; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Postmenopause; Retrospective Studies; Risedronic Acid; Teriparatide | 2012 |
Effect of risedronate on osteoblast differentiation, expression of receptor activator of NF-κB ligand and apoptosis in mesenchymal stem cells.
Topics: Animals; Apoptosis; Bone Density Conservation Agents; Cell Differentiation; Cells, Cultured; Etidronic Acid; Humans; Mesenchymal Stem Cells; Osteoblasts; RANK Ligand; Rats; Risedronic Acid | 2011 |
In vitro and in vivo antiplasmodial activities of risedronate and its interference with protein prenylation in Plasmodium falciparum.
Topics: Animals; Antimalarials; Chromatography, Thin Layer; Etidronic Acid; Inhibitory Concentration 50; Male; Mice; Mice, Inbred BALB C; Plasmodium falciparum; Protein Prenylation; Risedronic Acid; Terpenes | 2011 |
[Bilateral pathological sub-trochanteric fracture in a long-term biphosphonate user].
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Femoral Fractures; Fractures, Spontaneous; Humans; Risedronic Acid | 2011 |
Effects of risedronate on cortical and trabecular bone of the mandible in glucocorticoid-treated growing rats.
Topics: Anatomy, Cross-Sectional; Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Glucocorticoids; Male; Mandible; Minerals; Organ Size; Osteoblasts; Osteogenesis; Osteoporosis; Periosteum; Prednisolone; Rats; Rats, Wistar; Risedronic Acid; Time Factors; Tomography, X-Ray Computed | 2011 |
Atypical bilateral pedicle fracture in long-term bisphosphonate therapy.
Topics: Aged; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Low Back Pain; Lumbar Vertebrae; Radiography; Review Literature as Topic; Risedronic Acid; Spinal Fractures; Time Factors | 2011 |
Effects of risedronate in Runx2 overexpressing mice, an animal model for evaluation of treatment effects on bone quality and fractures.
Topics: Animals; Bone and Bones; Bone Density Conservation Agents; Bone Remodeling; Core Binding Factor Alpha 1 Subunit; Disease Models, Animal; Etidronic Acid; Female; Fractures, Bone; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Osteoporosis; Risedronic Acid; Up-Regulation | 2011 |
Risedronate does not reduce mechanical loading-related increases in cortical and trabecular bone mass in mice.
Topics: Animals; Body Weight; Bone and Bones; Etidronic Acid; Female; Fluorescent Dyes; Mice; Mice, Inbred C57BL; Organ Size; Risedronic Acid; Stress, Mechanical; Tibia; Weight-Bearing; X-Ray Microtomography | 2011 |
Adherence to osteoporosis medications amongst Singaporean patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Kaplan-Meier Estimate; Male; Medication Adherence; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Retrospective Studies; Risedronic Acid; Singapore | 2012 |
Shotgun proteomics analysis reveals new unsuspected molecular effectors of nitrogen-containing bisphosphonates in osteocytes.
Topics: Animals; Blotting, Western; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Gene Expression Profiling; Mice; Osteocytes; Protein Prenylation; Proteomics; Proto-Oncogene Proteins c-akt; Risedronic Acid; Tandem Mass Spectrometry | 2011 |
Crystallization products of risedronate with carbohydrates and their substituted derivatives.
Topics: Calorimetry, Differential Scanning; Carbohydrates; Crystallization; Etidronic Acid; Galactosides; Magnetic Resonance Spectroscopy; Molecular Structure; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; X-Ray Diffraction | 2011 |
Multiple vertebral compression fractures associated with post partum osteoporosis.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Fractures, Compression; Humans; Injections, Epidural; Lumbar Vertebrae; Osteoporosis; Physical Therapy Modalities; Postpartum Period; Radiography; Risedronic Acid; Spinal Fractures; Steroids; Thoracic Vertebrae; Treatment Outcome | 2011 |
Bisphosphonate treatment delays stress fracture remodeling in the rat ulna.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Bony Callus; Diaphyses; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Female; Fractures, Stress; Periosteum; Rats; Rats, Wistar; Risedronic Acid; Ulna Fractures | 2011 |
Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish Adherence Register Analysis (SARA).
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Drug Substitution; Drug-Related Side Effects and Adverse Reactions; Etidronic Acid; Female; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Male; Medication Adherence; Middle Aged; Organometallic Compounds; Osteoporosis; Raloxifene Hydrochloride; Registries; Retrospective Studies; Risedronic Acid; Sweden; Thiophenes | 2011 |
Bisphosphonate-related osteonecrosis of jaws in 3 osteoporotic patients with history of oral bisphosphonate use treated with single yearly zoledronic acid infusion.
Topics: Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Ibandronic Acid; Imidazoles; Infusions, Intravenous; Mandibular Diseases; Maxillary Diseases; Middle Aged; Osteoporosis, Postmenopausal; Risedronic Acid; Tooth Extraction; Tooth Socket; Zoledronic Acid | 2012 |
Prolonged bisphosphonate release after treatment in women with osteoporosis. Relationship with bone turnover.
Topics: Adult; Aged; Aged, 80 and over; Alendronate; Bone Remodeling; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2011 |
Simultaneous bilateral subtrochanteric fractures following risedronate therapy.
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Hip Fractures; Humans; Middle Aged; Risedronic Acid | 2011 |
In vitro disintegration studies of weekly generic and branded risedronate sodium formulations available in Canada.
Topics: Biological Availability; Bone Density Conservation Agents; Canada; Chemistry, Pharmaceutical; Drug Administration Schedule; Drugs, Generic; Etidronic Acid; Health Services Accessibility; Humans; In Vitro Techniques; Risedronic Acid; Solutions; Tablets | 2011 |
Ion pairs of risedronate for transdermal delivery and enhanced permeation rate on hairless mouse skin.
Topics: Administration, Cutaneous; Animals; Arginine; Bone Density Conservation Agents; Etidronic Acid; Excipients; Ions; Lysine; Mice; Mice, Hairless; Permeability; Polyamines; Risedronic Acid; Skin Absorption; Solubility; Solvents; Water; Xylenes | 2011 |
Different modalities of NaCl osmogen in biodegradable microspheres for bone deposition of risedronate sodium by alveolar targeting.
Topics: Administration, Inhalation; Animals; Biocompatible Materials; Bone and Bones; Bone Density Conservation Agents; Calorimetry, Differential Scanning; Cell Line; Cell Survival; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Etidronic Acid; Humans; Lactic Acid; Lung; Male; Microscopy, Electron, Scanning; Microspheres; Osmotic Pressure; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Pulmonary Alveoli; Rats; Risedronic Acid; Sodium Chloride; Solubility; Surface Properties; Tissue Distribution | 2011 |
Effect of stopping risedronate after long-term treatment on bone turnover.
Topics: Aged; Bone Density; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur; Humans; Lumbar Vertebrae; Middle Aged; Osteoporosis; Prevalence; Randomized Controlled Trials as Topic; Risedronic Acid; Spinal Fractures; Withholding Treatment | 2011 |
Effects of one year daily teriparatide treatment on trabecular bone material properties in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
Topics: Aged; Alendronate; Analysis of Variance; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Matrix; Crystallization; Drug Administration Schedule; Etidronic Acid; Female; Humans; Osteoporosis, Postmenopausal; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Spectrum Analysis, Raman; Teriparatide; Treatment Outcome | 2011 |
Distinguishing the proapoptotic and antiresorptive functions of risedronate in murine osteoclasts: role of the Akt pathway and the ERK/Bim axis.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cells, Cultured; Etidronic Acid; Extracellular Signal-Regulated MAP Kinases; Gene Deletion; In Vitro Techniques; Male; MAP Kinase Kinase 1; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitochondria; Models, Animal; Osteoclasts; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Risedronic Acid; Signal Transduction | 2011 |
Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Comparative Effectiveness Research; Diphosphonates; Drug Costs; Etidronic Acid; Female; Follow-Up Studies; Fractures, Bone; Humans; Ibandronic Acid; Insurance Claim Review; Longitudinal Studies; Male; Managed Care Programs; Medication Adherence; Middle Aged; Osteoporosis; Regression Analysis; Retrospective Studies; Risedronic Acid; United States | 2011 |
Topically administered Risedronate shows powerful anti-osteoporosis effect in ovariectomized mouse model.
Topics: Administration, Topical; Animals; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Mice; Mice, Inbred C57BL; Osteoporosis; Ovariectomy; Risedronic Acid; Skin; Tibia; X-Ray Microtomography | 2012 |
The association between automatic generic substitution and treatment persistence with oral bisphosphonates.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Drugs, Generic; Etidronic Acid; Female; Humans; Male; Medication Adherence; Osteoporosis; Retrospective Studies; Risedronic Acid; Sweden; Time Factors | 2012 |
Preventive effect of risedronate on bone loss and frailty fractures in elderly women treated with anastrozole for early breast cancer.
Topics: Aged; Aged, 80 and over; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Bone Density; Bone Density Conservation Agents; Bone Resorption; Breast Neoplasms; Calcium Carbonate; Cohort Studies; Combined Modality Therapy; Dietary Supplements; Etidronic Acid; Female; Follow-Up Studies; Humans; Neoplasm Staging; Nitriles; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Severity of Illness Index; Triazoles; Vitamin D | 2012 |
Three-year experience with risedronate therapy for patients with an increased fracture risk: assessment of proximal femoral bone density and geometry by DXA.
Topics: Absorptiometry, Photon; Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Follow-Up Studies; Fractures, Bone; Hip; Humans; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Risedronic Acid; Time Factors | 2012 |
Development and validation of a sensitive solid-phase-extraction (SPE) method using high-performance liquid chromatography/tandem mass spectrometry (LC-MS/MS) for determination of risedronate concentrations in human plasma.
Topics: Acetaminophen; Chromatography, High Pressure Liquid; Diazomethane; Drug Stability; Etidronic Acid; Hemolysis; Humans; Ibuprofen; Regression Analysis; Reproducibility of Results; Risedronic Acid; Sensitivity and Specificity; Solid Phase Extraction; Tandem Mass Spectrometry; Trimethylsilyl Compounds | 2012 |
Gastric ulcerogenic and healing impairment effects of risedronate, a nitrogen-containing bisphosphonate in rats. Comparison with alendronate and minodronate.
Topics: Alendronate; Animals; Diphosphonates; Dose-Response Relationship, Drug; Etidronic Acid; Imidazoles; Male; Nitrogen; Rats; Rats, Sprague-Dawley; Risedronic Acid; Stomach Ulcer; Wound Healing | 2011 |
Lipophilic analogs of zoledronate and risedronate inhibit Plasmodium geranylgeranyl diphosphate synthase (GGPPS) and exhibit potent antimalarial activity.
Topics: Animals; Antimalarials; Calorimetry; Crystallography, X-Ray; Diphosphonates; Enzyme Inhibitors; Erythrocytes; Etidronic Acid; Farnesyltranstransferase; High-Throughput Screening Assays; Humans; Imidazoles; Lipids; Mice; Models, Molecular; Parasitemia; Plasmodium; Plasmodium falciparum; Plasmodium vivax; Protein Binding; Risedronic Acid; Survival Analysis; Terpenes; Zoledronic Acid | 2012 |
Paget disease of bone - an update.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Humans; Imidazoles; Middle Aged; Osteitis Deformans; Risedronic Acid; Zoledronic Acid | 2012 |
Incidence of fractures of the femur, including subtrochanteric, up to 8 years since initiation of oral bisphosphonate therapy: a register-based cohort study using the US MarketScan claims databases.
Topics: Administration, Oral; Aged; Alendronate; Cohort Studies; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Femoral Fractures; Hip Fractures; Humans; Incidence; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Risedronic Acid; United States | 2012 |
Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Chronic Disease; Etidronic Acid; Fluorobenzenes; France; Humans; Middle Aged; Pioglitazone; Prescription Drugs; Pyrimidines; Randomized Controlled Trials as Topic; Risedronic Acid; Rosuvastatin Calcium; Sulfonamides; Tetrazoles; Thiazolidinediones; Valine; Valsartan | 2012 |
Risedronate improves bone mineral density in Crohn's disease: a complementary mechanism.
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Crohn Disease; Etidronic Acid; Female; Humans; Male; Risedronic Acid | 2012 |
Risedronate inhibits bone marrow mesenchymal stem cell adipogenesis and switches RANKL/OPG ratio to impair osteoclast differentiation.
Topics: Adipogenesis; Bone Density Conservation Agents; Bone Marrow Cells; Cell Differentiation; Cells, Cultured; Dose-Response Relationship, Drug; Etidronic Acid; Humans; Mechanistic Target of Rapamycin Complex 1; Mesenchymal Stem Cells; Multiprotein Complexes; Osteoclasts; Osteoprotegerin; RANK Ligand; Risedronic Acid; TOR Serine-Threonine Kinases | 2013 |
Age effect on bone mineral density changes in breast cancer patients receiving anastrozole: results from the ARBI prospective clinical trial.
Topics: Absorptiometry, Photon; Age Factors; Aged; Anastrozole; Antineoplastic Agents, Hormonal; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Breast Neoplasms; Drug Therapy, Combination; Etidronic Acid; Female; Humans; Middle Aged; Nitriles; Osteoporosis; Osteoporosis, Postmenopausal; Outcome and Process Assessment, Health Care; Prospective Studies; Randomized Controlled Trials as Topic; Risedronic Acid; Risk Assessment; Risk Factors; Time Factors; Triazoles | 2012 |
Osteoporosis, osteopenia and fracture risk: widening the therapeutic horizons.
Topics: Adult; Age Factors; Aged; Algorithms; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Etidronic Acid; Female; Fractures, Bone; Hip Fractures; Humans; Male; Middle Aged; Organometallic Compounds; Osteoporosis; Risedronic Acid; Spinal Fractures; Thiophenes | 2012 |
Pharmacovigilance of oral bisphosphonates: adverse effects manifesting in the soft tissue of the oral cavity.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alendronate; Blister; Bone Density Conservation Agents; Diphosphonates; Drug Monitoring; Etidronic Acid; Female; Gingival Diseases; Humans; Male; Middle Aged; Mouth Diseases; Oral Ulcer; Pharmacovigilance; Risedronic Acid; Sweden; Time Factors; Tongue Diseases | 2012 |
Efficacy of intravenously administered ibandronate in postmenopausal Korean women with insufficient response to orally administered bisphosphonates.
Topics: Administration, Intravenous; Administration, Oral; Aged; Aged, 80 and over; Alendronate; Asian People; Bone Density; Bone Density Conservation Agents; Collagen Type I; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Injections, Intravenous; Longitudinal Studies; Lumbar Vertebrae; Middle Aged; Osteoporosis, Postmenopausal; Peptides; Postmenopause; Retrospective Studies; Risedronic Acid | 2012 |
Unusual subtrochanteric femoral insufficiency fractures associated with the prolonged use of alendronate and risedronate: a report of two cases.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Drug Administration Schedule; Etidronic Acid; Female; Fractures, Stress; Hip Fractures; Humans; Middle Aged; Osteoporosis; Risedronic Acid | 2011 |
Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; France; Glucocorticoids; Humans; Incidence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2013 |
Successful treatment of osteomalacia caused by renal tubular acidosis associated with Sjögren's syndrome.
Topics: Acidosis, Renal Tubular; Bone Density Conservation Agents; Drug Therapy, Combination; Etidronic Acid; Female; Glucocorticoids; Humans; Hydroxycholecalciferols; Middle Aged; Osteomalacia; Prednisolone; Risedronic Acid; Sjogren's Syndrome; Sodium Bicarbonate; Treatment Outcome | 2013 |
Modulation of bone turnover in orchidectomized rats treated with raloxifene and risedronate.
Topics: Administration, Oral; Animals; Biomarkers; Bone and Bones; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Calcium; Cathepsin K; Cell Count; Drug Therapy, Combination; Etidronic Acid; Injections, Subcutaneous; Male; Orchiectomy; Osteoclasts; Osteocytes; Osteoporosis; Radiography; Raloxifene Hydrochloride; Random Allocation; Rats; Rats, Wistar; Risedronic Acid | 2013 |
[Simultaneous determination of alendronate, pamidronate, ibandronate and risedronate using ion chromatography with integrated pulsed amperometric detection].
Topics: Alendronate; Chromatography, Ion Exchange; Diphosphonates; Electrochemical Techniques; Etidronic Acid; Humans; Ibandronic Acid; Pamidronate; Risedronic Acid | 2012 |
The effect of risedronate (17.5 mg/week) treatment on quality of life in Japanese women with osteoporosis: a prospective observational study.
Topics: Aged; Aged, 80 and over; Asian People; Bone Density; Bone Density Conservation Agents; Comorbidity; Etidronic Acid; Female; Humans; Japan; Myocardial Ischemia; Osteoarthritis, Hip; Osteoporosis; Pain; Prospective Studies; Quality of Life; Risedronic Acid | 2012 |
Third-generation bisphosphonates for treatment of sensorineural hearing loss in otosclerosis.
Topics: Adult; Aged; Audiometry, Pure-Tone; Auditory Threshold; Bone Conduction; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Hearing Loss, Sensorineural; Humans; Imidazoles; Male; Middle Aged; Otosclerosis; Retrospective Studies; Risedronic Acid; Speech Perception; Tomography, X-Ray Computed; Treatment Outcome; Zoledronic Acid | 2012 |
In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger Vγ9Vδ2 T-cell antitumor cytotoxicity through ICAM-1 engagement.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Etidronic Acid; Female; Geranyltranstransferase; Hemiterpenes; Humans; Immunologic Factors; Intercellular Adhesion Molecule-1; Leukocytes, Mononuclear; Mice; Mice, Inbred NOD; Mice, SCID; Organophosphorus Compounds; Receptors, Antigen, T-Cell, gamma-delta; Risedronic Acid; T-Lymphocytes, Cytotoxic; Xenograft Model Antitumor Assays | 2012 |
Cost-effectiveness of denosumab in the treatment of postmenopausal osteoporosis in Canada.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Denosumab; Etidronic Acid; Female; Humans; Markov Chains; Middle Aged; Models, Econometric; Ontario; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid | 2012 |
Primary lymphoma of the mandible masquerading as bisphosphonate-related osteonecrosis of jaws.
Topics: Aged; Biopsy; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Diagnosis, Differential; Diagnostic Errors; Etidronic Acid; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Mandibular Diseases; Mandibular Neoplasms; Positron-Emission Tomography; Risedronic Acid | 2012 |
Fourier transform infrared imaging as a tool to chemically and spatially characterize matrix-mineral deposition in osteoblasts.
Topics: 3T3 Cells; Animals; Calcification, Physiologic; Calcium Phosphates; Chondrocytes; Collagen; Cross-Linking Reagents; Crystallization; Diphosphonates; Etidronic Acid; Mice; Microscopy, Fluorescence; Odontoblasts; Osteoblasts; Osteoclasts; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Time Factors | 2013 |
[Ocular myasthenia revealed by risedronate].
Topics: Aged, 80 and over; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Myasthenia Gravis; Risedronic Acid | 2012 |
Low-dose risedronate sodium protects bone cells after abrupt oestrogen withdrawal.
Topics: Adipocytes; Alkaline Phosphatase; Animals; Apoptosis; Bone Density Conservation Agents; Cell Differentiation; Cell Proliferation; Cells, Cultured; Cytoprotection; Dose-Response Relationship, Drug; Estrogens; Etidronic Acid; Female; Gene Expression; Humans; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteocytes; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2012 |
Intervention thresholds for denosumab in the UK using a FRAX®-based cost-effectiveness analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Algorithms; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Middle Aged; Models, Econometric; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Quality of Life; RANK Ligand; Risedronic Acid; Risk Assessment; Thiophenes; United Kingdom | 2013 |
How rebates, copayments, and administration costs affect the cost-effectiveness of osteoporosis therapies.
Topics: Bone Density Conservation Agents; Cost Sharing; Cost-Benefit Analysis; Diphosphonates; Drug Costs; Etidronic Acid; Female; Fractures, Spontaneous; Humans; Ibandronic Acid; Markov Chains; Middle Aged; Osteoporosis; Reimbursement Mechanisms; Risedronic Acid | 2012 |
Farsenyl pyrophosphate synthase is a potential molecular drug target of risedronate in Babesia bovis.
Topics: Animals; Babesia bovis; Cloning, Molecular; DNA, Complementary; DNA, Protozoan; Etidronic Acid; Geranyltranstransferase; Hemiterpenes; Inhibitory Concentration 50; Kinetics; Mice; Molecular Weight; Organophosphorus Compounds; Parasitemia; Protozoan Proteins; Risedronic Acid; Sequence Analysis, DNA | 2013 |
Novel fluorescent risedronates: synthesis, photodynamic inactivation and imaging of Bacillus subtilis.
Topics: Bacillus subtilis; Etidronic Acid; Fluoresceins; Fluorescent Dyes; Microbial Sensitivity Tests; Microscopy, Confocal; Organophosphonates; Photosensitizing Agents; Risedronic Acid; Spectrometry, Fluorescence | 2013 |
The observational study of delayed wound healing after tooth extraction in patients receiving oral bisphosphonate therapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Antibiotic Prophylaxis; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Caries; Diphosphonates; Etidronic Acid; Female; Humans; Male; Middle Aged; Oral Fistula; Periapical Periodontitis; Periodontitis; Risedronic Acid; Risk Factors; Time Factors; Tooth Extraction; Wound Healing | 2013 |
Risedronate increases osteoblastic differentiation and function through connexin43.
Topics: Animals; Cell Differentiation; Connexin 43; Etidronic Acid; HEK293 Cells; Humans; Mice; Osteoblasts; Osteogenesis; Risedronic Acid; Transcription, Genetic | 2013 |
Squamous metaplasia of the conjunctiva: a previously unrecognized adverse effect of risedronate sodium.
Topics: Aged, 80 and over; Bone Density Conservation Agents; Conjunctiva; Conjunctival Diseases; Epithelial Cells; Etidronic Acid; Female; Humans; Metaplasia; Middle Aged; Risedronic Acid | 2013 |
Risedronate-loaded Eudragit S100 microparticles formulated into tablets.
Topics: Administration, Oral; Bone Density Conservation Agents; Cellulose; Delayed-Action Preparations; Desiccation; Etidronic Acid; Excipients; Humans; Polymethacrylic Acids; Risedronic Acid; Tablets | 2014 |
No effect of risedronate on articular cartilage damage in the Dunkin Hartley guinea pig model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Bone Resorption; Calcification, Physiologic; Cartilage, Articular; Collagen Type II; Disease Models, Animal; Elasticity; Epiphyses; Etidronic Acid; Growth Plate; Guinea Pigs; Male; Osteoarthritis; Osteoclasts; Peptide Fragments; Risedronic Acid; Stifle; Tibia | 2013 |
Persistence with osteoporosis medication among newly-treated osteoporotic patients.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Medication Adherence; Middle Aged; Osteoporosis; Patient Compliance; Risedronic Acid | 2013 |
Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Hip Fractures; Humans; Incidence; Medication Adherence; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Treatment Outcome; United States | 2013 |
Is there a role for combination therapy for osteoporosis?
Topics: Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Osteoporosis; Risedronic Acid; Teriparatide | 2013 |
Improvement in bone properties by using risedronate adsorbed hydroxyapatite novel nanoparticle based formulation in a rat model of osteoporosis.
Topics: Adsorption; Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Chemistry, Pharmaceutical; Disease Models, Animal; Durapatite; Etidronic Acid; Femur; Nanoparticles; Osteoporosis; Porosity; Rats; Rats, Wistar; Risedronic Acid; Spectroscopy, Fourier Transform Infrared; Tibia; X-Ray Diffraction | 2013 |
Effect of parathyroidectomy versus risedronate on volumetric bone mineral density and bone geometry at the tibia in postmenopausal women with primary hyperparathyroidism.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Hyperparathyroidism, Primary; Middle Aged; Parathyroidectomy; Postmenopause; Risedronic Acid; Tibia; White People | 2014 |
Implications of local osteoporosis on the efficacy of anti-resorptive drug treatment: a 3-year follow-up finite element study in risedronate-treated women.
Topics: Aged; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Female; Femur Neck; Finite Element Analysis; Follow-Up Studies; Hip Fractures; Humans; Imaging, Three-Dimensional; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Analysis of docetaxel therapy in elderly (≥70 years) castration resistant prostate cancer patients enrolled in the Netherlands Prostate Study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Multicenter Studies as Topic; Netherlands; Prednisone; Prostatic Neoplasms, Castration-Resistant; Randomized Controlled Trials as Topic; Retrospective Studies; Risedronic Acid; Survival Analysis; Taxoids | 2013 |
UPLC-UV method for determination of risedronate in human urine.
Topics: Adult; Biological Availability; Chromatography, High Pressure Liquid; Drug Stability; Etidronic Acid; Humans; Linear Models; Reproducibility of Results; Risedronic Acid; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Young Adult | 2014 |
Oral bisphosphonates and the risk of Barrett's esophagus: case-control analysis of US veterans.
Topics: Aged; Alendronate; Barrett Esophagus; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Endoscopy, Digestive System; Etidronic Acid; Female; Gastroesophageal Reflux; Helicobacter Infections; Hernia, Hiatal; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Osteoporosis; Proton Pump Inhibitors; Risedronic Acid; Risk Factors; United States; Veterans; Waist-Hip Ratio | 2013 |
Oral bisphosphonate-related osteonecrosis of the jaws in dental implant patients: a case series.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Alendronate; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Dental Implants; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Hypertension; Ibandronic Acid; Male; Mandibular Diseases; Maxillary Diseases; Middle Aged; Retrospective Studies; Risedronic Acid; Risk Factors; Time Factors | 2013 |
Risedronate positively affects osteogenic differentiation of human mesenchymal stromal cells.
Topics: Adipocytes; Adolescent; Adult; Bone and Bones; Bone Density Conservation Agents; Cell Differentiation; Cells, Cultured; Core Binding Factor Alpha 1 Subunit; Etidronic Acid; Female; Gene Expression; Humans; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Risedronic Acid; Young Adult | 2013 |
Comparison of immunosuppressive and cytotoxic cells in angiosarcoma: development of a possible supportive therapy for angiosarcoma.
Topics: Aged; Aged, 80 and over; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Apyrase; Docetaxel; Drug Therapy, Combination; Enzyme Inhibitors; Etidronic Acid; Female; Forkhead Transcription Factors; Hemangiosarcoma; Humans; Macrophages; Male; Matrix Metalloproteinase 9; Poly(A)-Binding Proteins; Receptors, Cell Surface; Risedronic Acid; Skin Neoplasms; T-Cell Intracellular Antigen-1; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Taxoids | 2013 |
Cost effectiveness of denosumab versus oral bisphosphonates for postmenopausal osteoporosis in the US.
Topics: Aged; Aged, 80 and over; Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Cost-Benefit Analysis; Denosumab; Diphosphonates; Drug Costs; Etidronic Acid; Female; Health Care Costs; Humans; Insurance, Health, Reimbursement; Markov Chains; Osteoporosis, Postmenopausal; Risedronic Acid; Sweden; Thiophenes; United States | 2013 |
Bisphosphonate-related osteonecrosis of jaw (BRONJ) in Japanese population: a case series of 13 patients at our clinic.
Topics: Administration, Oral; Adrenal Cortex Hormones; Aged; Aged, 80 and over; Alendronate; Anti-Bacterial Agents; Arthritis, Rheumatoid; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Diabetes Complications; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infusions, Parenteral; Japan; Male; Middle Aged; Oral Surgical Procedures; Osteoporosis; Prostatic Neoplasms; Risedronic Acid; Treatment Outcome; Wound Healing; Zoledronic Acid | 2013 |
Oral bisphosphonates for paediatric osteogenesis imperfecta?
Topics: Bone Density Conservation Agents; Etidronic Acid; Female; Humans; Male; Osteogenesis Imperfecta; Risedronic Acid | 2013 |
Bisphosphonate-related osteonecrosis of the jaws: a potential alternative to drug holidays.
Topics: Aged; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Remodeling; Dental Care for Chronically Ill; Dental Pulp Diseases; Denture, Partial, Fixed; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Mandibular Diseases; Oral Surgical Procedures; Osteoblasts; Osteoclasts; Osteocytes; Osteoporosis; Patient Care Planning; Patient Care Team; Risedronic Acid; Root Caries; Tooth Extraction | 2013 |
Preparation, characterization, release kinetics, and in vitro cytotoxicity of calcium silicate cement as a risedronate delivery system.
Topics: Adsorption; Animals; Bone Cements; Bone Density Conservation Agents; Calcium Compounds; Etidronic Acid; Microscopy, Electron, Scanning; Osteoblasts; Rats; Rats, Sprague-Dawley; Risedronic Acid; Silicates; X-Ray Diffraction | 2014 |
Anti-resorptive agents reduce the size of resorption cavities: a three-dimensional dynamic bone histomorphometry study.
Topics: Animals; Bone Density Conservation Agents; Bone Remodeling; Bone Resorption; Etidronic Acid; Female; Ovariectomy; Raloxifene Hydrochloride; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2013 |
Osteoporosis drugs in real-world clinical practice: an analysis of persistence.
Topics: Adult; Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Substitution; Etidronic Acid; Female; Humans; Ibandronic Acid; Male; Middle Aged; Osteoporosis; Retrospective Studies; Risedronic Acid; Thiophenes | 2013 |
Suitability of liposomal carriers for systemic delivery of risedronate using the pulmonary route.
Topics: Administration, Inhalation; Aerosols; Amines; Animals; Bone and Bones; Bone Density Conservation Agents; Cholesterol; Drug Carriers; Drug Delivery Systems; Etidronic Acid; Liposomes; Lung; Male; Nebulizers and Vaporizers; Particle Size; Phospholipids; Rats; Risedronic Acid; Tissue Distribution | 2013 |
Substantial under-treatment among women diagnosed with osteoporosis in a US managed-care population: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Calcitonin; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Imidazoles; Managed Care Programs; Middle Aged; Osteoporosis; Raloxifene Hydrochloride; Retrospective Studies; Risedronic Acid; Teriparatide; United States; Zoledronic Acid | 2014 |
Osteoblastic cell secretome: a novel role for progranulin during risedronate treatment.
Topics: Animals; Blotting, Western; Cell Line; Cell Survival; Electrophoresis, Polyacrylamide Gel; Etidronic Acid; Humans; Intercellular Signaling Peptides and Proteins; Mass Spectrometry; Mice; Osteoblasts; Progranulins; Proteome; Reproducibility of Results; Risedronic Acid; Time Factors | 2014 |
What is the role for bisphosphonates in IBD?
Topics: Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Crohn Disease; Dietary Supplements; Etidronic Acid; Female; Humans; Male; Risedronic Acid; Vitamin D | 2014 |
Ionic complex of risedronate with positively charged deoxycholic acid derivative: evaluation of physicochemical properties and enhancement of intestinal absorption in rats.
Topics: Animals; Biological Availability; Bone Density Conservation Agents; Carrier Proteins; Deoxycholic Acid; Dose-Response Relationship, Drug; Drug Carriers; Etidronic Acid; Intestinal Absorption; Ions; Male; Membrane Glycoproteins; Membranes, Artificial; Molecular Structure; Permeability; Rats, Sprague-Dawley; Risedronic Acid; Solubility; Surface Properties; Time Factors | 2014 |
The cell cycle arrest and the anti-invasive effects of nitrogen-containing bisphosphonates are not mediated by DBF4 in breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Cycle Checkpoints; Cell Cycle Proteins; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diphosphonates; Drug Screening Assays, Antitumor; Etidronic Acid; Female; Humans; Imidazoles; Inhibitory Concentration 50; Neoplasm Invasiveness; Pamidronate; Risedronic Acid; Zoledronic Acid | 2014 |
Risedronate improves bone architecture and strength faster than alendronate in ovariectomized rats on a low-calcium diet.
Topics: Alendronate; Animals; Bone Density; Bone Density Conservation Agents; Calcium; Etidronic Acid; Female; Food, Formulated; Fractures, Bone; Ovariectomy; Rats; Rats, Sprague-Dawley; Risedronic Acid; Weight-Bearing | 2014 |
Immunomodulatory effect of bisphosphonate risedronate sodium on CD163+ arginase 1+ M2 macrophages: the development of a possible supportive therapy for angiosarcoma.
Topics: Antigens, CD; Antigens, Differentiation, Myelomonocytic; Arginase; Calcium Channel Blockers; Cytokines; Docetaxel; Etidronic Acid; Hemangiosarcoma; Humans; Immunologic Factors; Macrophages; Matrix Metalloproteinase 9; Models, Biological; Nitric Oxide Synthase Type II; Receptors, Cell Surface; Risedronic Acid; RNA, Messenger; Taxoids; Th2 Cells | 2013 |
A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography.
Topics: Administration, Intravenous; Administration, Oral; Alendronate; Alveolar Process; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Early Diagnosis; Etidronic Acid; Female; Humans; Image Processing, Computer-Assisted; Imidazoles; Male; Mandible; Mandibular Diseases; Middle Aged; Osteolysis; Osteosclerosis; Pamidronate; Risedronic Acid; Risk Factors; Time Factors; Tomography, X-Ray Computed; Zoledronic Acid | 2014 |
Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.
Topics: Absorptiometry, Photon; Aged; Aged, 80 and over; Alendronate; Alkaline Phosphatase; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Diphosphonates; Etidronic Acid; Female; Femur Neck; Follow-Up Studies; Hip Joint; Humans; Lumbar Vertebrae; Medication Adherence; Middle Aged; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid; Risk Factors; Smoking; Treatment Failure | 2014 |
Bisphosphonate-associated atypical subtrochanteric femur fractures in the older patient.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Humans; Osteoporosis, Postmenopausal; Radiography; Risedronic Acid | 2014 |
Infrared, Raman and NMR investigations of risedronate adsorption on nanocrystalline apatites.
Topics: Apatites; Etidronic Acid; Magnetic Resonance Spectroscopy; Nanoparticles; Risedronic Acid; Spectrum Analysis, Raman | 2014 |
Role of Triticum aestivum aqueous extract in glucocorticoid induced osteoporosis in rats.
Topics: Animals; Bone Density; Bone Resorption; Collagen; Etidronic Acid; Femur; Free Radical Scavengers; Glucocorticoids; Male; Osteoporosis; Plant Extracts; Prednisolone; Rats; Risedronic Acid; Tibia; Triticum | 2014 |
Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Cohort Studies; Denmark; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Middle Aged; Osteoporosis, Postmenopausal; Proportional Hazards Models; Risedronic Acid; Thiophenes | 2014 |
Novel Pullulan-Eudragit® S100 blend microparticles for oral delivery of risedronate: formulation, in vitro evaluation and tableting of blend microparticles.
Topics: Administration, Oral; Buffers; Chemistry, Pharmaceutical; Etidronic Acid; Glucans; Hydrogen-Ion Concentration; Microscopy, Electron, Scanning; Microspheres; Polymethacrylic Acids; Rheology; Risedronic Acid; Solutions; Tablets | 2014 |
Biomechanical and microstructural benefits of physical exercise associated with risedronate in bones of ovariectomized rats.
Topics: Animals; Biomechanical Phenomena; Bone and Bones; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Exercise Therapy; Female; Osteoporosis; Ovariectomy; Rats; Rats, Wistar; Risedronic Acid | 2014 |
Crystallization and preliminary neutron diffraction experiment of human farnesyl pyrophosphate synthase complexed with risedronate.
Topics: Crystallization; Crystallography, X-Ray; Etidronic Acid; Geranyltranstransferase; Humans; Models, Molecular; Neutron Diffraction; Polyisoprenyl Phosphates; Protein Conformation; Risedronic Acid; Sesquiterpenes | 2014 |
Effects of various squalene epoxides on coenzyme Q and cholesterol synthesis.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Cholesterol; Diabetes Mellitus, Experimental; Etidronic Acid; Hemiterpenes; Hep G2 Cells; Humans; Lovastatin; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Organophosphorus Compounds; Rats; Rats, Wistar; Risedronic Acid; Squalene; Tricarboxylic Acids; Ubiquinone | 2014 |
Effects of glucosamine and risedronate alone or in combination in an experimental rabbit model of osteoarthritis.
Topics: Animals; Bone Density Conservation Agents; Etidronic Acid; Female; Glucosamine; Humans; Osteoarthritis; Rabbits; Risedronic Acid | 2014 |
Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules.
Topics: Adsorption; Apatites; Calcium Phosphates; Delayed-Action Preparations; Diphosphonates; Drug Delivery Systems; Drug Interactions; Etidronic Acid; Risedronic Acid; Time Factors | 2014 |
Effective mucoadhesive liposomal delivery system for risedronate: preparation and in vitro/in vivo characterization.
Topics: Absorption, Physiological; Administration, Oral; Animals; Bone Density Conservation Agents; Caco-2 Cells; Etidronic Acid; Humans; Liposomes; Male; Metabolic Clearance Rate; Mucins; Oral Mucosal Absorption; Rats; Rats, Sprague-Dawley; Risedronic Acid | 2014 |
Design of pH-responsive alginate raft formulation of risedronate for reduced esophageal irritation.
Topics: Alginates; Chemistry, Pharmaceutical; Drug Design; Esophagus; Etidronic Acid; Glucuronic Acid; Hexuronic Acids; Humans; Hydrogen-Ion Concentration; Irritants; Risedronic Acid; Tablets; Viscosity | 2014 |
Synergistic effects of ethanol and isopentenyl pyrophosphate on expansion of γδ T cells in synovial fluid from patients with arthritis.
Topics: Adult; Aged; Arthritis, Rheumatoid; Cell Proliferation; Cell Survival; Drug Synergism; Ethanol; Etidronic Acid; Female; Hemiterpenes; Humans; Interferon-gamma; Lymphocyte Activation; Male; Middle Aged; Models, Biological; Organophosphorus Compounds; Phenotype; Receptors, Antigen, T-Cell, alpha-beta; Receptors, Antigen, T-Cell, gamma-delta; Risedronic Acid; Synovial Fluid; T-Lymphocyte Subsets | 2014 |
Systematic repurposing screening in xenograft models identifies approved drugs with novel anti-cancer activity.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Biphenyl Compounds; Cell Line, Tumor; Dacarbazine; Drug Approval; Drug Repositioning; Etidronic Acid; Female; High-Throughput Screening Assays; Humans; Male; Mice; Mice, Inbred C57BL; Mice, Nude; Mice, Transgenic; Neoplasms; Risedronic Acid; Temozolomide; Tetrazoles; Xenograft Model Antitumor Assays | 2014 |
Effect of risedronate in osteoporotic HIV males, according to gonadal status: a pilot study.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cholecalciferol; Drug Therapy, Combination; Etidronic Acid; HIV Infections; Humans; Hypogonadism; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Pilot Projects; Risedronic Acid; Testosterone; Treatment Outcome | 2014 |
A novel automated hydrophilic interaction liquid chromatography method using diode-array detector/electrospray ionization tandem mass spectrometry for analysis of sodium risedronate and related degradation products in pharmaceuticals.
Topics: Bone Density Conservation Agents; Chromatography, High Pressure Liquid; Etidronic Acid; Hydrophobic and Hydrophilic Interactions; Limit of Detection; Quality Control; Reproducibility of Results; Risedronic Acid; Spectrometry, Mass, Electrospray Ionization; Tablets; Tandem Mass Spectrometry | 2014 |
Residual effect after oral bisphosphonate treatment and healthy adherer effects--the Swedish Adherence Register Analysis (SARA).
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Comorbidity; Effect Modifier, Epidemiologic; Etidronic Acid; Female; Hospitalization; Humans; Incidence; Male; Medication Adherence; Middle Aged; Osteoporosis; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Assessment; Sweden; Withholding Treatment | 2015 |
Risedronate therapy for neurofibromatosis Type 1-related low bone mass: a stitch in time saves nine.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Male; Neurofibromatosis 1; Osteoporosis; Risedronic Acid; Young Adult | 2015 |
Preparation of risedronate nanoparticles by solvent evaporation technique.
Topics: Biological Availability; Calorimetry, Differential Scanning; Carboxymethylcellulose Sodium; Dextrans; Drug Carriers; Etidronic Acid; Excipients; Microscopy, Electron, Scanning; Nanoparticles; Particle Size; Permeability; Polyethylene Glycols; Polysorbates; Risedronic Acid; Sodium Dodecyl Sulfate; Solubility; Solvents; Technology, Pharmaceutical | 2014 |
The osteogenic activity of human mandibular fracture haematoma-derived progenitor cells is affected by bisphosphonate in vitro.
Topics: Adult; Aged; Alendronate; Alkaline Phosphatase; Cell Differentiation; Cell Proliferation; Diphosphonates; Etidronic Acid; Female; Fracture Healing; Hematoma; Humans; In Vitro Techniques; Male; Mandibular Fractures; Middle Aged; Osteogenesis; Risedronic Acid | 2015 |
Efficacy, effectiveness and side effects of medications used to prevent fractures.
Topics: Alendronate; Antibodies, Monoclonal, Humanized; Bone Density Conservation Agents; Calcium Compounds; Denosumab; Diphosphonates; Etidronic Acid; Evidence-Based Medicine; Hip Fractures; Humans; Ibandronic Acid; Imidazoles; Osteoporosis; Osteoporotic Fractures; Raloxifene Hydrochloride; Risedronic Acid; Risk Assessment; Spinal Fractures; Teriparatide; Thiophenes; Treatment Outcome; Vitamin D; Zoledronic Acid | 2015 |
Probenecid as a sensitizer of bisphosphonate-mediated effects in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Breast Neoplasms; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Survival; Connexins; Diphosphonates; Etidronic Acid; Female; Hemiterpenes; Humans; Ibandronic Acid; Imidazoles; MCF-7 Cells; Multidrug Resistance-Associated Proteins; Nerve Tissue Proteins; Organophosphorus Compounds; Osteoclasts; Phosphate Transport Proteins; Probenecid; Risedronic Acid; Zoledronic Acid | 2014 |
[Osteodeficiency in chronic pancreatitis: ways of correction].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bone and Bones; Bone Density; Bone Density Conservation Agents; Calcification, Physiologic; Calcium Carbonate; Cholecalciferol; Etidronic Acid; Female; Humans; Male; Middle Aged; Osteoporosis; Pancreatitis, Chronic; Risedronic Acid | 2014 |
Cranial base pathology in pediatric osteogenesis imperfecta patients treated with bisphosphonates.
Topics: Adolescent; Bone Density Conservation Agents; Child; Child, Preschool; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Follow-Up Studies; Humans; Imidazoles; Infant; Kaplan-Meier Estimate; Logistic Models; Male; Osteogenesis Imperfecta; Pamidronate; Platybasia; Retrospective Studies; Risedronic Acid; Skull Base; Zoledronic Acid | 2015 |
Risk of atypical femoral fracture during and after bisphosphonate use.
Topics: Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Cohort Studies; Diphosphonates; Etidronic Acid; Female; Femoral Fractures; Humans; Male; Middle Aged; Osteoporotic Fractures; Radiography; Retrospective Studies; Risedronic Acid; Risk Factors; Sex Factors; Sweden; Time Factors | 2015 |
Risedronate as an intra-abdominal sepsis mimic: a case report.
Topics: Abdominal Abscess; Aged; Diphosphonates; Etidronic Acid; Female; Humans; Osteoporosis; Risedronic Acid; Sepsis | 2015 |
Exploring methods for comparing the real-world effectiveness of treatments for osteoporosis: adjusted direct comparisons versus using patients as their own control.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Case-Control Studies; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Imidazoles; Incidence; Middle Aged; Netherlands; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Registries; Risedronic Acid; Risk Factors; Sweden; Treatment Outcome; Zoledronic Acid | 2017 |
Teriparatide vs risedronate for osteoporosis.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide | 2018 |
Teriparatide vs risedronate for osteoporosis - Authors' reply.
Topics: Bone Density; Bone Density Conservation Agents; Etidronic Acid; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid; Teriparatide | 2018 |
Mortality risk reduction differs according to bisphosphonate class: a 15-year observational study.
Topics: Aged; Alendronate; Bone Density Conservation Agents; Canada; Diphosphonates; Etidronic Acid; Female; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Osteoporosis; Osteoporotic Fractures; Prospective Studies; Risedronic Acid; Risk Factors; Risk Reduction Behavior | 2019 |
Time trends in oral bisphosphonate initiation in Ontario, Canada over 20 years reflect drug policy and healthcare delivery changes.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alendronate; Bone Density Conservation Agents; Diphosphonates; Drug Administration Schedule; Etidronic Acid; Female; Humans; Male; Ontario; Osteoporosis; Pharmacoepidemiology; Risedronic Acid; Sex Factors; Time Factors | 2019 |
Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
Topics: Alendronate; Bone Density Conservation Agents; Data Analysis; Diphosphonates; Etidronic Acid; Female; Humans; Middle Aged; Osteoporosis; Osteoporosis, Postmenopausal; Osteoporotic Fractures; Risedronic Acid | 2022 |
Beyond Antiresorptive Activity: Risedronate-Based Coordination Complexes To Potentially Treat Osteolytic Metastases.
Topics: Coordination Complexes; Diphosphonates; Etidronic Acid; Humans; Ligands; Risedronic Acid | 2023 |
Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Topics: Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis; Osteoporosis, Postmenopausal; Risedronic Acid | 2023 |
Cost-effectiveness of weekly gastro-resistant risedronate 35 mg, compared with weekly alendronate 70 mg tablets, in the treatment of postmenopausal osteoporosis in Spain.
Topics: Alendronate; Bone Density Conservation Agents; Cohort Studies; Cost-Benefit Analysis; Etidronic Acid; Female; Fractures, Bone; Humans; Osteoporosis, Postmenopausal; Quality-Adjusted Life Years; Risedronic Acid; Spain | 2023 |